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ABSTRACT 
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Thesis Title : Synthesis, characterization and evaluation of anti-cancer activities of 
some gold complexes with diamine, phosphine and dithiocarbamate 
ligands 
Major Field : Chemistry 
Date of Degree : June 2014 
Since the discovery of anticancer properties of cisplatin and its introduction in the clinical 
practice that was in 1978, a large number of coordination compounds of platinum and 
other metals have been investigated for their anticancer potency. In recent years, gold 
complexes have demonstrated a great potential for the design and development of new 
anticancer agents. In view of this potential, we prepared several gold(III) complexes and 
evaluated their antitumor properties. 
In this dissertation, series of gold(III) and gold(I) complexes are reported using various 
ligands such as diamine, phosphine, dithiocarbamate and mercaptobenzimidazole.  
The synthesized complexes were characterized using elemental analysis, various 
spectroscopic techniques including UV-Vis, FTIR spectroscopy, solution and solid-state 
NMR measurements; and X-ray crystallography. The data of CHN analysis supports the 
formation of the synthesized compounds.  The blue shift in N-H stretching frequency in 
mid-FTIR and the presence ofν(Au-N) in far-FTIR showed the coordination of -NH2 
group in 1,2-cyclohexane (1,2-DACH) with Au(III) center via nitrogen donor atoms. The 
solid-state 
13
C NMR chemical shift shows that ligands are strongly bound to the gold(III) 
and gold (I) center. UV-Vis spectra also indicate that the gold center in gold(III) 
compounds remains in the 3+ oxidation state.  The molecular structures of some 
complexes were determined by X- ray diffraction method. The X-ray crystallographic 
data reveals that the cyclohexyl ring of 1,2-DACH attains a chair conformation. The 
coordination geometry around the gold(III) and gold(I) ions is pseudo-square planar and 
liner, respectively, as indicated by X-ray crystallography analysis.  The stability of the 
xxviii 
 
complexes was checked by UV-Vis spectroscopy and NMR measurements. The 
electrochemical behavior of the complexes was also investigated through cyclic 
voltammetry. 
Spectroscopic data was essentially evaluated by comparing with calculated data from the 
built and optimized structure by GAUSSIAN 09 at the RB3LYP level with LanL2DZ 
bases set.  The computational study shows that the gold(III) adopts distorted square 
planar geometry. 
The potential of new complexes  as anticancer agents was investigated by measuring in 
vitro cytotoxicity in terms of IC50 and inhibitory effect on growth of human prostate 
(PC3) and gastric (SGC7901) cancer cell lines. According to the biological assays, all 
(1,2-DACH) gold(III) chloride complexes are promising candidates as anti-cancer agents 
with [bis-(cis-1,2-DACH)2Au(III)]Cl3 is the most active agent.  Some of our complexes 
show in vitro comparable and highercytotoxicity to cisplatin. 
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 ملخص الرسالة
  سعيد  سلمان الجارودي:الاسم الكامل
 
ٔ ذمٛٛى سًٛرٓا ضذ يجًٕعح يٍ انخلاٚا سهسهح جذٚذج يٍ يعمذاخ انزْة  تصنييع و توصيف:عنوان الرسالة
 انسشطاَٛح
 
  الكيمياء:التخصص
 
 4102\6\01 الموافق ل 5341\ 6 \9:تاريخ الدرجة العلمية
 
فئَّ لذ ذى انثحث فٙ عذد كثٛش يٍ يشكثاخ , انًضادج نهسشطاٌ  )nitalpsic(يُز إكرشاف انسًح انًًٛضج نخظائض 
خلال انسُٕاخ انحانٛح أظٓشخ . انثلاذٍٛ انرساًْٛح ٔغٛشْا يٍ انًعادٌ نذساسح إيكاَٛح إسرخذايٓا كًضاد نهسشطاٌ
إدساكا نٓزِ الايكاَاخ لًُا ترحضٛش عذد . يعمذاخ انزْة إيكاَاخ كثٛشج فٙ ذظًٛى ٔذطٕٚش عٕايم يضادج نهسشطاٌ
 .يٍ يعمذاخ انزْة ٔذمٛٛى خظائظٓا انًضادج نلأٔساو
ثُائٙ , فٕسفٍٛ , ثُائٙ ايُٛاخ : )III(ٔ  )I( فٙ ْزِ الاطشٔحح ذى ذٕثٛك سهسهح جذٚذج يٍ يعمذاخ انزْة 
 .ثٕٛكشتايٛد ٔ يشكثرٕ تُضٔ اًٚذاصٔل
نمذ ذى ذٕطٛف انًعمذاخ تعذ رنك تاسرخذاو جٓاص ذحهٛم انعُاطش ٔجٓاص يطٛافٛح الاشعح ذحد انحًشاء ٔجٓاص انشٍَٛ 
َرائج جٓاص٘ انشٍَٛ انُٕٔ٘ انًغُاطٛسٙ ٔيطٛافٛح الاشعح . انُٕٔ٘ انًغُاطٛسٙ انخاص تانسٕائم ٔانحانح انظهثح
كًا اٌ جًٛع انرحانٛم .   انًاَححN عثش رساخ )III(uAذحد انحًشاء ذظٓش ساتطح ذُاسمٛح نكلاتاخ ثُائٙ أيٍٛ يع 
 .ذؤٚذ ذكٍٕٚ ْزِ انًعمذاخ
 90 NAISSUAGنمذ ذى ذمٛٛى انُرائج انًطٛافٛح تًماسَرٓا يع انُرائج انًحسٕتح يٍ الاشكال انًثُٛح انًحسُح تاسرخذاو 
 ٚعرًذ شكم  )III( uAانذساسح انحساتٛح ذظٓش أٌ . ZD2LnaL يع يجًٕعح لٕاعذ PYL3BRعهٗ يسرٕٖ 
 . ُْذسٙ يشتع يسرٕ٘ يش ّٕ ِ
انًضادج نهسشطاٌ فٙ انًخرثش عهٗ خطٕط خلاٚا سشطاٌ  )III(نمذ ذى ذمٛٛى لذسج خظائض يعمذاخ عُظش انزْة 
تشكم عاو  جًٛع انًعمذاخ اظٓشخ خظائض  جٛذج نهًمأيح ضذ خلاٚا . 1097CGS ٔانًعذج 3CPانثشٔسراخ 
 انعايم الاكثش سًٛح 3lC])III(uA2)HCAD-2,1-sic(-sib[نمذ ٔجذ أٌ يعمذ . انسشطاٌ انًسرخذيح فٙ انذساسح
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1 CHAPTER 1 
INTRODUCTION 
Cancer is one of the diseases that contribute to the high mortality rate globally which is 
one of the major public health problems worldwide.  Annually, an estimated 10 million 
people worldwide are diagnosed with cancer, while approximately 6.2 million die from 
this disease [1,2].  One area that has gained prominence is the use of inorganic 
compounds as anticancer drugs. Since the serendipitous discovery of cis-
diaminedichloroplatinum(II) (cisplatin) by Rosenburg and co-workers in 1965 [3] (Figure 
1.1(a)) and its introduction in the clinical practice was in 1978 [4]. Cisplatin is one of the 
most effective drugs in the treatment of testicular, ovarian, bladder, head and neck 
cancers [5]. The discovery of the anticancer properties of cisplatin opened up new 
prospects in the exploitation of metal-based chemotherapeutics to struggle cancer. 
Despite the success of treating certain kinds of cancers with cisplatin there are several 
side effects, as well as the occurrence of intrinsic and acquired resistances, which limit 
the organotropic profile of the drug [6].  Some of the reasons that lead to this acquired 
resistance include reduced cellular uptake and deactivation of cisplatin by thiol 
containing biomolecules, such as glutathione [7].  This has generated continues interest in 
the development of not only platinum complexes but also other platinum group metal-
based complexes which could be less toxic and exhibit no cross-resistance in tumor cells 
as cisplatin.  As a result, this led to the discovery of interesting second-generation 
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platinum(II) antitumour complexes that carry ‗non-leaving‘ ligands other than ammonia.  
More than 3000 platinum analogues of cisplatin have been synthesized but only few have 
made it to the clinical stages [8].  Examples include carboplatin (Figure 1.1b), AMD-473 
(Figure 1.1c) and oxaliplatin (Figure 1.1d).  Carboplatin displays similar activities with 
cisplatin but also exhibits bone-marrow toxicity [9-10].  On the other hand, AMD-473 
showed promising in-vitro activity against cisplatin resistant A2780cisR cells [9-11]. 
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Figure 1.1 Structures of some anticancer platinum compounds 
 
Among the non-platinum transition metal complexes tested so far, gold complexes have 
demonstrated a great promise for the design and development of anticancer 
agents.Chrysotherapy, the use of gold compounds in medicine, refers to the fact that gold 
compounds, usually gold thiolates, are used clinically in the alleviation of the symptoms 
associated with rheumatoid arthritis. Representations of some of the commonly used 
compounds used in this context are shown in Fig. 1.2.  Aurothioglucose (solganol), which 
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is neutral, and the charged species aurothiomalate (myocrysin), aurothiosulphate 
(sanocrysin), aurothiopropanol sulphonate (allocrysin) and monomeric, neutral gold(I) 
species, triethylphosphinegold(I) tetraacetatothioglucose (auranofin) all have been 
successfully used over many years for the treatment of rheumatoid arthritis [12-15]. For 
instance, first comprehensive study of auranofin and auranofin analogues was published 
in 1986 [16]. In this study the invitro cytotoxicity of 62 gold compounds against both 
B16 melanoma and P388 leukemia cells was examined. The conclusion of this work was 
that a wide variety of phosphine-gold(I)-thiolates display significant cytotoxicity.  In 
terms of a possible structure/activity relationship several trends were apparent that the 
presence of a phosphine ligand was important to demonstrated significant cytotoxicity. 
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Figure 1.2 Structures of some gold-based drugs 
Gold compounds are attracting growing attention within the scientific community as 
potential anticancer agents. Indeed, following the success of platinum based anticancer 
complexes, several other metal compounds have been prepared and evaluated as 
experimental anticancer agents in the course of last two decades [17,18].  For instance, 
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gold(I) and gold(III) are among the tested classes of metal-based agents which have been 
given great attention [19].  Gold complexes have recently gained considerable attention 
as a class of compounds with different pharmacodynamic and kinetic properties than 
cisplatin [20]. Furthermore, the increasing number of scientific reports in the last decade 
testifies the important role played by Au(I) and Au(III) complexes in biochemical and 
chemical research [21-30]. 
Attention was directed towards gold compounds for two reasons: (1) gold(III) centers are 
isoelectronic to Pt(II) compounds and adopt square-planar configurations similar to that 
of cisplatin, and (2) gold(I) compounds are well known pharmaceuticals, some of which 
are currently being used to treat rheumatoid arthritis. Gold compounds have displayed 
strong tumor cell growth inhibition effects by a non-cisplatin-like mode of action. 
Antitumor effects of tetrahedral gold(I) complexes [Au(dppe)2]+ and related compounds 
are ascribed to their delocalized lipophilic cation properties [31–32]. 
Heterocyclic compounds and their metal complexes display a broad spectrum of 
pharmacological properties. For instance, preparation and characterization of four novel 
gold(I) complexes, [C28H26NPS2Au]Cl (Fig. 1.3a), C14H20N2OPSAu (Fig. 1.3b) 
C26H20N2OPSAu (Fig. 1.3c) and [C16H26NPS2Au]Cl (Fig. 1.3d) were obtained with 3-
benzyl-1,3-thiazolidine-2-thione or 5-phenyl-1,3,4-oxadiazole-2-thione and phosphines 
[33]. The compounds exhibited more cytotoxic than cisplatin to colon cancer (CT26WT) 
and metastatic skin melanoma (B16F10) tumor cell lines and presented a high selectivity 
index. 
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Figure 1.3 Structures of potential anticancer gold(I) complexes containing phosphine and heterocyclic compounds 
 
Kouroulis et al. described the in vitro activity of a series of gold(I) complexes, 
[Au(tpp)(mtzd)] (a) and [Au(tpp)(Clmbzt)] (b) as shown in Figure 1.4 against the 
leiomyosarcoma cancer cell line [34].   These complexes showed significant cytotoxic 
effects and were found more active than cisplatin to a large extent. 
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Figure 1.4 Structures of potential anticancer gold(I) complexes containing phosphine and thioamides compounds 
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Some of gold compounds have been entered clinical trials since a few of them are highly 
cytotoxic to solid cancer tumors in vitro and in vivo while causing minimal systemic 
toxicity [35–39]. Most gold(III) compounds display reduced affinity for DNA and it 
seems reasonable that DNA is neither the primary nor the exclusive target for most 
gold(III) complexes. Recent studies have proposed different modes of action for these 
compounds. For instance, gold(III)-porphyrin complexes, known gold-based DNA 
intercalators, induce intracellular oxidation and apoptosis through both caspase-
dependent and -independent mitochondrial pathways [39–41].  Furthermore, gold(III) 
complexes with dithiocarbamate ligands inhibit thioredoxin reductase activity, generate 
free radicals, increase ERK1/2 phosphorylation, affecting mitochondrial functions 
[36,42]. These compounds have also been described to cause a strong inhibition of the 
proteasome system, via both redox-dependent and -independent processes [43].  
Gold(III) compounds have greatly attracted researchers‘ attention in the last decade for 
their outstanding cytotoxic actions. It is a metal ion which typically adopts a four-
coordinate, square-planar geometry and is therefore expected to mimic the structural and 
electronic properties of platinum(II). Recent studies have shown that several gold(III) 
complexes are highly cytotoxic against different tumor cells [44–46], including some 
which are active even against the cisplatin-resistant cell lines [47–49]. Several lines of 
evidence suggest that gold(III) compounds produce their antiproliferativeeffects through 
innovative and non-conventional modes of action. For instance, the hypothesis that their 
biological effects are mediated by an antimitochondrial mechanism rather than by direct 
DNA damage, as it is the case for cisplatin and its analogs, has gained much credit during 
the last few years [50].   
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To obtain gold(III) complexes with superior chemotherapeutic index in terms of 
increased bioavailability, higher cytotoxicity, and lower side effects than cisplatin, 
Ronconi et al. synthesized new gold(III) dithiocarbamate derivatives with defined 
coordination geometry [51]the synthesized gold complexes were tested for their in vitro 
cytotoxic activity toward a panel of human tumor cell lines.  Remarkably, most of them, 
in particular gold(III) derivatives of N,N-dimethyldithiocarbamate (Compounds (a)&(c); 
Fig. 1.5) and thylsarcosinedithiocarbamate (Compounds (b)&(d); Fig. 1.5), were shown 
to be 1–4-fold more cytotoxic than cisplatin and to overcome to a large extent both 
intrinsic and acquired resistance to cisplatin. The choice of dithiocarbamate ligands was 
not accidental; they were being evaluated for their efficacy as inhibitors of cisplatin-
induced nephrotoxicity without decreasing its antitumor activity [52-54]. 
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Figure 1.5 Chemical structures of gold(III) dithiocarbamatecomplexes 
 
In the light of the above mentioned medicinal role of gold compounds, it is important to 
study the coordination chemistry of gold(III) and gold(I) from the point of view of 
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designing new drugs as well as to understand the biochemical mechanism of action of the 
known anticancer complexes.  
 
1.1 Current Status of the Problem  
1) Cisplatin has been used as an anticancer agent for the last few decades.  
Unfortunately, they have several major drawbacks. Common problems include 
cumulative toxicities of nephrotoxicity and cytotoxicity.  In addition to the serious 
side effects, the therapeutic efficacy is also limited by inherent or treatment-
induced resistant tumor cells. 
2) Even though over 28 new platinum(II) compounds have entered human clinical 
trials, only few of them, carboplatin, oxaliplatin, nedaplatin and lobaplatin, 
received approval and achieved routine clinical use. However, all these platinum( 
II) drugs are active in the same range of tumors and are still administered 
intravenously. As a result, their impact as anticancer drugs is still reduced by the 
significant side effects, such as gastrointestinal and hematological toxicity, and 
drug-resistance phenomena. 
3) Researchers have been focusing on the development and in vitro testing of both 
novel platinum- and other metals-based compounds with the aim of obtaining 
complexes with higher effectiveness, increased selectivity for tumor tissue, 
reduced toxicity, wider spectrum of activity, and able to overcome tumor 
resistance often associated with cisplatin treatment. 
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4) Regardless of the observed side effects, the successes achieved with cisplatin in 
cancer chemotherapy stimulated search for other coordinated metal complexes as 
potential anti-cancer agents.  For example, metal complexes offer an opportunity 
for the discovery of new antitumor drugs with truly new mechanisms of action by 
varying structural features in order to improve the physico-chemical and 
biological properties. 
5) Recent advances in this area demonstrated a great promise for the utilization of 
non-platinum complexes in cancer chemotherapy. 
6) Our interest in using gold for the development of anticancer agent arises from the 
fact that this metal has extensively been employed in medicinal inorganic 
chemistry during the last decades. 
7) Some gold(III) complexes, isoelectronic with antitumor platinum(II) complexes, 
have recently been evaluated in vitro tests, showing significant cytotoxic effects.  
8) The increasing number of scientific reports in the last decade testifies the 
important role played by Au(I) and Au(III) complexes in biochemical and 
chemical research. 
9) Auranofin (S-Au(I)- PEt3) presented an in vitro activity similar to or even greater 
than cisplatin. 
10) Auranofin and a number of its analogs showed potent cytotoxic activity against 
melanoma and leukemia cell lines in vitro and anti-tumor activity against 
leukemia in vivo. However, these complexes were completely inactive against 
solid tumors. The main observations from these experiments were that (i) lack of 
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potency in vitro correlates well with lack of anti-tumor activity; (ii) potent 
cytotoxicity in vitro does not necessarily translate into anti-tumor activity in vivo; 
and (iii) in vivo anti-tumor activity is generally optimized by ligation of Au(I) 
with a substituted phosphine. 
11) A large number of phosphine complexes (R3PAuX) have been evaluated and all 
exhibit in vitro potent cytotoxicity against tumor cells. 
12) The biological profile of the Au(I)diphosphine complexes exhibited high 
lipophilicity which allows them to penetrate cells and their high kinetic and 
thermodynamic stability which prevents unwanted side reactions in vivo. 
 
1.2 Aim of the Present Research 
(A) Synthesis of Ligands. 
1)  To synthesize various ammonium dithiocarbamates ligands functionalized 
with ethylenediamine (en), propylenediamine (pn), butylenediamine (bn) 
and 1,2-diaminocyclohexane (1,2-DACH) and their full chemical 
characterization. 
2) To synthesize various substituted benzimidazoline-2-thione ligands and 
their full chemical characterization. 
(B) Synthesis of Gold(I) Complexes. 
1) To synthesize variouschlorido phosphane gold(I) complexes of the type 
[R3PAuCl]. 
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2) To synthesize various phosphane dithiocarbamato gold(I) complexes of 
the type [R3PAu(DTC)], where DTC is dithiocarbamate.  
3) To synthesize variousdithiocarbamatobis-(phosphanegold(I)) complexes of 
the type [((Au(DTC))2(DPP)], where DCT and DPP are dithiocarbamate 
and bis-diphenylphosphine, respectively. 
(C) Synthesis of Gold(III) Complexes. 
1) To synthesize various 1,2-diaminocyclohexane chloridogold(III) chloride 
complexes of the type [(DACH)AuCl2]Cl, where DACH is 1,2-
diaminocyclohexane. 
2) To synthesizevarious 2-cyclohexanaminium dithiocarmato 
chloridogold(III) chloride complexes of the type [(DACH-DTC)AuCl2]Cl, 
where DACH-DTC is 2-cyclohexanaminium dithiocarmate. 
3) To synthesizevarious ammonia 1,2-diaminocyclohexane chloridogold(III) 
chloride complexes of the type [(DACH)Au(NH3)Cl]Cl2, where DACH is 
1,2-diaminocyclohexane. 
4) To synthesizevarious diammonia 1,2-diaminocyclohexane gold(III) 
chloride complexes of the type [(DACH)Au(NH3)2]Cl3, where DACH is 
1,2-diaminocyclohexane. 
5) To synthesize variousbis(1,2-diaminocyclohexane)gold(III) chloride 
complexes of the type [(DACH)2Au]Cl3, where DACH is 1,2-
diaminocyclohexane. 
6) To synthesize variousmixed-ligand 1,2-diaminocyclohexane 
ethylenediamine gold(III) chloride complexes of the type 
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[(DACH)(en)Au]Cl3, where DACH and en are 1,2-diaminocyclohexane 
and ethylenediamine, respectively. 
7)  To synthesize variousmixed-ligand1,2-diaminocyclohexane 1,3-
propylenediamine gold(III) chloride complexes of the type 
[(DACH)(pn)Au]Cl3, where DACH and pn are 1,2-diaminocyclohexane 
and 1,3-propylenediamine, respectively. 
 
All new synthesized compounds were characterized using various analytical and 
spectroscopic techniques including elemental analysis, UV-Vis and FTIR spectra; and 
solution as well as solid-state NMR measurements.  Also, their structure-activity 
relationships in tumor models will be examined and evaluated.  
 
The outcome of this research may ultimately, lead to the discovery of new type of anti-
cancer agents.  If we are successful it will not only benefit the people who suffer from 
cancer in Kingdom of Saudi Arabia but also the cancer victims of the entire world. 
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2 CHAPTER 2 
LITERATURE REVIEW 
Medical properties of gold have been explored throughout the history of 
civilization. Even ancient cultures in India and Egypt exploited gold and used it for 
various medicinal preparations. The earliest therapeutic application of gold can be traced 
back to 2500 B.C. in China where gold was used to treat smallpox, skin ulcers, and 
measles [55].  Moreover, at that time, people thought of gold as being immortal and 
everlasting, and associated gold with longevity. Some cultures still believe in the healing 
properties of gold. As an illustration, Japanese tradition suggests that thin gold-foils 
placed into tea, sake and food could be beneficial to human health. 
Although gold and gold complexes have historically been used for the treatment of a 
wide range of ailments, the rational use of gold in medicine began in the early 1920s 
when gold was clinically tested for its in vitro bacteriostatic effect. The first gold 
complex used for that purpose was gold cyanide, employed by bacteriologist Robert 
Koch to kill the mycobacteria, the causative agent of tuberculosis [56]. After its initial 
use for pulmonary tuberculosis, toxicity associated with that treatment was observed, and 
the treatment was switched to the less toxic gold(I) thiolate complexes. In the early 
1930s, the French physician Jacque Forestier introduced the same thiolate complexes for 
the treatment of rheumatoid arthritis, a condition which he believed was related to 
tuberculosis [57]. 
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The unintentionally discovery of the anticancer activity of cisplatin was made during an 
experiment in 1965 [58] which was conducted at Michigan State University by Barnett 
Rosenberg. He used a platinum electrode to apply an electric field to a colony of E. coli, 
which was observed to inhibit their growth [59]. A detailed investigation into the cause of 
this effect concluded that the platinum electrode was breaking down to generate 
platinum-(II) species in situ, which was stopping the cells from multiplying. This 
observation led to the development of cis-diamminedichloridoplatinum(II), commonly 
known as cisplatin, being approved by the American Food and Drugs Administration 
(FDA) for cancer therapy in December, 1978 [60]. Since that it has become the most 
widely used anticancer drug, with an estimated 70 % of patients receiving the compound 
as part of their treatment [61,62]. 
The accidental discovery of the anticancer properties of cisplatin, its platinum(II) 
analogues and their wide clinical application in current cancer treatments promoted a 
great deal of interest in the area of metal-based anticancer agents [63]. Cisplatin exhibits 
clinical activity against a wide range of different kinds of cancers. It remains one of the 
most significant anticancer agents in the clinical armamentarium [64]. Whilst the 
chemotherapeutic success of platinum is undeniable, it is by no means the perfect drug. It 
is not effective against many common types of cancer, drug resistance is common and it 
has a deplorable range of side effects, which can include nerve damage, hair loss and 
nausea. Disappointingly however, the countless clinical candidates in fifty years later, 
there have only been two more worldwide drug approvals for precious metal-containing 
anticancer drugs: carboplatin and oxaliplatin, both of which are direct analogues of 
cisplatin, approved in 1993 and 2002 respectively.  
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The mode of action of these platinum complexes is known: the chloride or dicarboxylate 
ligands are hydrolysed within the cell to generate a bis-aqua species, which binds 
irreversibly to DNA – usually to two adjacent guanine bases [65] and the cell, unable to 
replicate, defaults to apoptosis (controlled cell death) [66]. Within the extracellular milieu 
the physiological chloride ion concentration is ca. 100 mM, while inside cells it is ca. 4 
mM.  These conditions facilitate the aquation of cisplatin (Figure 2.1).  The aquated 
species would then easily react with the target molecule, DNA [67,68].  The binding of 
metal species to DNA is known to occur in two steps, leading to formation of two forms 
of adducts; intra-strand and inter-strand cross-links.  The formation of these adducts then 
blocks DNA transcription and replication causing repair (NER) pathway that would 
repair DNA damage [69].  However, DNA damage caused by cisplatin adducts is very 
poorly repaired in cells.  This is due to the fact that it induced intra-strand cross-links 
serve as binding targets for high-mobility-group proteins (HMG) [70] because of 
structural similarity between these intra-strand cross-links and the cells to undergo G2 
cell-cycle arrest.  Under normal circumstances a nucleotide cutting out the distortion in 
DNA structure, hence inhibiting DNA repair [67,70] 
Platinum-containing compounds such as cisplatin, carboplatin and oxaliplatin are widely 
used in the treatment of a variety of cancers. Newer, second generation platinum 
compounds like carboplatin and oxaliplatin were designed to improve efficacy 
particularly against cell lines that demonstrate second pass cisplatin resistance [71]. 
Tolerance to cisplatin-induced DNA damage has been suggested as a fundamental 
mechanism of drug resistance [72]. 
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Figure 2.1. Schematic representation of how cisplatin is activated and subsequently bind to DNA 
 
In the early 1980s, the rapidly emergent interest as well as demand has enthused for the 
design of alternative platinum and non-platinum-based anticancer agents in cancer 
chemotherapy in order to overcome both intrinsic and acquired resistance in cancer cell 
lines. Consequently, in recent years the interest in non-platinum metal complexes for 
cancer chemotherapy has been rapidly growing. Such consideration has further been 
stimulated by the possibility of developing new agents with a different mode of action 
and clinical profile from the well-established platinum based metallodrugs [73]. 
To circumvent the problem of drug-resistance in cisplatin-resistant cells, gold(III)-based 
complexes have been designed as a potential alternative to cisplatin [74,75]. Gold(III) 
complexes exhibit iso-electronic and iso-structural features with platinum(II) and have 
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similar uptake and DNA interference activity [75]. In addition, the higher charge of 
gold(III) compared to platinum(II) is an added  advantage for binding with DNA [76]. 
Among the several classes of metal complexes that have been taken into consideration as 
potential anticancer agents starting from the 1980‘s, only a few investigations have 
focused on d
8
 square planar gold(III) complexes in spite of their stringent similarity to 
platinum(II) complexes [77-81]. 
During the 1990s, the gold(III) compounds  emerged as potential anticancer agents 
showing improved stability both in solid and solution phases, lower toxicity and 
favorable in-vitro pharmacological profiles. For example in 1996, Parish, Buckley, 
reported a series of cytotoxic gold(III) compounds with damp ligands [damp = 
(dimethylamino)methyl]phenyl)] with encouraging results towards the anticancer activity 
(Figure 2.2)[82].  [(damp)AuCl2] has been tested in Vitro against a range of microbial 
strains and several human tumor lines, where it displays differential cytotoxicity similar 
to that of cisplatin against the ZR-75-1 human tumor xenograft [82].  
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Figure 2.2 Structure of [(damp)AuCl2] 
 
AuNaphth1 (Figure 2.3) is a gold(I) species, which contains the triethylphosphine moiety 
of auranofin and a naphthalimide ligand replacing the carbohydrate ligand of auranofin 
[83]. The drug design strategy for this novel gold complex was motivated by the aim to 
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replace the auranofin carbohydrate ligand, which is supposedly more relevant for the 
biodistribution of the compound than for its pharmacodynamic effects, by another 
bioactive ligand. As bioactive ligand the naphthalimide moiety was chosen based on the 
promising preclinical results of the naphthalimide class of antitumor drugs [84]. 
AuNaphth1 displayed promising cell growth inhibiting effects, induced apoptosis and 
inhibited Thioredoxin reductases (TR, TrxR). Mass spectrometric investigations on a 
cysteine containing model peptide showed that AuNaphth1 bound covalently to the 
cysteine residue under loss of its thionaphthalimide ligand, which indicates that the 
interaction with TrxR might also be based on a covalent binding mechanism. 
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Figure 2.3 Structure of Au-Napth-1 complex 
 
Exceptional biological properties have also been reported recently for gold phosphole 
complexes. These gold agents are characterized by a phosphacyclopentadiene ligand 
attached to the central metal and are potent inhibitors of TrxR and the related glutathione 
reductase. The complexGoPI (Figure 2.4) shows IC50values for enzyme inhibition in the 
low nanomolar range and is probably the most potent inhibitor of glutathione reductase 
reported so far [85,86]. 
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Figure 2.4 Structure of gold phosphole complex GoPI 
 
In this context, [Au(dppe)2]
+
 and its analogues (Figure 2.5) belong to the group of 
delocalized lipophilic cations (DLCs), which can pass through cellular membranes and 
accumulate in the mitochondria. Consequently, the lipophilicity of the compounds is a 
very important parameter in optimizing the biodistribution and activity. Structurally 
related bidentate phenyl and pyridyl phosphine complexes showed activity against 
cisplatin-resistant human ovarian cancer cells. Concerning the cytotoxicity the phenyland 
2-pyridyl analogues were superior to the 3- and 4-pyridyl complexes.  During exposure to 
the dinuclear 2-pyridyl derivative SMIV gold was mainly found in the mitochondrial 
fractions of CH1 cells compared to nuclear and cytosolic fractions highlighting the 
special role ofmitochondria for the antitumor potency of gold compounds. Interestingly, 
the in vitro hepatotoxicity of the complexes correlates with the lipophilicity and cellular 
uptake of the agents. The authors concluded that complexes with a medium lipophilicity 
might be optimal for further development [87,88]. 
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Figure 2.5 Schematic drawing of Au(I) complexes with multiple phosphine ligands 
 
The [Au(dppe)2]
+
 propylene analogue [Au(d2pypp)2]Cl showed selectivity against cancer 
cells in comparative experiments using normal and cancer breast cells and selectively 
induced apoptosis in breast cancer cells but not in normal cells. Apoptosis was induced 
via the mitochondrial pathway involving mitochondrial membrane potential 
depolarisation, depletion of the glutathione pool and caspase3 and caspase9 activation. 
The accumulation in the mitochondria was confirmed for the compound. Furthermore, 
the complex inhibited both thioredoxin and thioredoxin reductase activities [89,91]. 
The mixed-ligands gold phosphine compound chlorotriphenylphosphine1,3-
bis(diphenylphosphino)propanegold(I) [Au(dppp)(PPh3)Cl] was investigated in the 
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national cancer institute (NCI) 60 cell panel screening and showed median Lethal 
Dose(LC50) values in the low micromolar range in 29 cell lines. The 
resultsweremostmarked inMCF7 breast cancer cells with theLC50 value being below the 
lowest test concentration used (0.01mM). Unexpectedly, the compound was not active in 
leukemia cells [91]. Further studies on this agent were performed on a panel of human 
melanoma cell lines, in which the complex displayed IC50 values in the low micromolar 
range. An apoptotic response was noted with alterations in the nuclear morphology, loss 
of mitochondrial membrane potential, cytochrome C and Smac/DIABLO release from 
mitochondria into cytosol and enhanced caspase9 and caspase3 catalytic activity as well 
as a decreased expression of antiapoptotic proteins [92]. However, [Au(dppp)(PPh3)Cl] 
decomposes in solution under formation of monoand dinuclear complexes making the 
nature of the pharmacologically active species unclear [93].  
The dinuclear cationic complex [{AuCl(PPh3)}2(µ2-DIPHOS)] is the unexpected 
outcome of a study aiming at developing an ethylene analogue of [Au(dppp)(PPh3)Cl]. 
[{AuCl(PPh3)}2(µ2-DIPHOS)]showed activity against JR8, SKMel5 and 2/60 melanoma 
cell lines, however, it was less effective than [Au(DPPP)(PPh3)Cl] [93]. Four phosphine 
ligands at the gold center are realized in tetrakis((trishydroxymethyl)phosphine)gold(I) 
chloride [Au(P(CH2OH)3)4]Cl. The compound showed excellent activities (with IC50 
values in the low nanomolar range!) against prostate cancer, gastrointestinal and 
coloncarcinoma cells and prolonged the G1 phase of the cell cycle. In vivo studies in 
mice confirmed the positive results from the in vitro experiments showing a significantly 
prolonged survival of treated mice compared to the untreated control [94]. These and 
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preliminary pharmacokinetic data in dogs suggested the further development of the agent 
in clinical phase I trials [95]. 
Various other gold(I) species showed promising bioactivities. Some relevant examples 
are shown in Figure 2.6. IC50 values in the low micromolar range were obtained with 
triphenylphosphinegold(I) complexes with different sulfanylpropenoate ligands in Hela 
and A2780 cells (see [Au(PPh3)(HCLpspa) in Figure 2.6 for a relevant example).  The 
free ligands were devoid of activity [96].  The gold(I) 7-azacoumarin species 
[Au(TS)(PEt3)] displayed superior cytotoxic effects compared to cisplatin in A2780 cells 
and was also strongly active in a cisplatin-resistant variant of the cell line [97]. Similar 
results had been observed with the vitamin K3 derivative [AuPEt3(K3TSC)], which 
represents the first gold(I) complex with a thiosemicarbazone ligand [98]. 
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Figure 2.6 Structures of various bioactive gold(I) species 
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Et3PAu(S2CNEt2) was the most active agent within a series of dithiocarbamate and 
xanthatecomplexes in a panel of seven human cancer cell lines [99]. Water soluble 
cyclodiphosphazane gold(I) complexes exhibited antiproliferative effects in cultured 
HeLa cells, induced apoptosis and activated the p53 protein [100]. 
A series of cationic gold complexes with multidentate ligands, namely [Au(phen)Cl2]Cl, 
[Au(terpy)Cl]Cl2, [AuCl(dien)]Cl2, [Au(cyclam)](ClO4)2Cl and [Au(en)2]Cl3(Figure 2.7), 
showed reasonable stability in physiological like environment. The coordination to the 
polyamine ligands caused a marked stabilization of gold in the 3+ oxidation state as 
indicated by measurements of the reduction potentials. The stabilization was less evident 
for the less basic phenanthrene and terpyridine ligands. With exception of the cylam 
species [Au(cyclam)](ClO4)2Cl, all complexes exhibited good cytotoxic activities in 
A2780 human ovarian cancer cells. Furthermore, results obtained in cisplatin-resistant 
A2780 cells indicated that the compounds might overcome resistance phenomena. The 
free ligands were also investigated in the same assay. Whereas the free ethylenediamine 
derived ligands were devoid of any activity, the potency of free phenanthrene and 
terpyridine was comparable to that of the respective gold(III) complexes making the 
results of these two compounds difficult to interprete. Overall this study pointed out that 
the cytotoxicity of the ethylenediamine derived complexes was related to the presence of 
the gold(III) central atom, the activity was not related to good leaving groups (such as 
chlorine), no direct correlation of the antiproliferative effects and the reduction potentials 
was present and the strong stabilization of the gold(III) center led to a loss of activity (as 
indicated by the results with [Au(cyclam)](ClO4)2Cl.  For the compounds 
[Au(phen)Cl2]Cl and [Au(terpy)Cl]Cl2, which had also shown good stability under 
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physiological conditions, an easy reduction was observed in the presence of ascorbate or 
thiosulfate. This indicates that for these two complexes the release of their toxic ligands 
upon in vivo reduction might be the reason for the bioactivity [101] 
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Figure 2.7 Schematic drawings of gold(III) complexes with Au-N bond 
 
Gold(III) tetraarylporphyrins exhibited excellent cytotoxic activities mediated by 
apoptotic pathways [102]. Detailed pharmacological studies have been performed on 
gold(III) porphyrin 1a (Figure 2.8). It was found that the apoptosis inducing effects were 
related to caspase-dependent and caspase-independent mitochondrial pathways including 
the activation of caspase3 and caspase9.  Gold(III) porphyrin 1a treatment led to the 
release of cytochrome C, which itself activated caspase3 and caspase9 [103]. A 
proteomic analysis indicated the involvement of multiple pathways and showed that 
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cellular structure and stress related chaperone proteins, proteins involved in the formation 
of reactive oxygen species, proteins related to cell proliferation and others were in the 
altered clusters [104]. The toxicity of the porphyrin complex was not related to 
phototoxicity, it interacted with the DNA in a non-covalent manner and partly abrogated 
the cell cycle at G(0)–G(1).  The effects on apoptosis and on the cell cycle were 
dependent [105].More detailed studies on the mechanisms underlying the induction of 
apoptosis revealed that the mitogen activated protein kinases p38MAPK and ERK were 
transiently activated upon exposure to gold(III) porphyrin 1a, multiple phosphotyrosine 
proteins (namely cytoskeleton and cytoskeleton like proteins, kinase proteins and proteins 
involved in signal transduction)were involved in apoptosis related to p38MAPK and 
mitochondrial permeabilisation played an important role [106]. In a rat hepatocellular 
carcinoma model gold(III) porphyrin 1a significantly prolonged survival but did not lead 
to a drop down of the body weight of the rats or affected the plasma aspartate 
aminotransferase level. Furthermore, it induced necrosis and apoptosis in the tumor tissue 
but not in normal liver tissue [107]. 
N Au N
N
N
 
Figure 2.8 Schematic drawing of gold(III) porphyrin 1acomplex with Au-N bond 
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Bertrand et al. recently evaluated gold(I) derivatives of new caffeine-based gold(I) NHC 
complexes based on xanthine ligands (Figure 2.9) for their antiproliferative activities in 
different cancerous and nontumorigenic cell lines in vitro [108].  The bis-carbene 
caffeine-based complex [Au(MC)2][BF4] (4) has shown interesting anticancer properties 
in vitro against the human ovarian cancer cell line A2780 and its cisplatin resistant 
variant A2780/R, though it appeared to be poorly toxic in non cancerous HEK-293T cells 
in vitro, as well as in healthy tissues ex vivo. This latter result is of particular importance 
for the future development of new metallodrugs with reduced side-effects. 
 
Figure 2.9 Schematic drawings of caffeine-based gold(I) N-heterocyclic carbenes complexes 
 
27 
 
Also, Messori et al. described remarkable anticancer properties in vitro for two novel 
gold carbene compounds, namely, chlorido (1-butyl-3-methylimidazole-2-ylidene) 
gold(I) (1) and bis(1-butyl-3-methyl-imidazole-2-ylidene) gold(I) (2) (Figure 2.10).  Both 
compounds show a high stability in physiological-like media with no evidence of NHC or 
chloride detachment even over long observation times or upon challenging them with 
ascorbic acid or GSH. Notably, both complexes manifested similar and very pronounced 
antiproliferative effects toward the reference cancer cell line A2780; cisplatin resistance 
was completely overcome [109]. 
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Figure 2.10 Schematic drawings of gold(I) carbene complexes 
 
It is now a quite accepted opinion that the remarkable cytotoxic effects documented for 
several gold compounds are mainly the consequence of metalation and inactivation of 
selected crucial proteins [110]. In contrast to the availability of such diverse 
anticanceragents as mentioned above, gastric and prostate cancer inhibiting gold(III) 
agents have rarely been explored. 
Maiore et al. recently evaluated gold(III) derivatives of 2-substituted pyridines for their 
biological and pharmacological behavior [110]. Palanichamy et al. identified four 
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gold(III) compounds, [Au(Phen)Cl2]PF6, and its derivatives, exhibiting anticancer activity 
in both cisplatin sensitive and cisplatin resistant ovarian cancer cells [111].  Gabbiani et 
al. described remarkable anticancer properties in vitro for Au(III)bipy and Auoxo6 
compounds [112]. Kouodom et al. suggested rational design of gold(III)-dithiocarbamato 
peptidomimetics for the targeted anticancer chemotherapy [113].  Lessa et al. reported 
gold(I) and gold(III) complexes with glyoxaldehyde bis(thiosemicarbazones) as cytotoxic 
agents against human tumor cell lines and inhibition of thioredoxin reductase activity 
[114].In this connection, an attractive strategy has astutely been designed to regulate the 
chemical and physical behavior of biologically pertinent tetra-coordinate gold(III) 
complexes. Such concept is executed by inclusion of appropriate bidentate ligands in the 
well-known gold(III) complexes having anticancer properties. 
Dithiocarbamates are versatile ligands capable of forming complexes with most of the 
elements and able to stabilize transition metals in a variety of oxidation states [115]. This 
property of stabilizing high oxidation states in metal complexes reflects strong s-bonding 
characteristic of these ligands.  Although the sulphur atoms of dithiocarbamato ligands 
possess s-donor and n-back-donation characteristics of the same order of magnitude, 
these ligands have a special feature in that there is an additional n-electron flow from 
nitrogen to sulphur via a planar delocalized π- orbital system.  This effect results in strong 
electron donation and hence a high electron density on the metal leading to its next higher 
oxidation state [116]. While dithiocarbamate complexes have been known for over a 
century, with many thousands having been prepared, the vast majority of these contain 
only simple alkyl substituents such as methyl and ethyl. A developing interest in the area 
of dithiocarbamate chemistry is the functionalization of the backbone such that new 
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applications and interactions can be developed. This area is still in its early stages but 
already interesting potential applications.  Dithiocarbamates are a class of metal-
chelating, antioxidant compounds with various applications in medicine for the treatment 
of bacterial and fungal infections, and possible treatment of AIDS [117-119]. 
It is known that amines react with CS2 forming dithiocarbamates [120-125]. Recently, 
Yavari et al. [126] have reported new synthetic strategies to prepare dithiocarbamates due 
to their large application potential. Dithiocarbamates exhibit numerous biological 
activities [127-130] and they are used in agriculture [130-132] and as linkers in solid-
phase organic synthesis [133-135]. Further, dithiocarbamates are also widely used in 
medicinal chemistry and they have found application in cancer therapy [136,138]. 
Gold(III)-dithiocarbamato derivatives have been designed as potential anticancer agents, 
showing promising and outstanding properties [139,140]. In particular, the choice of 
dithiocarbamates as ligands was driven by their potential chemoprotective action toward 
renal toxicity, a major limiting factor in the use of platinum-based therapeutics in the 
clinic. Strong and irreversible binding of platinum to sulfur-containing biomolecules 
(including thiol groups of renal enzymes) is believed to alter the conformation of the 
biomolecules themselves and to lead to substantial changes of their biological functions 
up to inactivation, thus inducing gastro-, nephro-, and bone marrow toxicity [141–143].  
The accurate use and dosing of sodium diethyldithiocarbamate was proved successful in 
reducing cisplatin nephrotoxicity without decreasing its antitumor properties [144]. On 
the other hand, the overall nephroprotective benefits were somewhat limited by the acute 
toxicity profile, especially at neuronal level, exhibited by the free (i.e. not coordinated) 
dithiocarbamate [145]. Consequently, the design of metal-dithiocarbamato derivatives 
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has potential owing to the combination of the cytotoxicity of the metal center with the 
chemoprotective activity of the dithiocarbamato ligand, thus resulting in anticancer 
agents with high antiproliferative activity as well as reduced toxic side-effects. Moreover, 
along with the prevention of the intrinsic toxicity of the free dithiocarbamate, in the case 
of gold(III) complexes the chelating effect of the dithiocarbamato moiety is likely to 
stabilize the metal center in the +3 oxidation state, thus preventing reduction to gold(I) 
species or metallic gold (a well-known drawback of gold(III) derivatives often occurring 
under the normally reducing physiological conditions) [146]. 
Such optimistic literature reports on Au(III) complexes prompted us to carry out the 
synthesis of a number of mixed-ligand complexes [Au(diamine)Cl2]
+
 with thiones such as 
Imt, Diaz and Diap. Accordingly, we have synthesized mixed ligand gold(III) complexes 
by using different diamines and thiones.  These complexes have been characterized by 
CHNS analysis, Solid state IR and solid as well as solution NMR spectroscopic methods.  
Finally, the prepared Au(III)-thione complexes have also been evaluated in vitro as 
cytotoxic agents against C6 glioma cancer cell line. 
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3 CHAPTER 3 
OBJECTIVES 
The aim of this research is to synthesize new gold(III) complexes as potential anticancer 
agents. The main goals of the research work are as follows: 
3.1 Synthesis of Dithiocarbamate Ligands 
3.1.1 Synthesis of Ammonium Dithiocarbamate 
The un-substituted and mono/dialkylsubstituted diamines were used to synthesize the 
ammonium dithiocarbamate ligands.  Their structures are shown in Figure 3.1. 
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Figure 3.1 Structures of ammonium dithiocarbamate ligands 
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3.1.2 Synthesis of 2-Cyclohexanaminium dithiocarbamate 
Several of 1,2-Diaminecyclohexane were used to synthesize 2-cyclohexanaminium 
dithiocarbamate ligands.  Their structures are shown in Figure 3.2.  
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Figure 3.2 Structures 2-cyclohexanaminium dithiocarbamate ligands 
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3.1.3 Synthesis of 2-Mercaptobenzimidazole 
The un-substituted and substituted o-phylenediamines were used to synthesize various 2-
mercaptobenzimidazole (2-MBI) ligands. Their chemical structures are shown in Figure 
3.3. 
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Figure 3.3 Structures of 2-mercaptobenzimidazole ligands 
 
3.2 Synthesis of Chlorido(phosphane)gold(I) Complexes 
 
Various phospine shown in Figure 3.4 were used to synthesize the following 
chlridophosphane gold(I) complexes:  
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 R1 = Me,   R2 = Me,     R3 = Me           (24)
 R1 = Et,     R2 = Et,      R3 = Et             (25)
 R1 = i-Pr,   R2 = i-Pr,   R3 = i-Pr           (26)
 R1 = Ph,     R2 = Ph,    R3 = Cy             (27)
 R1 = Ph,     R2 = Ph,    R3 = Et              (28)
 R1 = Ph,     R2 = R3 = (NCCH2CH2)    (29)
 R1 =  R2 =  R3 = (NCCH2CH2)             (30)
Ph = Cy =
 R' = H                     (31)
 R' = p-CH3              (32)
 R' = m-CH3             (33)
 R' = o-CH3              (34)
 R' = p-OCH3           (35)
AuP
R3
R1
R2 Cl
R'
P Au
3
Cl
Chlorido Phosphane gold(I)
HAuCl3.3H2O
i)  Thiodiglycol, H2O/Acetone, 0-5 
o
C
ii) R3P/Acetone
 
Figure 3.4 Structures of phosphanegold(I) chloride complexes 
 
3.3 Synthesis of Dichlorido(1,2-diaminocylohexane)gold(III) Chloride 
Complexes 
Various isomers of 1,2-diaminocyclohexane (1,2-DACH) shown in Figure 3.5 were used 
to synthesize the followingdichlorido-1.2-(DACH)gold(III)chloride complexes: 
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Figure 3.5 Structures of dichlorido1,2-diaminocyclohexane gold(III) chloride complexes 
 
3.4 Synthesis of Azanechlorido(1,2-Diaminocyclohexane)gold(III) 
Chloride Complexes 
Various 1,2-diaminocyclohexane gold(III) chloride were used to synthesize newazane 
chlorido(1,2-diaminocyclohexanegold(III)chloride[1,2-
(DACH)Au(III)(NH3)Cl]Cl2complexes as shown in Figure 3.6. 
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Figure 3.6 Structures of azane chlorido 1,2-diaminocyclohexane gold(III) chloride complexes 
 
3.5 Synthesis of Diazane(1,2-diaminocyclohexane)gold(III) Chloride 
Complexes 
Dichlorido(1,2-diaminocyclohexane)gold(III) chloride were used to synthesize a new 
diazane(1,2-diaminocyclohexane)gold(III) chloride complexes [1,2-
(DACH)Au(III)(NH3)2]Cl3 complexes as shown in Figure 3.7. 
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Figure 3.7 Structures of diazane 1,2-diaminocyclohexane gold(III) chloride complexes 
 
3.6 Synthesis of Bis(1,2-Diaminocyclohexane)gold(III)Chloride 
Complexes 
Various 1,2-diaminocyclohexane were used to synthesize the bis(1,2-
diaminocyclohexane)gold(III)chloride complexes as shown in Figure 3.8. 
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Figure 3.8 Predicted structure of the synthesized bis(1,2-diaminocyclohexane)gold(III) chloride complexes 
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3.7 Synthesis of 1,2-Diaminocyclohexane(ethylenediamine)gold(III) 
Chloride Complexes 
Various 1,2-diaminocyclohexane,ethylenediamine and NaAuCl4.2H2O with were used to 
synthesize the 1,2-diaminocyclohexane(ethylenediamine)gold(III) chloride complexes as 
shown in Figure 3.9. 
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Figure 3.9 Predicted chemical structure of 1,2-diaminocyclohexane(ethylenediamine)gold(III)chloride complexes 
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3.8 Synthesis of 1,2-Diaminocyclohexane(propylenediamine)gold(III) 
Chloride Complexes 
Various 1,2-diaminocyclohexane,propylenediamine and NaAuCl4.2H2O with were used to 
synthesize the 1,2-diaminocyclohexane(propylenediamine)gold(III) chloride complexes as 
shown in Figure 3.10. 
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Figure 3.10 Predicted chemical structure of 1,2-diaminocyclohexane(propylenediamine)gold(III) chloride complexes 
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3.9 Synthesis of Ammoniumdithiocarbamatodichloridogold(III) 
Chloride Complexes 
Synthesizedammoniumdithiocarbamate ligands were used to synthesize 
ammoniumdithiocarbamatodichloridogold(III) chloridecomplexes as shown in Figure 3.11.  
CS2
CHCl3, RT, 24 hrs.
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[(2-Ammonioethyl)-Ethyl-DTC-Au(III)Cl2]Cl (58) [(2-Ammonioethyl)-i-Propyl-DTC-Au(III)Cl2]Cl (59)
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Figure 3.11 Chemical structure of ammoniumdithiocarbamato(dichlorido)gold(III) chloride complexes 
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3.10 Synthesis of Dichlorido(2-
cyclohexanaminiumdithiocarbamato)gold(III) Chloride 
Complexes 
2-Cyclohexanaminium dithiocarbamate ligands were used to synthesize dichlorido(2-
cyclohexanaminiumdithiocarbamato)gold(III) chloride complexes as shown in Figure 3.12.  
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Figure 3.12 Chemical structure of dichlorido(2-cyclohexanaminiumdithiocarbamato)gold(III)chloride complexes 
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3.11 Synthesis of Mixed-LigandDithiocarbamatophosphanegold(I) 
Complexes 
Various chloridotrialkylphosphanegold(I) with n,n´-di-alkyl-dithiocarbamate were used to 
synthesize dithiocarbamatophosphanegold(I) complexes as shown in Figure 3.13.  
R1 = Me,   R2 = Me,    R3 = Me,         R'1 = Me  (70)
R1 = Me,   R2 = Me,    R3 = Me,         R'1 = Et    (71)
R1 = Et,     R2 = Et,     R3 = Et,           R'1 = Me  (72)
R1 = Et,     R2 = Et,     R3 = Et,           R'1 = Et    (73)
R1 = i-Pr,   R2 = i-Pr,  R3 = i-Pr,         R'1 = Me   (74)
R1 = i-Pr,   R2 = i-Pr,  R3 = i-Pr,         R'1 = Et     (75)
R1 = Ph,     R2 = Ph,    R3 = Cy,          R'1 = Me   (76)
R1 = Ph,     R2 = Ph,    R3 = Cy,          R'1 = Et     (77)
R1 = Ph,     R2 = Ph,    R3 = Et,           R'1 = Me   (78)
R1 = Ph,     R2 = Ph,    R3 = Et,           R'1 = Et     (78)
R1 = Ph,     R2 = R3 = (NCCH2CH2), R'1 = Me   (80)
R1 = Ph,     R2 = R3 = (NCCH2CH2), R'1 = Et     (81)
R1 =  R2 = R3 = (NCCH2CH2),           R'1 = Me   (82)
R1 =  R2 = R3 = (NCCH2CH2),           R'1 = Et     (83)
P Au S
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S
P Au Cl
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NaSCSN(R'1)2
MeOH
R' = H,               R1=Me  (84)
R' = H,               R1=Et   (85)
R' = p-CH3,       R1=Me  (86)
R' = p-CH3,       R1=Et   (87)
R' = m-CH3,      R1=Me  (88)
R'
P Au
3
S
N
R1S
R1
R' = m-CH3,      R1=Et   (89)
R' = o-CH3,       R1=Me  (90)
R' = o-CH3,       R1=Et   (91)
R' = p-OCH3,    R1=Me  (92)
R' = p-OCH3,    R1=Et    (93  
Figure 3.13 Chemical structure of dithiocarbamato(trialkylphosphane)gold(I) complexes 
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3.12 Synthesis of Mixed-Ligand 5-Methyl-2-
mercaptobenzimidazolo(phosphane)gold(I) Complexes 
Various chloridophosphanegold(I) with 5-methyl-2-mercaptobenzimidazole were used to 
synthesize 5-methyl-2-mercaptobenzimidazolo(phosphane)gold(I) complexes as shown in 
Figure 3.14.  
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R1 = Me,    R2 = Me,  R3 = Me    (94)
R1 = Et,      R2 = Et,    R3 = Et     (95)
R1 = Ph,     R2 = Ph,    R3 = Ph    (96)
N
H
N
SH
i)  KOH (aq)
ii) (R1R2R3)3PAuCl, MeOH
R1 = Ph,     R2 = Ph,    R3 = Et     (97)
R1 = t-Bu,  R2 = t-Bu,  R3 = t-Bu (98)
R1 = i-Pr,   R2 = i-Pr,   R3 = i-Pr   (99)
RT, 2 hrs
 
Figure 3.14 Chemical structure of 5-methyl-2-mercaptobenzimidazolo(phosphane)gold(I)complexes 
 
3.13 Synthesis of Mixed-Ligand Substituted 2-
mercaptobenzimidazolo(trimethylphosphane)gold(I) Complexes 
Various substituted 2-mercaptobenzimidazole with chloridotrimethylphosphanegold(I) 
were used to synthesize substituted 2-mercaptobenzimidazolo(trimethylphosphane)gold(I) 
complexes as shown in Figure 3.15.  
47 
 
 
R1
R2
R3
N
H
N
S
R1 = H,        R2 = H,        R3 = H   (100)
R1 = H,        R2 = F,        R3 = H   (101)
R1 = H,        R2 = Cl,       R3 = H   (102)
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P
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H
N
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i)  KOH (aq)
ii) (Me)3PAuCl, MeOH RT, 2 hrs
R2
R1
R1 = H,        R2 = Cl,       R3 = Cl  (103)
R1 = NO2,   R2 = H,        R3 = H   (104)
R1 = H,        R2 = NO2    R3 = H   (105)  
Figure 3.15 Chemical structure of 5-methyl-2-mercaptobenzimidazolo(phosphane)gold(I) complexes 
 
3.14 Synthesis of Mixed-Ligand4-Nitro-2-
mercaptobenzimidazolo(phosphane)gold(I) Complexes 
Various chloridophosphanegold(I) with 4-nitro-2-mercaptobenzimidazole were used to 
synthesize 4-nitro-2-mercaptobenzimidazolo(phosphane)gold(I) complexes as shown in 
Figure 3.16.  
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R1 = t-Bu,  R2 = t-Bu,  R3 = t-Bu  (110)
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Figure 3.16 Chemical structure of 4-nitro-2-mercaptobenzimidazolo(phosphane)gold(I) complexes 
 
3.15 Synthesis of Mixed-Ligand 5-Nitro-2-
mercaptobenzimidazolo(phosphane)gold(I) Complexes 
Various chloridophosphanegold(I) with 5-nitro-2-mercaptobenzimidazole were used to 
synthesize 5-nitro-2-mercaptobenzimidazolo(phosphane)gold(I)complexes as shown in 
Figure 3.17.  
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Figure 3.17 Chemical structure of 5-nitro-2-mercaptobenzimidazolo(phosphane)gold(I) complexes 
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3.16 Synthesis of Substituted 2-Mercaptobenzimidazolo1,3-Bis(2,6-di-
isopropylphenyl)imidazol-2-ylidene Gold(I) Complexes 
Various substituted 2-mercaptobenzimidazole withchlorido1,3-bis(2,6-di-
isopropylphenyl)imidazol-2-ylidene gold(I) were used to synthesize substituted IPr 2-
mercaptobenzimidazolo gold(I) (IPr = 1,3-bis(2,6-di-isopropylphenyl)imidazol-2-ylidene) 
as shown in Figure 3.18.  
NN
(Z)
Au
i-Pr
i-Pr
i-Pr
i-Pr
S
R1 = H,        R2 = H,        R3 = H   (116)
R1 = H,        R2 = CH3,   R3 = H   (117)
R1 = H,        R2 = F,        R3 = H   (118)
R1 = H,        R2 = Cl,       R3 = H   (119)
R1 = H,        R2 = Cl,       R3 = Cl  (120)
R1 = NO2,   R2 = H,        R3 = H   (121)
R1 = H,        R2 = NO2    R3 = H   (122)
N
H
N
R1 R2
R3
 
Figure 3.18 Chemical structure ofIPr(2-mercaptobenzimidazolo)gold(I) complexes 
 
3.17 Synthesis of Dinuclear2-MBI{1,3-
bis(diphenylphosphino)methane}gold(I)Complexes 
Various substituted 2-mercaptobenzimidazole with dichlorido1,3-
bis(diphenylphosphino)methane gold(I) were used to synthesizedinucleardinuclear2-
MBI{1,3-bis(diphenylphosphino)methane}gold(I) complexes as shown in Figure 3.19.  
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Figure 3.19 Chemical structure of dinuclear2-MBI{1,3-bis(diphenylphosphino)methane}gold(I)complexes 
 
3.18 Characterization of GoldComplexes 
The complexes (1)-(129) were characterized by melting point (MP) and elemental analysis 
techniques. 
3.19 Structural Analysis of GoldComplexes 
The complexes werethen structurally analyzed by Mid Infrared (MIR), Far Infrared (FIR) 
and Ultra-Violet (UV)/Visible (Vis) spectroscopic methods; 
1
H, 
13
C, 
15
N solution and
13
C 
solid state Nuclear Magnetic Resonance (NMR) measurements. X-ray crystallography 
was employed for structure determination of crystalline complexes. 
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3.20 Study of Anticancer Properties of Gold Complexes 
The anticancer properties of gold complexes were studied in-vitro against a panel of 
human cancer cell lines in order to evaluate their potential as possible anticancer agents. 
3.21 Study of Electrochemical Properties of Gold Complexes 
The cyclic voltammetry behaviors of gold complexes were studied to determine the 
complexes‘ reduction potentialsin order to evaluate their stabilities. 
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4 CHAPTER 4 
EXPERIMENTAL 
4.1 Chemicals 
HAuCl4·3H2O was obtained from Strem Chemicals Co., while acetone, absolute ethanol, 
acetonitrile, D2O and CD3OD were obtained from Fluka Chemicals Co. 1,2-
Diaminoethane, 1,3-Diaminopropane, 1,4-Diaminobutane, N-ethyl-1,2-diaminoethane, 
N-propyl-1,2-diaminoethane and N-isopropyl-1,2-diaminoethane were purchased from 
Sigma Aldrich. N,N΄-dimethyl-1,2-diaminoethane, N,N΄-diethyl-1,2-diaminoethane, 
N,N΄-dipropyl-1,2-diaminoethane and N,N΄-diisopropyl-1,2-diaminoethane were 
obtained from Alfa Aesar. 
Imidazole, L-histidine and L-glycine were obtained from Sigma-Aldrich, L-
13
C3-cysteine 
and L- methioninewere obtained from Isotech, USA. Sodium tetrachloroaurate (III) 
dihydrate, Imidazolidine-2-thione (Imt), 1,3-Diazinane-2-thione (Diaz), 1,3-Diazipane-2-
thione (Diap), Imidazole, were purchased from Sigma-Aldrich. 
Potassium cyanide was purchased from Fisher Scientific Co. Potassium thiocynate was 
obtained from J. T. Baker Chemicals Co. The 
15
N label diamines ligands and 
15
N and 
13
C 
label potassium cyanide were obtained from Cambridge Isotope Labs, USA. All other 
reagents as well as solvents were obtained from Aldrich Chemical Co., and used as 
received. 
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4.2 Cell Lines 
Human gastric SGC7901 and prostate PC3 cancer cell lines were provided by American 
Type Culture Collection (ATCC). Cells were cultured in Dulbecco‘s Modified Eagle 
Medium (DMEM) supplemented with 10 % Fetal Calf Serum (FCS), penicillin (100 kU 
L
-1
) and streptomycin (0.1 g L
-1
) at 37 ºC in a 5 % CO2 -95 % air atmosphere. MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) was 
purchased from Sigma Chemical Co, St.Louis, MO, USA. 
4.3 Synthesis of Dithiocarbamate Ligands 
All reactions were generally carried out using research grade chemicals and solvents. All 
ligands were subsequently characterized by melting point (MP) and elemental analysis 
techniques. Elemental analyses were performed on Perkin Elmer Series 11 (CHNS/O), 
Analyzer 2400. Melting points for complexes were carried out on BǕCHI 510 melting 
point apparatus.  
4.3.1 Synthesis of AmmoniumdithiocarbamateLigands 
The synthesis of ammonium dithiocarbamate ligands(1)-(13)were according to a 
modified literature procedure[147], by dissolving of 30 mmol of un-substituted and 
mono/dialkylsubstituted diamines in 70 ml of CHCl3.  In a separate beaker, solution of 
2.6 g (35 mmol) of CS2in 10 ml CHCl3was prepared. The previous solution was added 
dropwise to the later solution at 0 
o
C and stirred for overnight at RTcausing precipitation 
of a white product.  This was filtered and washed with CHCl3(10 mL) and air-dried. The 
product yield was in the range of 91-95 % 
54 
 
Products were characterized by melting point (M.P.) and elemental analysis as given in 
Table 4.1 Melting point and Elemental analysis of ammonium dithiocarbamate 
ligandsand their predicted chemical structures are shown in Figure 3.1. 
 
Table 4.1 Melting point and Elemental analysis of ammonium dithiocarbamate ligands 
Ligand 
M. P. Found (Calculated) % 
(ºC) %C %H %N %S 
(2-Ammonioethyl)-DTC (1) - 26.12(26.45) 5.93(5.92) 20.47(20.56) 47.12(47.07) 
(3-Ammoniopropyl)-DTC (2) - 31.85(31.97) 6.68(6.71) 18.59(18.64) 42.59(42.68) 
(4-Ammoniobutyl)-DTC (3) - 36.34(36.55) 7.12(7.36) 17.12(17.05) 38.94(39.03) 
(2-Ammonioethyl)-Methyl-DTC (4) 142-144 31.87(31.97) 6.62(6.71) 18.59(18.64) 42.75(42.68) 
(2-Ammonioethyl)-Ethyl-DTC (5) 138-140 36.39(36.55) 7.41(7.36) 17.12(17.05) 39.12(39.03) 
(2-Ammonioethyl)-iso-Propyl-DTC (6) 127-129 40.32(40.41) 7.83(7.91) 15.76(15.71) 36.12(35.96) 
Methyl[2-(methylammonio)ethyl]-DTC (7) 149-151 36.37(36.55) 7.42(7.36) 17.09(17.05) 39.11(39.03) 
Ethyl[2-(ethylammonio)ethyl]-DTC (8) 139-141 43.64(43.71) 8.43(8.38) 14.43(14.56) 33.19(33.34) 
n-Propyl[2-(n-propylammonio)ethyl]-DTC (9) 145-147 48.93(49.05) 9.06(9.15) 12.64(12.71) 29.19(29.10) 
iso-Propyl[2-(iso-propylammonio)ethyl]-DTC (10) 139-141 49.12(49.05) 9.11(9.15) 12.77(12.71) 29.16(29.10) 
(3-Ammoniopropyl)methyl-DTC (11) 144-146 36.73(36.55) 7.42(7.36) 17.09(17.05) 39.11(39.03) 
(3-Ammoniopropyl)ethyl-DTC (12) 135-137 40.37(40.41) 7.95(7.91) 15.67(15.71) 35.84(35.96) 
Ethyl[3-(ethylammonio)propyl]-DTC (13) 163-165 46.43(46.56) 8.83(8.79) 13.62(13.57) 31.15(31.08) 
 
4.3.2 Synthesis of 2-Cyclohexanaminium Dithiocarbamate Ligands 
The synthesis of 2-cyclohexanaminium dithiocarbamate ligands(14)-(16)were according 
to a modified literature procedure[147], by dissolving of 3.42 g (30 mmol) of (1,2)-
diaminocyclohexane in 70 ml of CHCl3.  In a separate beaker, solution of 2.6 g (35 
mmol) of CS2in10 ml CHCl3was prepared. The previous solution was added dropwise to 
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the later solution at 0 
o
C and stirred overnight at RT causing precipitation of awhite 
product.  This was filtered and washed with CHCl3(10 mL) and air-dried.The product 
yield was in the range of 91-93 % 
Products were characterized by elemental analysis as given in Table 4.2 Melting point 
and elemental analysis of 2-cyclohexanaminium dithiocarbamate ligands and their 
predicted chemical structures are shown in Figure 3.2. 
Table 4.2 Melting point and elemental analysis of 2-cyclohexanaminium dithiocarbamate ligands 
Complex 
Found (Calculated) % 
%C %H %N %S 
[cis-(1,2)-2-cyclohexanaminium)]-DTC (13) 44.22(44.17) 7.46(7.41) 17.75(14.72) 33.75(33.69) 
[trans-(±)-(1,2)-2-cyclohexanaminium)]-DTC (14) 44.25(44.17) 7.48(7.41) 17.68(14.72) 33.78(33.69) 
[trans-(+)-(1,2)-2-cyclohexanaminium)]-DTC (15) 44.21(44.17) 7.39(7.41) 17.79(14.72) 33.73(33.69) 
 
4.3.3 Synthesis of 2-Mercaptobenzimidazole Ligands 
The synthesis of substituted 2-mercaptobenzimidazole ligands(17)-(23)were according to 
a literature procedure[148], by mixing of 15 mmol of substituted-o-phenylenediamine 
and841 mg (15mmol) of potassium hydroxide with 1.29 g (17mmol) of carbon disulfide 
in50 ml of 95% ethanol and 7 ml of water in a 250 ml round bottom flask heated under 
reflux for 3 hours except complexes (22) and (23) were refluxed for 24 hrs  in presence of 
Et3N as a catalyst.  Then added 1-1.5 g of charcoal cautiously and the mixture is further 
heated at the reflux for 10 minutes the charcoal is removed by filtration. The filtrate is 
heated to 60-70
o
C, 100 ml of warm water is then added and acidified with dilute acetic 
acid with good stirring (pH = 4-5). The product separated as glistening colored crystals.  
The mixture is placed in a refrigerator for overnight to complete the crystallization. The 
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product is collected on a buckner funnel and dried over night at 40
o
C. The dried product 
was recrystallised with ethanol. The product yield was in the range of 90-93 %.  Products 
were characterized by melting point (M.P.) and elemental analysis as given in Table 4.3 
Melting point and elemental analysis of Table 4.3 Melting point and elemental analysis of 
and their predicted chemical structures are shown in Figure 3.3. 
Table 4.3 Melting point and elemental analysis of substituted 2-mercaptobenzimidazole ligands 
Ligand 
M. P. Found (Calculated) % 
(ºC) %C %H %N %S 
2-Mercaptobenzimidazole (17) 303-304 55.72(55.97) 4.09(4.03) 18.53(18.65) 21.29(21.35) 
5-Me-2-Mercaptobenzimidazole (18) 294-296 58.25(58.51) 5.05(4.91) 16.98(17.06) 19.48(19.53) 
5-F-2-Mercaptobenzimidazole (19) 293-294 49.84(49.99) 3.06(3.00) 16.49(16.66) 19.01(19.07) 
5-Cl-2-Mercaptobenzimidazole (20) 308-310 45.22(45.53) 2.81(2.73) 15.05(15.17) 17.28(17.35) 
5,6-di-Cl-2-Mercaptobenzimidazole (21) 244-246 38.25(38.37) 1.89(1.84) 12.68(12.79) 14.78(14.64) 
5-NO2-2-Mercaptobenzimidazole (22) 283-285 43.01(43.07) 2.62(2.58) 21.48(21.53) 16.33(16.43) 
4-NO2-2-Mercaptobenzimidazole (23) 349-351 42.98(43.07) 2.63(2.58) 21.45(21.53) 16.28(16.43) 
 
4.4 Synthesis of Chlorido(phosphane)gold(I) Precursor Complexes 
HAuCl4.3H2O was reduced by thiodiglycol in aqueous acetone. The solution was cooled 
to 0-5 °C and added dropwise to a solution of R3P in acetone. A clear colorless solution 
resulted; this was stirred for 30 min; then the solvent was concentrated by evaporation at 
room temperature. The products of chloridophosphanegold(I) complexes (24)-(35) were 
obtained as a white to cream-colored solid by addition of water and was recrystallized 
from aqueous methanol and dried overnight in a vacuum at 30 
o
C [149].The products 
were in the range 76-93% 
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Products were characterized by elemental analysis as given in Table 4.4 Melting point 
and elemental analysis of chloridophosphanegold(I) complexesand their predicted 
chemical structures are shown in Figure 3.4. 
Table 4.4 Melting point and elemental analysis of chloridophosphanegold(I) complexes 
Complex 
Found (Calculated) % 
%C %H 
(Me)3PAuCl (24) 11.62(11.68) 2.99(2.94) 
(Et)3PAuCl (25) 20.43(20.56) 4.35(4.31) 
(i-Pr)3PAuCl (26) 27.42(27.53) 5.47(5.39) 
(Ph)2(Cy)PAuCl (27) 43.03(43.17) 4.28(4.23) 
(Ph)2(Et)PAuCl (28) 37.52(37.65) 3.43(3.38) 
(Ph)(NCCH2CH2)2PAuCl (29) 32.02(32.13) 2.97(2.92) 
(NCCH2CH2)3PAuCl (30) 25.29(25.40) 2.91(2.84) 
(Ph)3PAuCl (31) 37.43(37.65) 3.44(3.38) 
(p-CH3-Ph)3PAuCl (32) 46.82(46.99) 4.01(3.94) 
(m-CH3-Ph)3PAuCl (33) 46.86(46.99) 4.03(3.94) 
(o-CH3-Ph)3PAuCl (34) 46.79(46.99) 4.04(3.94) 
(p-OCH3-Ph)3PAuCl (35) 42.98(43.13) 3.67(3.62) 
 
4.5 Synthesis of Dichlorido(1,2-diaminocylohexane)gold(III) Chloride 
Complexes 
Gold(III) complexes of cis-1,2-diaminocyclohexane (36), trans-(±)-1,2-
diaminocyclohexane (37) and purely optical active isomer of (S,S)-(+)-1,2-
diaminocyclohexane (38)were synthesized by a general method described in literature for 
similar compounds [150]by dissolving of 199 mg (0.50 mmol) sodium 
tetrachloroaurate(III) dehydrate NaAuCl4·2H2O, in minimum amount of absolute ethanol 
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at ambient temperature. In a separate beaker, solution of 57 mg (0.50 mmol) of the 
diaminocyclohexane in least amount of absolute ethanol was prepared, both solutions 
were mixed (total of 40ml) and stirred for around 30min until clear solution was 
obtained, which was filtered and concentrated to 10 ml solvent then left for crystallization 
in the refrigerator.  The produced solid was dried under vacuum. The product was in the 
range of 91–98% yield. 
Products were characterized by melting point (M.P.) and elemental analysis as given in 
Table 4.5 Melting point and elemental analysis of dichlorido(1,2-
diaminocylohexane)gold(III) chloride complexesand their predicted chemical structures 
are shown in Figure 3.5. 
Table 4.5 Melting point and elemental analysis of dichlorido(1,2-diaminocylohexane)gold(III) chloride complexes 
Complex M. P. (°C) 
Found(Calc.)%     
H C N 
[cis-1,2-(DACH)Au(III)Cl2]Cl (36) 201–206 3.35(3.38) 17.22(17.26) 6.67(6.71) 
[trans-(±)-1,2-(DACH)Au(III)Cl2]Cl (37) 170 deco. 3.32(3.38) 17.21(17.26) 6.68(6.71) 
[(S,S)-(+)-1,2-(DACH)Au(III)Cl2]Cl (38) 174 deco. 3.29(3.38) 17.18(17.26) 6.65(6.71) 
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4.6 Synthesis of Azanechlorido(1,2-Diaminocyclohexane)gold(III) 
Chloride Complexes. 
Azanechlorido(1,2-diaminocyclohexane)gold(III) chloridewere synthesized by dissolving 
209 mg of the correspondingdichlorido 1,2-diaminocyclohexane gold(III) chloride 
complexes [1,2-(DACH)Au(III)Cl2]Cl in 15 ml of methanol.  Then, the solution was 
cooled to 0 °C in ice bath and added dropwise to anaqueous solution of ammonium 
hydroxide [1 eq (0.5 mmol), 8.5 mg of NH3(aq)] in 5 ml of methanol. The solution is 
stirred for 30 min under gentle atmospheric nitrogen. Among the addition of the 
ammonium hydroxide solution, the solution color changed from pale yellow to clear 
orange color. The orange solution is filtered to remove any apparent insoluble impurities, 
and the solvent evaporated to obtain orange solid complexes (39)-(41) which were dried 
overnight in a vacuum. 
Products were characterized by elemental analysis as given inTable 4.6 Elemental 
analysis of azanechlorido(1,2-diaminocyclohexane)gold(III) chloride complexesand their 
predicted chemical structures are shown in Figure 3.6. 
Table 4.6 Elemental analysis of azanechlorido(1,2-diaminocyclohexane)gold(III) chloride complexes 
Complex 
Found(Calc.)%     
H C N 
[cis-1,2-(DACH)Au(III)(NH3)Cl]Cl2 (39) 3.99(3.94) 16.73(16.58) 9.59(9.67) 
[trans-(±)-1,2-(DACH)Au(III)(NH3)Cl]Cl2 (40) 3.96(3.94) 16.71(16.58) 9.61(9.67) 
[(S,S)-(+)-1,2-(DACH)Au(III)(NH3)Cl]Cl2 (41) 3.91(3.94) 16.50(16.58) 9.64(9.67) 
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4.7 Synthesis of Diazane(1,2-diaminocyclohexane)gold(III) Chloride 
Complexes. 
Diazane(1,2-diaminocyclohexane)gold(III) chloride complexes (42-44)were synthesized 
by dissolving 209 mg of the correspondingdichlorido 1,2-diaminocyclohexane gold(III) 
chloride complexes [1,2-(DACH)Au(III)Cl2]Cl in 15 ml of methanol.  Then, the solution 
was cooled to 0 °C in ice bath and added dropwise to a aqueous solution of ammonium 
hydroxide [2 eq (1 mmol), 17 mg of NH3(aq)] in 5 ml of methanol. The solution is stirred 
for 30 min under gentle atmospheric nitrogen flow.  Addition of the ammonium 
hydroxide solution to the precursor gold complex, the solution color changed from pale 
yellow to clear orange color. The solution is filtered to remove any apparent insoluble 
impurities, and the solvent evaporated to obtain orange solid complexes (42)-(44) which 
were dried overnight in vacuum. 
Products were characterized by elemental analysis as given in Table 4.7 Elemental 
analysis of diazane(1,2-diaminocyclohexane)gold(III) chloride complexesand their 
predicted chemical structures are shown in Figure 3.7. 
Table 4.7 Elemental analysis of diazane(1,2-diaminocyclohexane)gold(III) chloride complexes 
Complex 
Found(Calc.)%     
H C N 
[cis-1,2-(DACH)Au(III)(NH3)2]Cl3 (42) 4.51(4.46) 15.83(15.96) 12.54(12.41) 
[trans-(±)-1,2-(DACH)Au(III)(NH3)2]Cl3 (43) 4.50(4.46) 15.79(15.96) 12.52(12.41) 
[(S,S)-(+)-1,2-(DACH)Au(III)(NH3)2]Cl3 (44) 4.49(4.46) 15.89(15.96) 12.49(12.41) 
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4.8 Synthesis of Bis(1,2-Diaminocyclohexane)gold(III) Chloride 
Complexes 
Bis(1,2-DACH)gold(III) chloride complexes of cis-1,2-diaminocyclohexane (45), trans-
(±)-1,2-diaminocyclohexane (46) and purely optical active isomer of (S,S)-(+)-1,2-
diaminocyclohexane (47) were synthesized by a general method described in literature 
for similar compounds [151], by dissolving 340 mg (1.0 mmol) chloroauric acid 
trihydrate HAuCl4·3H2O in 3ml of water at ambient temperature. In a separate beaker, a 
solution of 228 mg (2.0 mmol) of the diaminocyclohexane in 2ml of diethyl ether was 
prepared; both solutions were mixed, gummy yellow precipitate was formed.  Then, upon 
adding 9 ml of aqueous ethanol solution (7:1, EtOH:H2O) to the latter solution and 
stirring for around 1 hr, a white precipitate of [Au(DACH)2]Cl3 formed.  The product was 
isolated and dissolved in 1ml of water and recrystallized with addition of 5 ml ethanol. 
The produced solid was dried under vacuum. The product yield was in the range of 65-70 
%.  Products were characterized by melting point (M.P.) and elemental analysis as given 
in Table 4.8and their predicted chemical structures are shown in Figure 3.8. 
Table 4.8 Melting point and elemental analysis of bis(1,2-DACH)gold(III) chloride complexes 
Complex M. P. (°C) 
Found(Calc.)%     
H C N 
[(cis-1,2-DACH)2Au(III))]Cl3 (45) 203 deco. 5.28(5.31) 27.03(27.11) 10.61(10.54) 
[(trans-(±)-1,2-DACH)2Au(III))]Cl3 (46) 180 deco. 5.23(5.31) 26.97(27.11) 10.62(10.54) 
[(1S,2S)-(+)-DACH)2Au(III))]Cl3 (47) 177 deco. 5.25(5.31) 26.99(27.11) 10.65(10.54) 
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4.9 Synthesis of 1,2-Diaminocyclohexane(ethylenediamine)gold(III) 
Chloride Complexes. 
The synthesis of mixed-ligand 1,2-Diaminocyclohexane(ethylenediamine)gold(III) 
complexes(48)-(50)usingcis-1,2-diaminocyclohexane and ethylenediamine, trans-(±)-1,2-
diaminocyclohexane and ethylenediamine and purely optical active isomer of (S,S)-(+)-
1,2-diaminocyclohexane and ethylenediamine were according to a modified literature 
procedure[150], by dissolving of 398 mg (1.0 mmol) sodium tetrachloroaurate(III) 
dehydrate NaAuCl4·2H2O in minimum amount of absolute ethanol at ambient 
temperature. In a separate beaker, solution of 114 mg (1.00 mmol) of the 
diaminocyclohexane in least amount of absolute ethanol was prepared, both solutions 
were mixed dropwise and stirred for around 30 min until a clear solution was obtained, 
which was then filtered.  In a separate beaker, a solution of 120 mg (1.0 mmol) of the 
ethylenediamine in least amount of absolute ethanol was prepared and added dropwise to 
the filtrated solution.  Then, stirring was continued at RT overnight resulting in white 
precipitate.  The product was separated, dissolved in 2ml of water and filtered through 
celite pad to remove NaCl.  Addition of 100 ml of cold methanol to the filtrate resulted in 
white solid precipitate which was filtered and washed with cold methanol. The 
produced solid dried under reduced pressure with P2O5, yielding the corresponding gold 
complexes with 75–80% yield.  Products were characterized by melting point (M.P.) and 
elemental analysis as given in Table 4.9and their predicted chemical structures are shown 
in Figure 3.9. 
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Table 4.9 Melting point and elemental analysis of 1,2-diaminocyclohexane(ethylenediamine)gold(III)chloride 
complexes 
Complex M. P. (°C) 
Found(Calc.)%     
H C N 
[(cis-1,2-DACH)Au(III)(en)]Cl3 (48) 161-163 6.57(6.64) 22.26(22.59) 13.05(13.17) 
[(trans-(±)-1,2- DACH)Au(III)(en)]Cl3 (49) 175-178 6.59(6.64) 22.32(22.59) 13.01(13.17) 
[(1S,2S)-(+)- DACH)Au(III)(en)]Cl3 (50) 176-178 6.60(6.64) 22.48(22.59) 13.03(13.17) 
 
4.10 Synthesis of 1,2-Diaminocyclohexane(propylenediamine)gold(III) 
Chloride Complexes. 
The synthesis of mixed ligandgold complexes of cis-1,2-diaminocyclohexane and 1,3-
propylenediamine (51), trans-(±)-1,2-diaminocyclohexane and 1,3-propylenediamine 
(52) and purely optical active isomer of (S,S)-(+)-1,2-diaminocyclohexane and 1,3-
propylenediamine (53) were according to modified literature procedure [150], by 
dissolving of 398 mg (1.00 mmol) sodium tetrachloroaurate(III) dehydrate 
NaAuCl4·2H2O in minimum amount of absolute ethanol at ambient temperature. In a 
separate beaker, solution of 114 mg (1.00 mmol) of the diaminocyclohexane in least 
amount of absolute ethanol was prepared, both solutions were mixed dropwise and stirred 
for around 30 min until a clear solution was obtained, which was filtered.  In a separate 
beaker, a solution of 120 mg (1.0 mmol) of the 1,3-propylenediamine in least amount of 
absolute ethanol was prepared and added dropwise to the filtrated solution.  Then, stirring 
was continued at RT for overnight resulting in a white precipitate.  The product was 
separated, dissolved in 2ml of water and filtered through celite pad to remove NaCl.  
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Addition of 100 ml of cold methanol to the filtrate resulted in white solid precipitate 
which was filtered and washed with cold methanol. The produced solid was dried under 
reduced pressure with P2O5, yielding the corresponding gold complexes. The product 
yield was in the range of 75–80 %.  Products were characterized by melting point (M.P.) 
and elemental analysis as given in Table 4.10 and their predicted chemical structures are 
shown in Figure 3.10. 
 
Table 4.10 Melting point and elemental analysis of 1,2-diaminocyclohexane(propylenediamine)gold(III)chloride 
complexes 
Complex M. P. (°C) 
Found(Calc.)%     
H C N 
[(cis-1,2-DACH)Au(III)(pn)]Cl3 (51) 161-163 6.57(6.88) 24.26(24.61) 12.61(12.75) 
[(trans-(±)-1,2- DACH)Au(III)(pn)]Cl3 (52) 171-173 6.55(6.88) 24.37(24.61) 12.59(12.75) 
[(1S,2S)-(+)-DACH)Au(III)(pn)]Cl3 (53) 173-175 6.59(6.88) 24.41(24.61) 12.65(12.75) 
 
4.11 Synthesis of Ammoniumdithiocarbamatodichloridogold(III) 
Chloride Complexes. 
The syntheses of ammoniumdithiocarbamatodichloridogold(III) chloride complexes of 
(54)-(66) were performedfollowing a modifiedliterature procedure [152].  To a stirred 
suspension of the corresponding ammonium dithiocarbamate (0.5 mmol) in DMF (2 ml), 
cooled at 0
o
C in ice bath was added droupwise199 mg (0.500 mmol) of sodium 
tetrachloroaurate(III) dehydrate NaAuCl4·2H2Odissolved in 2 ml of ether. After 
completion of the addition of two reactants, the reaction mixture was then wormed to RT 
65 
 
and stirred for 1 hour.  The products were obtained as a yellow or orange solid by 
addition of 50 ml of ether.  Then, the solvent was decanted and the solid was washed 
three times with 10 ml of ether.  The produced solid was dried under flow of N2 gas, 
yielding the corresponding gold complexes. The product yield was in the range of 75-
80%.  Products were characterized by elemental analysis, IR and 
13
C NMR as given, 
respectively, in Table 4.11, Table 4.12, Table 4. 13andTable 4.14. Their predicted 
chemical structures are shown in Figure 3.11. 
 
Table 4.11 Elemental analysis of ammoniumdithiocarbamatodichloridogold(III) chloride complexes 
Complex 
Found (Calculated) % 
%C %H %N %S 
[(en-DTC)Au(III)Cl2]Cl (54) 8.15(8.21) 1.86(1.83) 6.31(6.37) 14.61(14.59) 
[(pn-DTC)Au(III)Cl2]Cl (55) 10.51(10.59) 2.26(2.22) 6.12(6.18) 14.22(14.14) 
[(bn-DTC)Au(III)Cl2]Cl (56)  12.75(12.84) 2.62(2.59) 5.92(5.99) 13.76(13.71) 
[(N-Me-en-DTC)Au(III)Cl2]Cl (57) 10.51(10.59) 2.25(2.22) 6.13(6.18) 14.21(14.14) 
[(N-Et-en-DTC)Au(III)Cl2]Cl (58) 12.76(12.84) 2.52(2.59) 5.93(5.99) 13.67(13.71) 
[(N-i-Pr-en-DTC)Au(III)Cl2]Cl (59) 14.89(14.96) 2.96(2.93) 5.77(5.82) 13.39(13.32) 
[(N,N´-di-Me-en-DTC)Au(III)Cl2]Cl (60)  12.78(12.84) 3.03(2.59) 5.95(5.99) 13.66(13.71) 
[(N,N´-di-Et-en-DTC)Au(III)Cl2]Cl (61)  16.87(16.96) 3.28(3.25) 5.61(5.65) 13.07(12.94) 
[(N,N´-di-n-Pr-en-DTC)Au(III)Cl2]Cl (62)  20.56(20.64) 3.89(3.85) 5.31(5.35) 12.21(12.25) 
[(N,N´-di-i-Pr-en-DTC)Au(III)Cl2]Cl (63)  20.56(20.64) 3.90(3.85) 5.31(5.35) 12.20(12.25) 
[(N-Me-pn-DTC)Au(III)Cl2]Cl (64) 12.77(12.84) 2.64(2.59) 5.95(5.99) 13.65(13.71) 
[(N-Et-pn-DTC)Au(III)Cl2]Cl (65) 14.87(14.96) 2.96(2.93) 5.78(5.82) 13.27(13.32) 
[(N,N´-di-Et-pn-DTC)Au(III)Cl2]Cl (66)  18.76(18.85) 3.62(3.56) 5.46(5.50) 12.53(12.58) 
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Table 4.12 IR frequencies, υ (cm-1) for ammoniumdithiocarbamatodichloridogold(III) chloride complexes 
Compound υ(N–H) υshift υ(C–NSS) υshift υ(SC=S) υ(SC–S) υ(N
+–H2) 
(en-DTC) (1) 3310 m 
 
1490 s 
 
1051 980 s 2793, 2721 
[(en-DTC)AuCl
2
]Cl  (54) 3471 m 161 1590 s 100 - 978 s 2797 
(pn-DTC) (2) 3311m 
 
1495 s 
 
1056 974 s 2795 
[(pn-DTC)AuCl
2
]Cl (55) 3425 m 114 1554 s 59 - 965 s 2764 
(bn-DTC) (3) 3201 m 
 
1497 s 
 
1029 929 s 
 
[(bn-DTC)AuCl
2
]Cl (56) 3412 m 211 1567 s 70 - 922 s 
 
 
Table 4. 13 Far-IR frequencies, υ (cm-1) for ammoniumdithiocarbamatodichloridogold(III) chloride complexes 
Compound Au–S Au–Cl 
[(en-DTC)AuCl
2
]Cl  (54) 423, 362 334, 329 
[(pn-DTC)AuCl
2
]Cl (55) 431, 367 338, 326 
[(bn-DTC)AuCl
2
]Cl (56) 451, 374 341, 331 
 
Table 4.14  13C NMR chemical shifts of free ligands and ammoniumdithiocarbamatodichloridogold(III) chloride 
complexes in D2O 
Compound  C=S δshift C1 δshift C2 C3 C4 
(en-DTC) (1) 215  44.1  39.6 - - 
[(en-DTC)AuCl
2
]Cl  (54) 203 12 42.4 1.7 38.3   
(pn-DTC) (2) 213  44.7  37.6 27.2 - 
[(pn-DTC)AuCl
2
]Cl (55) 198 15 40.6 4.1 35.7 24.3  
(bn-DTC) (3) 211  47.5  39.9 25.5 25.0 
[(bn-DTC)AuCl
2
]Cl (56) 201 10 44.3 3.2 38.4 22.7 22.1 
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4.12 Synthesis of Dichlorido(2-
cyclohexanaminiumdithiocarbamato)gold(III) Chloride 
Complexes 
The synthesis of the dichlorido(2-cyclohexanaminiumdithiocarbamato)gold(III) 
chloridecomplexes (67)-(69) were performed following a modifiedliterature procedure 
[152].  To a stirred suspension of 2-cyclohexanaminium dithiocarbamate (0.5 mmol) in 
DMF (2 ml) and cooled at 0 
o
C in ice bath was added dropwise 199 mg (0.500 mmol) 
sodium tetrachloroaurate(III) dihydrate NaAuCl4·2H2O dissolved in 2 ml of ether. After 
completion of the addition of two reactants, the reaction mixture was then wormed to RT 
and stirred for 1 hour.  The products were obtained as a yellow or orange solid by 
addition of 50 ml of ether.  Then, the solvent was decanted and the solid was washed 
three times with 10 ml of ether.  The produced solid was dried under a flow of N2 gas, 
yielding the corresponding gold complexes. The product yield was in the range of 84-
88%.  The elemental analysis data as given in Table 4.15 and their predicted chemical 
structures are shown in Figure 3.12. 
Table 4.15 Melting point and elemental analysis of dichlorido(2-cyclohexanaminiumdithiocarbamato)gold(III) 
chloride complexes 
Complex 
Found (Calculated) % 
%C %H %N %S 
[(cis-(1,2)-DACH-DTC)Au(III)Cl2]Cl (67) 8.15(8.21) 1.86(1.83) 6.31(6.37) 14.61(14.59) 
[(trans-(±)-(1,2)-DACH-DTC)Au(III)Cl2]Cl (68) 10.51(10.59) 2.26(2.22) 6.12(6.18) 14.22(14.14) 
[(1S,2S)-(+)-DACH-DTC)Au(III)Cl2]Cl (69)  12.75(12.84) 2.62(2.59) 5.92(5.99) 13.76(13.71) 
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4.13 Synthesis of Mixed-Ligand Dithiocarbamatophosphanegold(I) 
Complexe. 
There has been a great interest in the synthesis of derivatives containing the P–Au(I)–S 
unit because they are related to Auronafin, a drug used against the rheumatoid arthritis 
[101].  The synthesis of the dithiocarbamatotrialkylphosphanegold(I) complexes(70)-(93) 
were synthesized following a modifiedliterature procedure [153].  To a stirred suspension 
ofchloridotrialkylphosphanegold(I) (0.50 mmol) in methanol (20 ml), cooled at 0 
o
C in 
ice bath under atmospheric nitrogen gas flow, wasadded dropwisesodium 
dimethyldithiocarbamate (DMDT) or sodium diethylditiocarbamate (DEDT) (0.50 mmol) 
solution dissolved in 5 ml of methanol. Rapidly, the solid was dissolved and the resulting 
yellow or orange solution was stirred for about 2 h. Then, the solution was filtered to 
remove insoluble materials.  Evaporation of methanol at RT afforded a yellow or orange 
solid which was dissolved in diethyl ether (10 ml). To remove the byproduct sodium 
chloride, the organic layer was washed with water and extracted, dried with anhydrous 
Na2SO4 and filtered. Complete removal of the solvent afforded 
dithiocarbamatotrialkylphosphanegold(I) as a yellow or orange solid.  It was dried under 
reduced pressure at RT overnight over P2O5, yielding the corresponding gold complexes 
with 81-86% yield. Products were characterized by elemental analysis, mid-IR, far-IR,
13
C 
NMR and 
31
P NMR as given, respectively, in Table 4.16, Table 4.17, Table 4.18, Table 
4.19 and Table 4.20. Their predicted chemical structures are shown in Figure 3.13. 
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Table 4.16 Elemental analysis of dithiocarbamatotrialkylphosphanegold(I) complexes 
Complex 
Found (Calculated) % 
%C %H %N %S 
(Me)3PAu(I)(DMDT) (70) 18.26(18.32) 3.86(3.84) 3.48(3.56) 16.23(16.32) 
(Me)3PAu(I)(DEDT) (71) 22.65(22.81) 4.59(4.55) 3.30(3.32) 15.17(15.22) 
(Et)3PAu(I)(DMDT) (72) 24.75(24.83) 4.90(4.86) 3.18(3.22) 14.76(14.73) 
(Et)3PAu(I)(DEDT) (73) 28.43(28.51) 4.51(5.44) 2.98(3.02) 13.61(13.84) 
(i-Pr)3PAu(I)(DMDT) (74) 30.01(30.19) 5.74(5.70) 2.88(2.93) 13.32(13.43) 
(i-Pr)3PAu(I)(DEDT) (75) 33.18(33.27) 6.23(6.18) 2.69(2.77) 12.76(12.69) 
(Ph)2(Cy)PAu(I)(DMDT) (76) 42.93(43.08) 4.70(4.65) 2.31(2.39) 10.61(10.95) 
(Ph)2(Cy)PAu(I)(DEDT) (77) 44.84(45.02) 5.13(5.09) 2.25(2.28) 10.33(10.45) 
(Ph)2(Et)PAu(I)(DMDT) (78) 38.32(38.42) 3.99(3.98) 2.58(2.64) 12.14(12.07) 
(Ph)2(Et)PAu(I)(DEDT) (79) 40.56(40.79) 4.54(4.50) 2.86(2.90) 11.61(11.46) 
(Ph)(NCCH2CH2)2PAu(I)(DMDT) (80) 33.53(33.78) 3.62(3.59) 7.79(7.88) 11.91(12.02) 
(Ph)(NCCH2CH2)2PAu(I)(DEDT) (81) 36.28(36.37) 4.17(4.13) 7.41(7.48) 11.35(11.42) 
(NCCH2CH2)3PAu(I)(DMDT) (82) 28.16(28.24) 3.62(3.55) 10.76(10.98) 12.60(12.57) 
(NCCH2CH2)3PAu(I)(DEDT) (83) 31.14(31.23) 4.20(4.12) 10.34(10.41) 11.85(11.91) 
(Ph)3PAu(I)(DMDT) (84) 43.36(43.53) 3.68(3.65) 2.38(2.42) 11.16(11.07) 
(Ph)3PAu(I)(DEDT) (85) 45.31(45.47) 4.58(4.15) 2.27(2.31) 10.63(10.56) 
(p-CH3Ph)3PAu(I)(DMDT) (86) 46.16(46.38) 4.43(4.38) 2.22(2.25) 10.21(10.32) 
(p-CH3Ph)3PAu(I)(DEDT) (87) 47.75(48.07) 4.85(4.81) 4.12(4.16) 9.77(9.87) 
(m-CH3Ph)3PAu(I)(DMDT) (88) 46.09(46.38) 4.43(4.38) 2.21(2.25) 10.22(10.32) 
(m-CH3Ph)3PAu(I)(DEDT) (89) 47.75(48.07) 4.86(4.81) 4.09(4.16) 9.76(9.87) 
(o-CH3Ph)3PAu(I)(DMDT) (90) 46.12(46.38) 4.41(4.38) 2.23(2.25) 10.19(10.32) 
(o-CH3Ph)3PAu(I)(DEDT) (91) 46.79(48.07) 4.84(4.81) 4.08(4.16) 9.91(9.87) 
(p-CH3OPh)3PAu(I)(DMDT) (92) 42.82(43.05) 4.09(4.06) 2.12(2.09) 14.49(9.58) 
(p- CH3OPh)3PAu(I)(DEDT) (93) 44.52(44.76) 4.53(4.48) 2.03(2.01) 9.18(9.10) 
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Table 4.17 Mid-IR frequencies, υ(cm-1) for dithiocarbamatotrialkylphosphanegold(I)complexes 
Compound υ(C–NSS)  υshift υ(SC=S)  υshift υ(SC–S)  υshift 
DMDT  1359 s  -  1043 s  -  963s  -  
DEDT  1356 s  -  1064 s  -  986 s  -  
Me
3
PAu(I)DMDT (70) 1369 s  10  974 s  -69  958 s  -5  
Me
3
PAu(I)DEDT (71) 1374 s  18  986 s  -78  951 s  -35  
Et
3
PAu(I)DMDT (72) 1367 s  8  996 s  -47  973 s  -10  
Et
3
PAu(I)DEDT (73) 1371 s  15  1002  -62  984s  -2  
i-Pr
3
PAu(I)DMDT (74) 1368 s  9  994  -49  977s  -9  
 
Table 4.18 Far-IR frequencies, υ(cm-1) for dithiocarbamatotrialkylphosphanegold(I)complexes 
Compound υ(Au-S) υ(Au-P) 
Me
3
PAu(I)DMDT (70)  392  332  
Me
3
PAu(I)DEDT (71)  381  335  
Et
3
PAu(I)DMDT (72)  375  331  
Et
3
PAu(I)DEDT (73)  379  334  
i-Pr
3
PAu(I)DMDT (74)  380  328  
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Table 4.19 13C NMR chemical shifts of precursor complexes and dithiocarbamatotrialkylphosphanegold(I) 
complexes in CDCl3 
Compound  C=S  C1  C2  C3  C1´  C2´  
Me
3
PAu(I)Cl (70) -  16.3, 16.0  -  -  -  -  
Me
3
PAu(I)DMDT (70)  207  16.6, 16.3  -  -  45.2  -  
Me
3
PAu(I)DEDT (71)  206  16.4. 16.1  9.0  -  -  - 
Et
3
PAu(I)Cl (72)  -  18.3, 18.0  -  -  
  
Et
3
PAu(I)DMDT (72)  208  18.4, 18.2  8.8  -  45.0  -  
Et
3
PAu(I)DEDT (73)  205  18.2, 17.9  9.3  35.7  49.0  12.6  
i-Pr
3
PAu(I)Cl (74)  -  24.1, 23.3  20.3  20.3  -  -  
i-Pr
3
PAu(I)DMDT (74)  208  23..9, 23.7  20.1  20.1  45.0  -  
 
Table 4.2031P NMR chemical shifts of precursor complexes and dithiocarbamatotrialkylphosphanegold(I)complexes 
in CDCl3 
Compound  P  δshift 
Me
3
PAu(I)Cl (70) -11  
 
Me
3
PAu(I)DMDT (70)  -8.7  2.3  
Me
3
PAu(I)DEDT (71)  -8.8  2.2  
Et
3
PAu(I)Cl (72)  29.4  
 
Et
3
PAu(I)DMDT (72)  31.9  2.5  
Et
3
PAu(I)DEDT (73)  32.2  2.8  
i-Pr
3
PAu(I)Cl (74)  -36.7  
 
i-Pr
3
PAu(I)DMDT (74)  -35.1  1.6  
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4.14 Synthesis of Mixed-Ligand 5-Methyl-2-
mercaptobenzimidazolo(phosphane)gold(I) Complexes. 
The synthesis of the 5-methyl-2-mercaptobenzimidazolo(phosphane)gold(I)complexes of 
(94)-(99) were performed following a literature procedure [153,154]. Suspension of 
substituted 5-methyl-2-mercaptobenzimidazole (1.0 mmol) in distilled water (20 ml) was 
treated with a solution of KOH 1.0 N (5.0ml, 5.0 mmol). The resulting clear solution was 
then added to 5 ml ofa methanolic solution of 1.0 mmol chlorido phosphane gold(I) under 
stirring for 2 hours. The produced precipitate was then filtered off, washed with waterand 
dried for 6 hours in oven at 40 
o
C.  The product was in the range of 92–95% yield.  
Products were characterized by melting point (M.P.) and Elemental analysis as given in 
Table 4.21 and their predicted chemical structures are shown in Figure 3.14. Figure 4.1 
shows the X-ray structure of (5-Me-2-MBI)Au(I)P(Ph)3 (96). 
Table 4.21 Melting point and elemental analysis of 5-methyl-2-mercaptobenzimidazolo(phosphane)gold(I) 
complexes 
Complex 
M. P. Found (Calculated) % 
(ºC) %C %H %N %S 
(5-Me-2-MBI)Au(I)P(Me)3 (94) 241-243 30.01(30.28) 7.78(7.70) 6.38(6.42) 7.21(7.35) 
(5-Me-2-MBI)Au(I)P(Et)3 (95) 183-185 34.94(35.15) 4.69(4.64) 5.72(5.86) 6.65(6.70) 
(5-Me-2-MBI)Au(I)P(Ph)3 (96) 208-210 49.75(50.17) 3.62(3.56) 4.42(4.50) 5.01(5.15) 
(5-Me-2-MBI)Au(I)P(Ph)2(Et)(97) 154-156 45.89(46.00) 3.89(3.86) 4.65(4.88) 6.61(5.58) 
(5-Me-2-MBI)Au(I)P(t-Bu)3 (98) 232-234 42.51(42.70) 6.14(6.09) 4.93(4.98) 5.62(5.70) 
(5-Me-2-MBI)Au(I)P(i-Pr)3 (99) 179-181 39.12(39.23) 5.47(5.42) 5.23(5.38) 6.09(6.16) 
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Figure 4.1 X-ray structure of (Ph)3PAu(I)(5-Me-2-MBI) (96) 
 
4.15 Synthesis of Substituted2-
mercaptobenzimidazolo(trimethylphosphane)gold(I) Complexes. 
The synthesis of the substituted 2-mercaptobenzimidazolotrimethylphosphanegold(I) 
complexes of (100)-(105) wereperformed following a literature procedure [153,154 ]. 
Suspension of the substituted2-mercaptobenzimidazole (1.0 mmol) in distilled water (20 
ml) was treated with a solution of KOH 1.0 N (5.0ml, 5.0 mmol). The resulting clear 
solution was then added to it 5 ml ofa methanolic solution of 308.5 mg (1.00 mmol) 
chloridotrialkylphosphanegold(I) under stirring for 2 hours. The produced precipitate was 
then filtered off, washed with waterand dried for 6 hours in oven at 40 
o
C.  The product 
was in the range of 93-96% yield.  Products were characterized by melting point (M.P.) 
and elemental analysis as given in Table 4.22 and their predicted chemical structures are 
shown in Figure 3.15. 
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Table 4.22 Melting point and elemental analysis of substituted 2-mercaptobenzimidazolotrimethylphosphanegold(I) 
complexes 
Complex 
M. P. Found (Calculated) % 
(ºC) %C %H %N %S 
(2-MBI)Au(I)P(Me)3 (100) - 28.32(28.45) 3.40(3.34) 6.54(6.63) 7.83(7.95) 
(5-F-2-MBI)Au(I)P(Me)3 (101) 225-227 27.04(27.28) 3.03(2.98) 6.28(6.36) 7.22(7.28) 
(5-Cl-2-MBI)Au(I)P(Me)3(102) 168-170 26.14(26.30) 2.92(2.87) 6.03(6.13) 6.89(7.02) 
(5,6-di-Cl-2-MBI)Au(I)P(Me)3 (103) 238-240 24.15(24.46) 2.53(2.46) 5.65(5.70) 6.46(6.53) 
(5-NO2-2-MBI)Au(I)P(Me)3 (104) 170-172 25.63(25.71) 2.75(2.80) 8.92(8.99) 6.76(6.86) 
(4-NO2-2-MBI)Au(I)P(Me)3 (105) 180-182 25.59(25.71) 2.86(2.80) 8.94(8.99) 6.79(6.86) 
 
4.16 Synthesis of Mixed-Ligand 4-Nitro-2-
mercaptobenzimidazolo(phosphane)gold(I) Complexes. 
The synthesis of the 4-nitro-2-mercaptobenzimidazolotrialkylphosphanegold(I) 
complexes of (106)-(111) were performed following the literature procedure 
[153,154].Suspension of the substituted 4-nitro-2-mercaptobenzimidazole (1.0 mmol) in 
distilled water (20 ml) was treated with a solution of KOH 1.0 N (5.0ml, 5.0 mmol). The 
resulting clear solution was then added to 5 ml ofa methanolic solution of 1.0 mmol 
chloridophosphinegold(I) under stirring for 3 hours. The produced precipitate was then 
filtered off, washed with waterand dried for 6 hours in oven at 40 
o
C.  The product was in 
the range of 95-96% yield.  Products were characterized by melting point (M.P.) and 
elemental analysis as given in Table 4.23and their predicted chemical structures are 
shown in Figure 3.16. 
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Table 4.23 Melting point and elemental analysis of 4-nitro-2-mercaptobenzimidazolotrialkylphosphanegold(I) 
complexes 
Complex 
M. P. Found (Calculated) % 
(ºC) %C %H %N %S 
(4-NO2-2-MBI)Au(I)P(Et)3 (106) 138-140 30.45(30.66) 3.86(3.76) 8.19(8.25) 6.25(6.30) 
(4-NO2-2-MBI)Au(I)P(Ph)2(Et) (107) 117-119 41.23(41.66) 3.21(3.16) 6.91(6.94) 5.24(5.30) 
(4-NO2-2-MBI)Au(I)P(Ph)(Et)(Me) (108) 280-282 35.18(35.37) 3.16(3.15) 7.68(7.73) 5.84(5.90) 
(4-NO2-2-MBI)Au(I)P(Ph)3(109) 238-240 45.48(45.95) 2.96(2.93) 6.32(6.43) 4.81(4.91) 
(4-NO2-2-MBI)Au(I)P(t-Bu)3 (110) 230-232 38.17(38.45) 5.35(5.26) 7.02(7.08) 5.49(5.40) 
(4-NO2-2-MBI)Au(I)P(i-Pr)3 (111) 120-122 34.54(34.85) 4.62(4.57) 7.56(7.62) 5.78(5.82) 
 
4.17 Synthesis of Mixed-Ligand 5-Nitro-2-
Mercaptobenzimidazolophosphanegold(I) Complexes. 
The synthesis of the 5-nitro-2-mercaptobenzimidazolotrialkylphosphanegold(I) 
complexes of (112)-(115) were performed following the literature procedure [153,154]. 
Suspension of the5-nitro-2-mercaptobenzimidazole (1.0 mmol) in distilled water (20 ml) 
was treated with a solution of KOH 1 N (5ml, 5 mmol). The resulting clear solution was 
then added to 5 ml ofa methanolic solution of 1.0 mmol chloridophosphanegold(I) under 
stirring for 3 hours. The produced precipitate was then filtered off, washed with waterand 
dried for 6 hours in oven at 40 
o
C.  The product was in the range of 91-94% yield.  
Products were characterized by melting point (M.P.) and elemental analysis as given in 
Table 4.24 and their predicted chemical structures are shown in Figure 3.17. 
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Table 4.24 Melting point and elemental analysis of 5-NO2-2-mercaptobenzimidazolophosphanegold(I) complexes 
Complex 
M. P. Found (Calculated) % 
(ºC) %C %H %N %S 
(5-NO2-2-MBI)Au(I)P(Et)3 (112) 183-185 30.48(30.66) 3.89(3.76) 8.15(8.25) 6.27(6.30) 
(5-NO2-2-MBI)Au(I)P(Ph)2(Et) (113) 154-156 41.36(41.66) 3.23(3.16) 6.89(6.94) 5.23(5.30) 
(5-NO2-2-MBI)Au(I)P(Ph)3(114) 208-210 45.67(45.95) 2.97(2.93) 6.36(6.43) 4.85(4.91) 
(5-NO2-2-MBI)Au(I)P(t-Bu)3 (115) 232-234 38.23(38.45) 5.29(5.26) 7.04(7.08) 5.36(5.40) 
 
4.18 Synthesis of Substituted 2-Mercaptobenzimidazolo{1,3-Bis(2,6-di-
isopropylphenyl)imidazol-2-ylidene}gold(I) Complexes. 
The synthesis of the substituted 2-Mercaptobenzimidazolo(IPr)gold(I) (IPr = 1,3-bis(2,6-
di-isopropylphenyl)imidazol-2-ylidene) complexes of (116)-(122) were performed 
following the similar literature procedure [153,154]. Suspension of substituted2-
mercaptobenzimidazole (0.50 mmol) in distilled water (10.0 ml) was treated with a 
solution of KOH 1.0 N (2.5ml, 2.5 mmol). The resulting clear colored solution was then 
added to it 5 ml ofa methanolic solution of 311.0 mg (0.50 mmol) chlorido{1,3-Bis(2,6-
di-isopropylphenyl)imidazol-2-ylidene}gold(I) under stirring for 3 hours. The produced 
precipitate was then filtered off, washed with waterand dried for 6 hours in oven at 40 
o
C.  
The product was in the range of 87-93% yield.  Products were characterized by Elemental 
analysis as given in Table 4.25 and their predicted chemical structures are shown in 
Figure 3.18. 
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Table 4.25 Melting point and elemental analysis of 2-mercaptobenzimidazolo(IPr)gold(I) complexes 
Complex 
Found (Calculated) % 
%C %H %N %S 
(2-MBI)Au(I)P(IPr) (116) 55.15(55.50) 5.81(5.75) 6.51(7.61) 4.31(4.36) 
(5-Me-2-MBI)Au(I)P(IPr) (117) 55.46(56.07) 5.94(5.91) 7.31(7.47) 4.21(4.28) 
(5-F-2-MBI)Au(I)P(IPr) (118) 53.43(54.18) 5.57(5.48) 7.36(7.43) 4.21(4.25) 
(5-Cl-2-MBI)Au(I)P(IPr) (119) 52.67(53.02) 5.43(5.37) 7.31(7.27) 4.04(4.16) 
(5,6-di-Cl-2-MBI)Au(I)P(IPr) (120) 50.24(50.75) 5.09(5.01) 6.87(6.96) 3.94(3.99) 
(5-NO2-2-MBI)Au(I)P(IPr) (121) 51.86(52.30) 5.35(5.29) 8.78(8.97) 4.06(4.11) 
(4-NO2-2-MBI)Au(I)P(IPr) (122) 51.76(52.30) 5.34(5.29) 8.87(8.97) 4.03(4.11) 
 
4.19 Synthesis of Dinuclear2-MBI{1,3-
bis(Diphenylphosphino)methane}gold(I) Complexes 
The synthesis of dinuclear2-MBI{1,3-bis(Diphenylphosphino)methane}gold(I)complexes 
of (123)-(129) were performed following similar literature procedure [153,154]. 
Suspension of a substituted2-mercaptobenzimidazole (0.33 mmol) in distilled water (7 
ml) was treated with a solution of KOH 1.0 N (1.7ml, 1.7 mmol). The resulting clear 
solution was then added to 2 ml ofa methanolic solution of 283 mg (0.330 mmol) 
chlorido(DPPM)gold(I) [(DPPM = 1,3-bis(diphenylphosphino)methane] under stirring 
for 3 hours. The produced precipitate was then filtered off, washed with waterand dried 
overnight in a vacuum at 30 
o
C.  The product was in the range of 93-96% yield.  Products 
were characterized by melting point (M.P.) and elemental analysis as given in Table 4.26 
and their predicted chemical structures are shown in Figure 3.19. 
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Table 4.26 Melting point and elemental analysis of Dinuclear 2-MBI{1,3-bis(Diphenylphosphino)methane}gold(I) 
complexes 
Complex 
Found (Calculated) % 
%C %H %N %S 
{(2-MBI)Au(I)}2(DPPM) (123) 43.26(43.50) 3.04(3.00) 5.14(5.20) 5.89(5.96) 
{(5-Me-2-MBI)Au(I)}2(DPPM) (124) 41.75(42.10) 2.76(2.72) 4.97(5.04) 5.61(5.76) 
{(5-F-2-MBI)Au(I)}2(DPPM) (125) 44.32(44.57) 3.32(3.28) 5.01(5.07) 5.76(5.81) 
{(5-Cl-2-MBI)Au(I)}2P(DPPM) (126) 40.61(40.89) 2.68(2.64) 4.78(4.89) 5.65(5.60) 
{(5,6-di-Cl-2-MBI)Au(I)}2(DPPM) (127) 38.27(38.57) 2.36(2.32) 4.56(4.61) 5.12(5.28) 
{(5-NO2-2-MBI)Au(I)}2(DPPM) (128) 39.89(40.15) 2.66(2.59) 7.12(7.20) 5.43(5.50) 
{(4-NO2-2-MBI)Au(I)}2(DPPM) (129) 39.85(40.15) 2.64(2.59) 7.15(7.20) 5.52(5.50) 
 
4.20 Spectroscopic Characterization 
4.20.1 Elemental Analysis 
Elemental analysis and melting points were performed on Perkin Elmer Series 11 
(CHNS/O), Analyzer 2400 and BǕCHI 510 melting point apparatus respectively. The 
CHN/CHNS results of metal complexes are given in Tables 4.1-4.26. 
4.20.2 Mid-IR and Far-IR studies 
The solid state Mid-IR spectra of the ligands and the compounds (1)-(129) were 
performed on a Perkin–Elmer FTIR 180 spectrophotometer or NICOLET 6700 FTIR 
using KBr pellets over the range 4000–400 cm-1and solid state Far-IR spectra were 
recorded for complexes at 4 cm
–1
 resolution at room temperature using CsCl disks on a 
Nicolet 6700 FT-IR with Far-IR beam splitter. 
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4.20.3 UV-Vis Studies 
Electronic spectra were obtained using Lambda 200, Perkin-Elmer UV-Vis spectrometer.   
UV-Vis spectroscopy was, also, used to determine the stability of the complexes in a 
physiological buffer (40 mM phosphate, 4 mM NaCl, pH 7.4).  Electronic spectra were 
recorded on freshly prepared buffered solutions of each complex at room temperature. 
Then, their electronic spectra were monitored over certain time at 37 
o
C. All electronic 
spectral data obtained were given in tabulated form.  
4.20.4 Solution NMR Measurements 
The solution 
1
H and 
13
C NMR experiments were performed on Jeol 500 MHz NMR 
Spectrometer at 297 K using ca. 0.10 M solution of the complexes in the deuterated 
solvents (D2O, DMSO, CDCl3 and CD3OD. etc.). The 
1
H NMR spectra were obtained on 
a Jeol 500 MHz NMR spectrometer operating at a frequency of 500 MHz. 
13
C NMR 
spectra were obtained at 125.65 MHz with 
1
H broadband decoupling at 297K. The 
spectral conditions were: 32k data points, 0.967s acquisition time, 1.00s pulse delay and 
45
o
 pulse angle. 
1
H and 
13C NMR Chemical shifts (δ) values were referenced to 
tetramethylsilane (TMS), 1,4-dioxane as, CD3OD and dimethyl sulfoxide (DMSO). 
31
P NMR spectra were obtained on Jeol 500 MHz Spectrometer operating at frequency 
202.35 MHz with 
1
H broadband decoupling at 297K. The spectral conditions were: 32k 
data points, 0.963 s acquisition time, 2.50 s pulse delay and 45
o
 pulse angle. 
31
P NMR 
chemical shifts (δ) values were external referenced to 0 ppm of 85% H3PO4in D2O 
solvent. 
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4.20.5 Solid State NMR Measurements 
13
C solid-state NMR was recorded on a Bruker 400 MHz spectrometer at ambient 
temperature of 25
o
C. Samples were packed into 4 mm zirconium oxide rotors. Cross 
polarization and high power decoupling were employed. Pulse delay of 7.0 s and a 
contact time of 5.0 ms were used in the CPMAS experiments. The magic angle spinning 
rates were 4 and 8 kHz. Carbon chemical shifts were referenced to TMS by setting the 
high frequency isotropic peak of solid adamantane to 38.56 ppm 
 
4.20.6 NMR Studies for StabilityDetermination 
Selected complexes were tested for their stability in water, DMSO and mixed solvent of 
DMSO/water solution by 
13
C and 
1
H NMR.  The hygroscopic  nature of DMSO could 
unfortunately lead to stability issue [155].  To investigate the structural stability of the 
complexes, NMR spectra of the complexes dissolved in D2O, DMSO and mixed DMSO-
d6/D2O (v/v: 3/1) solution were obtained on immediate dissolution and latter at certain 
time at RT in DMSO or mixed DMSO-d6/D2O and at 37 
o
C in D2O .  A minimum of 30 
mg/ml of representative gold complexes were subjected to 
1
H and 
13
C NMR spectra 
analysis following dissolution in D2O and DMSO-d6/D2O (v/v: 3/1, 1ml).  Immediate 
dissolution and duplicate samples were then stored at RT and 37 
o
C, respectively, and 
analyzed again after 24 h and on day 3 or 7 to determine compounds‘ stability over this 
time period.  
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4.21 X-ray Structure Determination 
The crystal structure determination was carried out on Bruker Single Crystal X-ray 
Diffractometer. For crystalline gold(III) complexes, X-ray quality single crystals were 
mounted in a thin-walled glass capillary on a Bruker-Axs Smart Apex diffractometer 
equipped with graphite monochromatized Mo Kα radiation (λ = 0.71073 Å). The data 
were collected using SMART software[156]. The data integration was performed using 
SAINT[157]. An empirical absorption correction was carried out using SADABS[158]. 
The structure was solved with direct methods and refined by full matrix least square 
methods based on F
2
, using the structure determination package SHELXTL [159] based 
on SHELX 97 [160]. Graphics were generated using ORTEP-3 [161] and MERCURY 
[162].  
Single crystal data collection was also performed at 173K (–100°C) on a Stoe Mark II-
IPD System [163] equipped with a two-circle goniometer and usingMoKα graphite 
monochromated radiation. Diffraction data was collected using ω rotation scans of 0°–
180° at ϕ = 0° and of 0°–180° at ϕ = 90° with stepΔω = 1.0°, exposures of 1 minute per 
image, 2θrange = 2.29°–59.53° and dmin–dmax = 17.779–0.716 Å. The distance between 
the imaging plate and the sample was 100 mm. Structure was solved by direct methods 
using the program SHELXS-97 [160].The refinement and all further calculations were 
carried out using SHELXL-97 [160]. The H-atoms were either located from Fourier 
difference maps and freely refined or included in calculated positions and treated as 
riding atoms using SHELXL default parameters. The non-H atoms were refined 
anisotropically, using weighted full-matrix least-squares on F
2
. Empirical or 
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multiscanabsorption corrections were applied using and MULSCANABS routines in 
PLATON [164.] 
4.22 Computational Study 
The structures of some complexes were built and optimized using GAUSSIAN09 
Revision A.1 program package [165]and GAUSSIAN03, Revision B.04 program package 
[166] at DFT/B3LYP level with LANL2DZ (Los Alamos ECP plus double-zeta) basis set 
[167,168]. Geometry optimization for the built structures was also carried out using the 
same software program.  
4.23 Electrochemistry 
The electrochemical experiments were performed at room temperature using a 
potentiostat (SP-300, BioLogic Science Instruments) controlled by EC-Lab v10.34 
software package.  All the measurements were performed on solutions deaerated by 
bubbling ultrapure nitrogen for 15 min. The potential values here reported were measured 
with respect to the saturated calomel electrode (SCE) serves as a reference electrode.  
The cyclic voltammetry of the complexes (1), (2) and (3) were measured at scan rate of 
50 mV/s on a reference buffer (40 mM phosphate, 4 mM NaCl, pH 7.4) using platinum as 
working electrode and graphite as a counter electrode with a concentration of 1.0 mM at 
RT.  Ferrocene was used as pseudo reference to calibrate the working electrode.  The 
couple  Fe
III/II 
 formal potential of ferrocene occur at E°´ = +0.44 V (vs SCE) in 0.1M 
Bu4NPF6 acetonitrile solution which is similar to the report value under the same 
experimental condition [169].  Conversion to values vs ENH was obtained upon adding 
+0.24 V to the relevant SCE values. 
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4.24 AnticancerProperties 
Human gastric cancer SGC7901 cells and prostate cancer cells PC3 were incubated.  
MTT assay were used to detect cell proliferation and assess the inhibitory effect on the 
proliferation of SGC7901 and PC3 cells.  In one culture plate, human gastric cancer 
SGC7901 and PC3 cells were treated with the gold(III) complex and the control (water) 
and in the second plate, only the complex and SGC7901 cells were kept in these two sets 
for an entire day (24 h) and for 3 days (72 h). In other sets, complexes with fixed 
concentration were employed to determine the growth inhibitory effect for both PC3 and 
SGC7901 cells. After being treated with complexes, cell viability was examined by MTT 
assay. 
4.24.1 Assessment of Cell Proliferation 
MTT assay was used to obtain the number of living cells in the sample. SGC7901 and 
PC3 cells were seeded on 96-well plates at a predetermined optimal cell density to ensure 
exponential growth in the duration of the assay. After 24 h pre-incubation, growth 
medium was replaced with experimental medium containing the appropriate drug or 
control. Six duplicate wells were set up for each sample, and cells untreated with drug 
served as control. Treatment was conducted at 24 h and 72 h sequentially. After 
incubation, 10 μL MTT (6 g/L, Sigma) was added to each well and the incubation was 
continued for 4 h at 37 °C. After removal of the medium, MTT stabilization solution 
(dimethylsulfoxide:ethanol = 1:1) was added to each well, and shaken for 10 min until all 
crystals were dissolved. Then, optical density was detected in a micro plate reader at 550 
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nm wavelength using an ELISA reader. Each assay was performed in triplicate. Cell 
number and viability were determined by trypan blue dye exclusion analysis. 
4.24.2 in vitro Cytotoxic assay for Cisplatin Sensitive Prostate (PC3) and 
Cisplatin Resistance Gastric (SGC7901) Cells 
MTT assay was used to obtain the number of living cells in the sample. SGC7901 and 
PC3 cells were seeded on 96-well plates at a predetermined optimal cell density to ensure 
exponential growth in the duration of the assay. After 24 h pre incubation, growth 
medium was replaced with experimental medium containing the appropriate drug or 
control. Six duplicate wells were set up for each sample, and cells untreated with drug 
served as control. Treatment was conducted at 24, and 72 h respectively. After 
incubation, 10 μL MTT (6 g/L, Sigma) was added to each well and the incubation was 
continued for 4 h at 37 °C. After removal of the medium, MTT stabilization solution 
(dimethylsulfoxide:ethanol = 1:1) was added to each well, and shaken for 10 min until all 
crystals were dissolved. Then, optical density was detected in a micro plate reader at 550 
nm wavelength using an ELISA reader. Each assay was performed in triplicate. Cell 
number and viability were determined by trypan blue dye exclusion analysis. 
Prostate PC3 and Human gastric SGC7901 cells were used in this study. Cells were 
cultured in Dulbecco‘s Modified Eagle Medium (DMEM) supplemented with 10 % fetal 
calf serum (FCS), penicillin (100 kU L
-1
) and streptomycin (0.1 g L
-1
) at 37 ºC in a 5 % 
CO2 -95 % air atmosphere. Human gastric SGC7901 cells, prostate PC3 were incubated 
with these compounds at fixed concentrations or with water as control to assess the 
inhibitory effect on cell proliferation. The standard MTT assay has been used to assess 
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inhibitory effect on cells growth. The cell survival versus drug concentration is plotted. 
Cytotoxicity was evaluated with reference to the IC50 value.  The half maximal inhibitory 
concentration (IC50) is a measure of the effectiveness of a compound in inhibiting 
biological or biochemical function. According to the FDA, IC50 represents the 
concentration of a drug or compound or complex that is required for 50 % inhibition in 
vitro. It is evaluated from the survival curves as the concentration needed for a 50 % 
reduction of survival. IC50 values are expressed in M [170]. IC50 values were calculated 
from dose-response curves obtained in replicate experiments.   
4.24.3 Assay For Inhibitory Effect Complexes (1-129) on Prostate (PC3) 
and Gastric (SCG7901) Cancer Cells 
MTT assay was used to obtain the number of living cells in the sample. Human gastric 
cancer SGC7901 and prostate cancer PC3 cells were seeded on 96-well plates at a 
predetermined optimal cell density i.e.ca 6,000 cells/100 µL per well in 96-well plates to 
ensure exponential growth in the duration of the assay. After 24 h pre incubation, growth 
medium was replaced with experimental medium containing the appropriate drug using 
gold complex or control using water. Six duplicate wells were set up for each sample, and 
cells untreated with drug served as control. In one sets of culture plate, human gastric 
cancer SGC7901 and human prostate PC3 cells were treated with the complexes (1-129) 
as drug and the control (water) for 24, 48 and 72 h. In other sets, complexes with fixed 
concentration i.e. 10 µM were employed to determine the growth inhibitory effect for 
both PC3 and SGC7901 cells separately.  After incubation, 10 μL MTT (6 g/L, Sigma) 
was added to each well and the incubation was continued for 4 h at 37 °C. After removal 
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of the medium, MTT stabilization solution [Dimethyl sulfoxide (DMSO): Ethanol = 1:1] 
was added to each well, and shaken for 10 min until all crystals were dissolved. Then, 
optical density was detected in a micro plate reader at 550 nm wavelength using an 
Enzyme-Linked Immuno-Sorbent Assay (ELISA) reader. After being treated with the 
complexes, cell viability was examined by MTT assay. Each assay was performed in 
triplicate. MTT assay for inhibitory effect has been used for all synthesized complexes 
(1-129) against PC3 and SGC7901 cells. These cells were treated with various 
concentrations of complexes (1-129) for 24-72 h. 
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5 CHAPTER 5 
RESULTS AND DISCUSSION 
5.1 Gold(III) 1,2-Diaminocyclohexane dichloridoComplexes 
This work reports the synthesis of gold(III) complexes of the type [(DACH)AuCl2]Cl 
derived from sodium tetrachloroaurate(III) dihydrate NaAuCl4·2H2O, where DACH is 
1.2-diaminocyclohexane, have been synthesized. 
5.1.1 MID-IR and Far-IR Spectroscopic Studies 
Table 5.1 lists the significant IR bands of free DACH ligand and their gold(III) 
complexes.  The N-H stretching band, which occurs around 3300 cm
-1
 for the free ligands 
shifts towards higher frequency (blue shift) upon complexation by about 150 cm
-1
.  
Another important vibrational band observed in IR spectra is the C-N stretching which 
also showed a slight shift to higher wave number indicating a shorter C-N bond in the 
complex than in the free ligand. The N-H band appears at much higher frequency in 
trans-DACH complexes and in the cis-DACH complex compare with free ligands. For 
example, the N-H frequency shift is about 137 and 364 cm
-1 
in complexes (37) and (38) 
respectively, while this shift is about 93 cm
-1 
in complex (36). The larger N-H wave 
number shifts designate the strong coordination of ligands in complexes (37) and (38) 
with the gold(III) centre.  This may be due to the different in the stereochemistry of the 
cis and trans-1,2-DACH-gold(III).  
88 
 
Table 5.1 IR frequencies, ν(cm-1) for [(1,2-DACH)Au(III)Cl2]Cl complexes 
Complex υ(N–H) υshift υ(C–N) υshift 
cis-(±)-1,2-(DACH) 3356 m, 3286 m  1092s  
(36) 3414 w 93 1183 s 91 
trans-(±)-1,2-(DACH) 3348 m, 3271 m, 3183 m  1082 m  
(37) 3485 w, 3420 w, 3384 w 137, 149, 201 1175 m 93 
(S,S)-(+)-1,2-(DACH) 3340 m, 3252 m, 3167 m  1082 m  
(38) 3604 m, 3340 m, 3306 m 364, 88, 139 1171 m 89 
 
Table 5.2 lists the significant IR bands of NaAuCl4precursor complex and gold(III) 
complexes (36-38).  Far-IR showed absorption bands at 353 and 367cm
-1
 for symmetric 
and asymmetric stretching of the Au-Cl, which is consistent with Au-Cl stretching mode 
trans to nitrogen [171,172]. Another group of bands at 395 and 437cm
-1
 could be 
assigned for the symmetric and asymmetric stretching of the Au–N bond [173].  The red 
shift of the DACH complexes with respect to the auric acid shows the weakening of the 
Au-Cl bond.  
Table 5.2 Far-IR frequencies, ν(cm-1) for [(1,2-DACH)Au(III)Cl2]Clcomplexes. 
Species υ(Au–Cl) υ(Au–N) 
NaAuCl4 369  
(36) 352, 367 437 
(37) 353, 365 437 
(38) 353, 366 395, 436 
 
5.1.2 UV-Vis Studies 
The λmax values for the complexes studied are shown inTable 5.3.  Au(III) complexes 
show absorption in the region 250–350nm (40000–28570cm−1) which correspond to 
LMCT transitions signal at 300nm that could be assigned to Cl→Au charge transfer by 
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analogy to auric acid absorption spectra which give a band at 320nm [174], where this 
transition of high extinction coefficient cannot be assigned to the symmetry forbidden d-d 
transition. According to crystal field theory for d
8
 complexes the LUMO orbital is dx
2
-y
2
, 
so ligand to metal charge transfer could be due to pσ→dx
2
-y
2
 transition [175]. The 
electronic spectra of these compounds remain unchanged which is consistent with the fact 
that the gold centre remains in the +3 oxidation state. 
Table 5.3 UV–Vis spectra λmax for [(1,2-DACH)Au(III)Cl2]Cl complexes 
Complex λmax (nm) 
HAuCl4 320.0 
NaAuCl4 292.5 
(36) 302.5 
(37) 301.6 
(38) 301.5 
 
5.1.3 Solution NMR Studies 
The 
1
H and 
13
C NMR chemical shifts of compounds (36)-(38) along with their 
corresponding free ligand are listed in Table 5.4 and Table 5.5, respectively.  Also, the 
1
H 
and 
13
C NMR spectra of complexes (36)-(38)areshown in Figures 5.1 and 5.2, 
respectively.  Complexes (36)-(38)depicted one half of the total expected signals because 
the presence of the C2 symmetry axis. 1,2-diaminocyclohexane ring is considered as a 
rigid conformer that allowed to distinguish equatorial H3 and H4 from axial H3 and H4 
at room temperature.  
1
H NMR downfield shift was observed for complexes with respect 
to the free diamine ligands.  The significant downfield shift was observed at 3.59 ppm for 
(36) complex with respect to the free DACH ligand at 2.23 ppm.  This can be attributed 
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to the donation of nitrogen lone pairs to the gold that causes de-shielding of the proton(s) 
next to the bonding nitrogen. On the other hand, 
13
C NMR downfield shift was observed 
only for the carbon next to the bonding nitrogen and the others carbons in the complex 
showed upfield shift.  For instance, chemical shift of C3 and C4 for complex 1 observed 
at 26.78 and 21.43 ppm, respectively,  whereas, for free diamine ligand it occurs at 35.26 
and 26.36 ppm.  It is also worth to mention that complexes (36)-(38), even though they 
have same skeleton of DACH, their NMR chemical shifts aren‘t the same due to different 
in their stereochemistry upon complexation. 
Table 5.4 1H NMR chemical shifts of free ligands and [(1,2-DACH)Au(III)Cl2]Clcomplexes in CD3OD 
Compound 
1H(δ in 
ppm) 
    
 
H1,H2 
 
H3,H6 
(eq) 
H3,H6 
(ax) 
H4,H5 
(eq) 
H4,H5 
(ax) 
(36´) 2.23, m 1.85, m 1.69, m 1.28, m 1.12, m 
(37´) 2.25, m 1.85, m 1.68, m 1.28, m 1.11, m 
(38´) 2.24, m 1.85, m 1.69, m 1.28, m 1.11, m 
(36) 3.60,m 1.95,m 1.73,m 1.58,m 1.40 ,m 
(37) 3.04,m 2.18,m 1.69,m 1.54,m 1.22 ,m 
(38) 3.09,m 2.20,m 1.67,m 1.55,m 1.22 ,m 
 
Table 5.5 13C NMR chemical shifts of free ligands and [(1,2-DACH)Au(III)Cl2]Cl complexes in CD3OD. 
Compound 
13C(δ in ppm) 
 C1,C2 C3,C6 C4,C5 
(36´) 58.20 35.26 26.36 
(37´) 58.46 35.55 26.63 
(38´) 58.27 35.32 26.43 
(36) 63.33 26.78 21.43 
(37) 65.87 33.58 24.85 
(38) 65.94 33.47 24.65 
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Figure 5.1The 500-MHz 1H solution NMR spectrum of [(1,2-DACH)Au(III)Cl2]Cl complexes 
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Figure 5.2 The 125.65-MHz 13C{1H} solution NMR spectrum of[(1,2-DACH)Au(III)Cl2]Cl complexes 
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5.1.4 Solid State NMR 
The 
13
C CPMAS NMR spectral data for complexes (36-38) are shown in Table 5.6.  At 
the spinning rate of 8 kHz, only the isotropic signals were observed for the carbons, 
indicating small anisotropy due to the sp
3
 hybridization of these atoms.  Compared to 
solution chemical shifts, substantial de-shielding in solid state is observed with similarity 
in the chemical shift among all synthesized complexes (Table 5.6) which is a clear 
indication of the stability of the prepared complexes.  Solid state NMR spectra of 
complexes (36) showed two sets of peaks with equal intensity which supports the idea of 
the inequivalency of all six carbon atoms of DACH.  This indicates that complex (36) in 
the solid state lacks C2 symmetry.  However, complexes (37) and (38) showed C2 
symmetry in the solid state as shown in Figure 5.3 and Table 5.6. 
Table 5.6 Solid 13C NMR chemical shifts of [(1,2-DACH)Au(III)Cl2]Cl complexes. 
Compound 
13C(δ in ppm) 
 C1,C2 C3,C6 C4,C5 
(36) 69.20, 65.35 30.98 27.02, 22.12 
(37) 69.60 37.37 27.99 
(38) 70.21 37.86 29.16 
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Figure 5.3 Solid state 13C{1H} NMR spectra of complexes 36 & 37 
 
96 
 
The chemical shifts of 69.2-70.21 ppmin solid state 
13
C NMR, for complex (36-38) are 
slightly higher than that of the solution NMR chemical shifts 63.33-65.94 ppm (Table 
5.5) which is a clear indication of the stability of the prepared complexes in solid state as 
well as the conservation of the bond topology in solution as in the solid form.  
5.1.5 Crystal structure of complexes (36) and (37) 
Figure 5.4 showed the crystal structure of complex (36).  The gold(III) ion is bonded to 
two nitrogen atoms of the cis-cyclohexane-1,2-diamine ligand and two chloride ions in a 
distorted square planar geometry (Figure 5.4). The two Au-N bond distances are not 
significantly different (2.029(4) Å while Au-Cl bond distances are 2.261(1) Å and 
2.268(1) Å respectively (Table 5.7 and Table 5.8). The Cl-Au-Cl and N-Au-N bond 
angles are 91.83(5) ° and 83.9(2) ° respectively. The later value reflects the chelation 
strain of the diamine ligand. These values are similar to those found in dichlorido-
(ethylenediamine-N,N')-gold(III) chloride dehydrate [176] and dichlorido-(1,2-
ethanediamine)-gold(III) nitrate [177]. The cyclohexyl ring adopts a chair conformation. 
The square planar geometry and the five-membered ring strain impose a torsion angle 
N1-C1-C2-N2 of 49.80°. All amine hydrogen atoms are engaged in hydrogen bonding 
with Cl
-
 counter ion. To the best of our knowledge this is the first X-ray structure of a 
gold complex based on cyclohexane-1,2-diamine [178]. A molecule of ethanol is present 
in the lattice. It presents an orientation disorder on a two-fold rotation axis. The metal 
complex molecules pack head to tail to generate molecular chains along the c axis, which 
in turn pack into layers, parallel to the ac plane (Figure 5.5). These are separated by 
sheets hosting columns of disordered ethanol molecules and Cl
- 
counter ions having 
hydrogen bonding interactions with the NH2 groups of adjacent layers. 
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The crystal structure of complex (37) is depicted in Figure5.6.  In this case the 
asymmetric unit contains two cationic molecules of the gold complex, two chloride 
counter ions and one crystallization water molecule. Similarly to (36), in both molecules 
the gold(III) ion is bonded to two nitrogen atoms of the trans-cyclohexane-1,2-diamine 
ligand and two chloride ions (Figure 5.6). The geometry is distorted square planar with 
Au-N and Au-Cl bond distances in the ranges (2.029(6)-2.054(7) Å) and (2.259(3)-
2.276(2) Å) respectively,  similar N-Au-N bond angles of 84.1(2) ° in addition to Cl-Au-
Cl bond angles in the range (91.4(1)-93.81(8) °). The coordination sphere bond distances 
and bond angles are similar to those of compound (36). The two cyclohexyl rings adopt a 
chair conformation with N1-C1-C6-N2 and N3-C7-C12-N4 torsion angle of 55.78° and 
52.33° respectively. Hydrogen bonding interactions take place between the amino groups 
and the chloride counter ions. 
Table 5.7 Crystal and structure refinement data for compounds (36) and (37) 
Compound (36) (37) 
CCDC deposit no. 831613 850216 
Empirical formula  C14 H34 Au2 Cl6 N4 O C12 H30 Au2 Cl6 N4 O 
Formula weight  881.09 853.03 
Temperature (K) 297(2) 295(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Orthorhombic Monoclinic 
Space group  Pbcn P21 
Unit cell dimensions   
a (Å) 19.792(1) 9.5898(7) 
b (Å) 12.4662(7) 8.6106(6) 
c (Å) 10.3212(6) 14.477(1) 
 (°)  95.307(1) 
Volume (Å
3
) 2546.5(2) 1190.3(2) 
Z 4 2 
Calc. density (g.cm-3) 2.298 2.38 
Absorp. coefficient (mm-1) 12.152 12.994 
F(000) 1656 796 
Crystal size (mm) 0.40 x 0.37 x 0.26 0.52 x 0.49 x 0.16 
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 range (o) 1.93 - 28.29 1.41 - 28.28   
Limiting indices -26 ≤ h ≤ 26   -12 ≤ h ≤ 12 
  -16 ≤ k ≤ 16   -11 ≤ k ≤ 11 
  -13 ≤ l ≤ 13   -19 ≤ l ≤  19 
Max and min transmission Tmin = 0.0850, Tmax= 0.1443 Tmin = 0.0564, Tmax= 0.2244 
Data/restraints/parameters 3162 / 0 / 128  5835 / 2 / 230 
Goodness-of-fit on F
2
 1.051 1.017 
Final R indices [I >2(I)] R1 = 0.0246, wR2 = 0.0631  R1 = 0.0308, wR2 = 0.0739 
R indices (all data) R1 = 0.0288, wR2 = 0.0654  R1 = 0.0329, wR2 = 0.0747 
Largest diff. Peak   and hole (e Å
-3
) 1.766 and -1.544 0.796 and -1.555 
 
Table 5.8 Selected bond lengths (Å) and bond angles (o) for compounds (36) and (37) 
(36) (37) 
Au1-N1 2.029(4) Au1-N1 2.029(6) Au2-N3 2.029(6) 
Au1-N2 2.030(3) Au1-N2 2.031(5) Au2-N4 2.054(7) 
Au1-Cl1 2.261(1) Au1-Cl1 2.274(2) Au2-Cl3 2.259(3) 
Au1-Cl2 2.268(1) Au1-Cl2 2.276(2) Au2-Cl4 2.266(2) 
   
N1-Au1-N2  83.9(2) N1-Au1-N2 84.3(2) N3-Au2-N4  84.1(2) 
N1-Au1-Cl1  91.7(1) N1-Au1-Cl1 92.0(2) N3-Au2-Cl3  92.2(2) 
N2-Au1-Cl1  175.4(1) N2-Au1-Cl1 176.2(2) N4-Au2-Cl3  176.2(2) 
N1-Au1-Cl2  176.0(1) N1-Au1-Cl2 174.2(2) N3-Au2-Cl4  176.4(2) 
N2-Au1-Cl2  92.6(1) N2-Au1-Cl2  89.9(2) N4-Au2-Cl4  92.3(2) 
Cl1-Au1-Cl2  91.83(5) Cl1-Au1-Cl2  93.81(8) Cl3-Au2-Cl4  91.4(1) 
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Figure 5.4 X-ray structure of [cis-(1,2-DACH)Au(III)Cl2]Cl (36) 
 
Figure 5.5 Molecular packing in [cis-(1,2-DACH)Au(III)Cl2]Cl (36) 
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Figure 5.6 X-ray structure of compound [trans-(1,2-DACH)Au(III)Cl2]Cl (37) 
 
5.1.6 Effect of Complexes (36)-(38)on cell proliferation 
The cytotoxicity assay was performed with compounds(36-38) on PC3 and SGC7901 
cells. The bioassay tests were completed for compounds (36-38) under various 
experimental conditions.  The cytotoxicity assay was performed with various 
concentrations of the synthesized gold(III) complexes on PC-3 and SGC-7901 cells. The 
experimental PC-3 and SGC- 7901 cells were treated with various concentrations of (36), 
(37) and (38) for 24–72 h and the cell viability was determined as described above by 
MTT assay and the results are shown in Table 5.9and Table 5.10 as well as in Figures 
5.7–5.13.  As depicted in Figures 5.7-5.9, cis-(±)-1,2-(DACH)-gold complex exhibited 
potentially high activity against gastric cancer cell SGC-7901 and human prostate cancer 
cells after 24 and 72 h of treatment with 10 μM.  Whereas, trans-(±)-1,2-(DACH) and 
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purely chiral trans-(-)-1,2-(DACH) gold complexes showed moderate inhibition against 
SGC-7901 and PC-3 cell lines under the same assay experimental condition. From 
Figures 5.10-5.12, it is also quite clear that gold(III) complexes under study showed 
concentration dependent cytotoxic effect on cancerous cells PC-3 and SGC-7901.It can 
be concluded from Figures 5.8, 5.9, 5.11and 5.12 that there isn‘t significant different in 
the bioactivity between trans-(1R,2R)-(DACH) isomer and trans-(1S,2S)-(DACH) 
isomer. To the best of our knowledge these are the first bioassay tests reported for 
gold(III) complex based on cyclohexane-1,2-diamine. 
In a time dependent activity studies, it is revealed that after 72 h of the experiment with 
compound (36) on PC-3 cell, the cell proliferation is bit higher than that of the SGC-7901 
cells at fixed 10 μM concentration (Figure 5.7). Furthermore, in Figure 5.13, the bioassay 
tests results demonstrate that the compound (36) at 10 μM concentrations has higher anti-
proliferation effect in comparison with the same concentrations of compounds(37)and 
(38). 
Table 5.9 Effect of compound (36) on PC3 cell line and SGC-7901 cell line (mean, SD) after incubation for 24h and 
72h 
 PC3 Cell line                      SGC-7901 Cell line 
Group Day 1 (24 h) Day 3 (72 h) Day 1 (24 h) Day 3 (72 h) 
Control 0.75 ± 0.02 1.39 ± 0.11 0.54 ± 0.02 1.09 ± 0.06 
(36) 0.70 ± 0.29 0.81 ± 0.17 0.79 ± 0.40 0.85 ± 0.23 
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Table 5.10 Cytotoxicity of the compound [cis-(1,2-DACH)Au(III)Cl2]Cl (36) toward different tumor cell lines. The 
data were collected after 72h exposure to compound 
Compounds SGC-7901 PC3 
Cisplatin 1.1 0.1 7.3 0.5 
[cis-(1,2-DACH)Au(III)Cl2]Cl(36) 8.5 ± 0.2 8.1 ± 0.2 
 
 
Figure 5.7 Effect of cis-(±)1,2-(DACH)-gold(III)complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured by MTT 
assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5. 8 Effect of trans-(±)1,2-(DACH)-gold(III) complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured by MTT 
assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.9 Effect of (S,S)-(+)-1,2-(DACH)-gold(III) complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured by MTT 
assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.10 Effect of cis-(±)-1,2-(DACH)-gold complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. The cells 
were treated with various concentrations for 24 h. The anti-proliferative effect was measured by MTT 
assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.11 Effect of trans-(±)-1,2-(DACH)-gold complex  on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured by 
MTT assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.12 Effect of (S,S)-(+)-1,2-(DACH)-gold(III) complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. 
The cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.13 Effect of compounds 37 and 36 on cell growth in (A) PC-3 and (B) SGC-7901 cells. The cells were 
treated with 10 µM for day 1, day2 and day 3.  The anti-proliferative effect was measured by MTT 
assay. Results were expressed as the mean, SD. *P<0.05 
 
5.1.7 Conclusion 
 Gold along with its therapeutic and beneficial effect on human health is among the most 
ancient of all metals used in medicine.  The use of gold complexes in modern medicine 
has allowed information regarding toxicological and clinical administration to become 
available along with valuable studies concerning its metabolism and molecular targets. 
Therefore, gold has become one of the most promising metals for drug development in 
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medicine.  Three mono gold(III) complexes based on DACH with different 
configurations were prepared.  These gold(III) complexes were characterized using 
elemental analysis, solution and solid NMR, UV, Mid-IR, Far-IR spectroscopy and X-ray 
crystallography.  The analytical data showed strong support for the formation of the type 
[(DACH)AuCl2]Cl complex. Also, the X-ray crystallography demonstrates that gold 
coordination sphere of this complex adopts distorted square planar geometry.  According 
to our biological assays, complex (36) with cis configuration is a more promising 
candidate as an anti-cancer agent than the trans isomers (37) and (38). The exact 
mechanisms are not clearly known, but the inhibitory effect of [(cis-DACH)AuCl2]Cl on 
the proliferation of rapidly dividing cells may be attributed to the induction of cell cycle 
blockage, interruption of the cell mitotic cycle, programmed cell death (apoptosis) or 
premature cell death (necrosis). Therefore, [(cis-DACH)AuCl2]Cl might be a promising 
chemo preventative and chemotherapeutic agent against human gastric carcinogenesis. 
As cytotoxic activity of [(cis-DACH)AuCl2]Cl complex is high towards some cancer cell 
lines; further biological evaluation for this class of complexes is worthy of efforts 
especially in order to evaluate activities in vivo. 
 
5.2 Gold(III) Complexes of Bis(1,2-Diaminocyclohexane) Ligands 
This work reports the synthesis of bis-diaminocyclohexane containing gold(III) 
complexes of the type [Au(1,2-DACH)2]Cl3, where,1,2-DACH = 1,2-
Diaminocyclohexaneusing trihydrate tetrachloroauric acid HAuCl4.3H2O as gold(III) 
precursor and different isomers of 1,2-Diaminocyclohexane (1,2-DACH)i.e. cis-1,2-
DACH, trans-(±)-1,2-DACH and (S,S)-(+)-(1,2-DACH) as ligands. 
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5.2.1 Mid and Far-IR Spectroscopic Studies 
The most significant bands recorded in the IR spectra of free ligands, mono- and bis-
DACH complexes have been reported in Table 5.11and Table 5.12.  It is noted that N-H 
stretching vibrations of complexes (45-47) exhibit, in the range 3333-3438 cm
-1
, blue 
shifting compared with the amino (-NH2) group of the corresponding free ligands. This is 
most likely due to stronger H-bonding interactions in the free ligands as compared to the 
coordinated-NH2 corresponding complexes (45-47). The amino coordination with Au(III) 
ions and Au-N bond formation can be supported by the presence of ν(Au-N) at 419-428 
cm
-1
 as indicated by Far-IR data [174].  The C-N stretching bands also showed a 
significant shift to higher wave number indicating a shorter C-N bond in the complex 
than in the free ligand.  Furthermore, there was no signal observed at 352 and 367 cm
-1
 
corresponding to the symmetric and asymmetric stretching of the Au-Cl, indicating the 
absence of the gold mono-DACH complex. The bis-DACH complexes show N-H 
stretching frequencies generally lower in comparison with mono-DACH complexes 
(Table 10), most probably due to stronger hydrogen bonding interactions with the 
chloride anions in the bis-DACH complexes. Furthermore the Au-N stretching 
frequencies are consistent with weaker Au-N bond strength in complexes (45-47) 
compared to the mono-DACH complexes. 
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Table 5.11 Mid-IR frequencies, ν(cm-1) for [(1,2-DACH)2Au(III)]Cl3 complexes 
Complex ν(N-H) νshift ν(C-N) νshift 
(36´) 3356 m, 3286 m  1092s  
(36) 3414 w 93 1183 s 91 
(45) 3409m, 3338 m 53, 52 1185 s 93 
(37´) 3348 m, 3271 m, 3183 m  1082 m  
(37) 3485 w, 3420 w, 3384 w 137, 149, 201 1175 m 93 
(46) 3416m, 3364m, 3333m 68, 93, 150 1176 m 94 
(38´) 3340 m, 3252 m, 3167 m  1082 m  
(38) 3604 m, 3340 m, 3306 m 364, 88, 139 1171 m 89 
(47) 3438 m, 3410m, 3368 m 98, 158, 201 1181 m 99 
 
Table 5.12 Far-IR frequencies, ν(cm-1) for [(1,2-DACH)2Au(III)]Cl3complexes 
Species Au-Cl Au-N 
HAuCl4 369 - 
(36) 352, 367 437 
(45) - 428 
(37) 353, 365 437 
(46) - 419 
(38) 353, 366 395, 436 
(47) - 427 
 
5.2.2 Solution NMR Characterization 
The 
1
H and 
13
C NMR chemical shifts of free ligands along with their corresponding 
complexes (45-47) are listed in Table 5.13 and Table 5.14, respectively. Figures 5.14 and 
5.15 show the
1
H and 
13
C NMR spectra, respectively.  The spectra of complexes (46) and 
(47), show one quarter of the total expected signals observed because of the D2d 
symmetry. Whereas, 
13
C NMR spectra of complexes (45) indicated the presence of C2 
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symmetry axis as one half of the total expected carbon peaks were noticed. The 1,2-
diaminocyclohexane (DACH) ring is considered as a rigid conformer that allowed to 
distinguish equatorial H3 and H4 from axial H3 and H4 at room temperature. The signals 
of C-H protons connected through carbon to the amino (-NH2) groups occur at 2.96-3.62 
ppm as a multiplet, shifting downfield compared with the corresponding signals (2.23-
2.25 ppm) in the free diamine ligands. The significant downfield shift was observed at 
3.62 ppm for complex (45)with respect to the free DACH ligand at 2.23 ppm. This can be 
attributed to the donation of nitrogen lone pairs to the gold(III) center that causes de-
shielding of the proton(s) next to the bonding nitrogen. 
13
C NMR downfield shift was 
observed only for the carbon next to the bonding nitrogen. Conversely, the others carbons 
of the coordinated ligand (DACH) in the complex showed upfield shift.  For instance, 
chemical shift of C3 and C4 for complex (45) observed at 26.46 and 20.80 ppm, 
respectively, whereas, for free 1,2-diaminocyclohexane(1,2-DACH) ligand it occurs at 
35.26 and 26.36 ppm.  It is also worth-mentioning that complexes (45-47), even though 
they have the same skeleton of DACH, their carbon chemical shifts were not the same 
due to a different stereochemistry upon complexation. 
Table 5.13 1H NMR chemical shifts of free ligands and corresponding [(1,2-DACH)2Au(III)]Cl3complexes in D2O 
Compound H1,H2,H1́,H2́ 
H3,H6,H3́,H6́ H3,H6,H3́,H6́ H4,H5,H4́,H5́ H4,H5,H4́,H5́ 
Equatorial Axial equatorial axial 
(36´) 2.23, m 1.85, m 1.69, m 1.28, m 1.12, m 
(45) 3.62, m 1.94,m 1.77, m 1.57, m 1.38, m 
(37´) 2.25, m 1.85, m 1.68, m 1.28, m 1.11, m 
(46) 2.97, m 2.05, m 1.48, m 1.39, m 1.03, m 
(38´) 2.24, m 1.85, m 1.69, m 1.28, m 1.11, m 
(47) 2.96, m 2.03, m 1.47, m 1.47, m 1.03, m 
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Table 5.14 Solution 13C NMR chemical shifts of free ligands and corresponding [(1,2-DACH)2Au(III)]Cl3 complexes 
in D2O 
Compound  
13C (δ in ppm) 
 
C1,C2, C1́,C2 ́ C3,C6, C3́,C6 ́ C4,C5, C4́ ́,́C5 ́
(36´) 58.2 35.26 26.36 
(45) 61.87, 61.80 26.46, 26.24 20.8 
(37´) 58.46 35.55 26.63 
(46) 64.56 32.93 24.15 
(38´) 58.27 35.32 26.43 
(47) 64.49 32.93 24.1 
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Figure 5.14 The 500-MHz 1H solution NMR spectra of [(1,2-DACH)2Au(III)]Cl3 (45-47) complexes 
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Figure 5.15 The 500-MHz 1H solution NMR spectra of [(1,2-DACH)2Au(III)]Cl3 (45-47) complexes 
5.2.3 Solid State NMR Characterization 
At the spinning rate of 4 kHz, only the isotropic signals were observed for the carbons, 
indicating small anisotropy due to the sp
3
 hybridization of these atoms, except for 
compound (45)where a minor anisotropy was observed as shown in Figure 5.16. It, also, 
illustrates the four different peaks for the carbons connected to the amino (-NH2) group 
with equal intensity which supports the idea of the inequivalency of the four carbon 
atoms, indicating that gold coordination sphere adopts a distorted square planer 
geometry.  Compared to solution chemical shifts, significant de-shielding in solid state is 
observed with similarity in chemical shift trend among all compounds (45-47) as given in 
Table 5.15 which is a clear indication of stability of the compounds (45-47) in solid state.  
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Figure 5.16 Solid state 13C{1H} NMR spectrum of complex [(cis-1,2-DACH)2Au(III)]Cl3(45) 
 
Table 5.15 Solid state 13C NMR chemical shifts of free ligands and corresponding [(1,2-DACH)2Au(III)]Cl3 (45-47) 
complexes 
Compound  
13C (δ in ppm) 
 
C1,C2, C1́,C2 ́ C3,C6, C3́,C6 ́ C4,C5, C4́ ́,́C5 ́
(36) 69.20, 65.35 30.98 27.02, 22.12 
(45) 
66.61, 65.45, 64.57, 
63.79 
30.09, 29.49, 28.46, 
27.77 
23.54, 22.62 
(37) 69.6 37.37 27.99 
(46) 69.14 36.89 28.42 
(38) 70.21 37.86 29.16 
(47) 68.39, 66.74 , 66.61 36.41 28.66, 26.32 
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5.2.4 X-ray Crystal Structure of Complexes (45) and (46) 
For compound (46), all attempts to grow single crystals using different solvents and 
techniques always led to the formation of co-crystals of mono- and bis(trans-(±)-1,2-
DACH)gold(III) complexes as shown in Figure 15.19.  The optimized crystal growth was 
observed in water over two weeks.  However, complex(46) was stableas dissolved in 
water as it is observed by solution 
1
H and
13
C NMR in D2O. For instance, Figure 15.17 
shows the 
13
C NMR spectrum of complex(46) (a), the co-crystals of mono-and bis{trans-
(±)-1,2-DACH)}Au(III) (b) along with its mono-{trans-(±)-1,2-DACH)}Au(III) (c). As 
shown in Figure 15.17(b), compound (46) and its mono-1,2-DACH gold compound 
exhibit different chemical shift for C2 and C3.  The chemical shift of C2 and C3 for 
complex(46) observed at 64.46 and 32.82 ppm, respectively, whereas, for its 
corresponding mono-1,2-DACH compound it occurs at 65.68 and 33.15 ppm.  
Comparison of 
13
C NMR spectrum of the co-crystal with both the mono-1,2-DACH and 
bis-1,2-DACH compounds confirms the identity of complex(46) as bis-1,2-DACH 
compound. 
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Figure 5.17 Solution 13C{1H} NMR spectra of compound (46) (a), co-crystal of mono- and bis(trans-DACH)gold(III) 
(b) and mono-trans-(DACH)gold(III) (c) 
 
The X-ray molecular structure of compound[Au{cis-1,2-DACH)}2]Cl3(45) is  shown in 
Figure 5.18.It crystallizes as crystal of the bis(1,2-DACH)-chelate [{(R,S)-
(DACH)}2Au]Cl3.  The asymmetric unit contains two Au(1,2-DACH) moieties with the 
gold(III) ions each located on an inversion center. In both molecules, the metal ion is 
bonded to four nitrogen atoms of two cis-cyclohexane-1,2-diamine ligands in a distorted 
square planar geometry. The Au-N bond distances are in the range 2.031(2) - 2.038(2) Å 
and the N-Au-N chelate bond angles are 83.77(7)° and 83.22(7)° respectively for 
molecules (45) and (46) (Table 5.16). These values are similar to those reported for 
bis(ethylene-1,2-diamine)gold(III)tris(perrhenate) [179]. The cyclohexyl rings adopt a 
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chair conformation. The square planar geometry and the five-membered ring strain 
impose torsion angles N1-C1-C2-N2 of 51.31° and N3-C7-C12-N4 of 47.91° 
respectively for molecules (45) and (46). Amine hydrogen atoms are engaged in 
hydrogen bonding interactions with Cl
-
 counter ions and the hydration water molecules 
generating a three-dimensional hydrogen bonding network (Figure 5.20). 
Compound (46) crystallizes as a (1:1) co-crystal of the bis-chelate [{(S,S)-(1,2-
DACH)}2Au]Cl3 and the monochelate [(S,S)-(1,2-DACH)AuCl2]Cl(Figure 5.19). The 
structure of the first component of the co-crystal, namely [{(S,S)-(1,2-DACH)}2Au]Cl3,is 
distorted square planar with the Au-N bond distances in the range 2.013(6) - 2.049(6) Ǻ 
and the two N-Au-N chelate bond angles being 83.3(2) and 83.7(2)°respectively. These 
geometrical values are similar to those found for (45) and other bis(diamino)gold(III) 
compounds [179]. Similarly to compound (45), the cyclohexyl rings adopt a chair 
conformation and the NH2 groups have hydrogen bonding interactions with the chlorides 
and water molecules. The structure of the second component of the co-crystal: [Au{(S,S)-
(+)-(DACH)}2Cl2]Cl, has been reported previously by our group [180].  H atoms of 
DACH were placed a calculated positions using a riding model for both compounds (45) 
and (46). Both compounds crystallize as hydrates in the water solvent, while the water H 
atoms in (45) were located on the Fourier difference map and refined isotropically, those 
of compound (46) could not be located and therefore could not be placed at adequate 
positions.  Crystal and structure refinement data are given in Table 5.16. Selected bond 
lengths and bond angles are given in Table 5.17. 
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Table 5.16 Crystal and structure refinement data for compounds (45) and (46) 
Compound (45) (46) 
CCDC deposit no. 889510 925974 
Empirical formula C12H34AuCl3N4O3 C18H46Au2Cl6N6O2 
Formula weight 585.75 985.24 
Crystal size/mm 0.42 × 0.35 × 0.25 0.29 × 0.26 × 0.20 
Wavelength/Å 0.71073 0.71073 
Temperature/K 297 (2) 296 (2) 
Crystal symmetry Triclinic Monoclinic 
Space group P -1 P 21 
Unit cell dimensions   
a/Å 7.5342 (3) 7.3996 (13) 
b/Å  11.7086 (5) 20.650 (4) 
c/Å 12.0149 (5) 10.5543 (19) 
α/° 103.096 (1) 90 
β/° 91.041 (1) 93.558 (3) 
γ/° 104.119 (1) 90 
Volume (Å
3
) 998.11 (7) 1609.6 (5) 
Z 2 2 
Calc. density (g.cm-3) 1.949 2.033 
μ(Mo-Kα)/mm-1 7.79 9.63 
F(000) 576 944 
θ Limits/° 1.8–28.3 1.9–28.3 
Collected reflections 13644 21865 
Unique reflections(Rint) 4175(0.021) 7311(0.043) 
Observed reflections [I  > 2σ (I)] 4932 7964 
Goodness-of-fit on F
2
 1.05 1.01 
R1(F), [I  > 2σ (I)] 
0.016 0.029 
wR2 (F
2), [I  > 2σ(I)] 0.042 0.072 
Largest diff. Peak   and hole (e Å
-3
) 0.99, -1.10 2.01, -0.89 
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Table 5.17 Selected bond lengths (Å) and bond angles (o) for compounds (45) and (46) 
                                               Bond Angles (°)                                           Bond Lengths (Å)  
Compound (45)    
N2—Au1—N2
i
 180.00 (13) Au1—N2 2.0314 (17) 
N2—Au1—N1 83.77 (7) Au1—N2
i
 2.0314 (17) 
N2
i
—Au1—N1 96.23 (7) Au1—N1 2.0375 (18) 
N2—Au1—N1
i
 96.23 (7) Au1—N1
i
 2.0375 (18) 
N2
i
—Au1—N1
i
 83.77 (7) Au2—N4 2.0309 (18) 
N1—Au1—N1
i
 180.00 (13) Au2—N4
ii
 2.0309 (18) 
N4—Au2—N4
ii
 180.00 (14) Au2—N3
ii
 2.0346 (18) 
N4—Au2—N3
ii
 96.78 (7) Au2—N3 2.0346 (18) 
N4
ii
—Au2—N3
ii
 83.22 (7) N1—C1 1.505 (3) 
N4—Au2—N3 83.22 (7)   
N4
ii
—Au2—N3 96.78 (7)   
N3
ii
—Au2—N3 180.00 (9)   
C1—N1—Au1 109.95 (13)   
 
   
Compound (46)    
N1—Au1—N2 84.80 (19) Au1—N1 2.038 (4) 
N1—Au1—Cl2 90.78 (14) Au1—N2 2.040 (5) 
N2—Au1—Cl2 175.57 (15) Au1—Cl2 2.272 (2) 
N1—Au1—Cl1 175.01 (14) Au1—Cl1 2.2727 (17) 
N2—Au1—Cl1 90.21 (15) Au2—N5 2.013 (6) 
Cl2—Au1—Cl1 94.21 (9) Au2—N6 2.029 (5) 
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Symmetry codes: (i) −x+1, −y+2, −z+1; (ii) −x, −y, −z 
 
Figure 5.18 X-ray molecular structure of compound[(cis-1,2-DACH)2Au(III)]Cl3 (45) 
N5—Au2—N6 83.7 (2) Au2—N4 2.034 (6) 
N5—Au2—N4 95.5 (2) Au2—N3 2.049 (6) 
N6—Au2—N4 179.2 (3) N1—C1 1.488 (7) 
N5—Au2—N3 178.8 (2)   
N6—Au2—N3 97.5 (2)   
N4—Au2—N3 83.3 (2)   
C1—N1—Au1 107.9 (3)   
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Figure 5.19 X-ray molecular structures of the two components of co-crystal [(trans-1,2-DACH)2Au(III)]Cl3(46) 
 
 
 
Figure 5.20 Hydrogen bonding network in compound[(cis-1,2-DACH)2Au(III)]Cl3 (45) 
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5.2.5 UV-Vis Spectra 
The λmaxvalues for the compounds studied along with their corresponding mono-DACH 
compounds are shown in Table 5.18.  The gold(III) compounds (45), (46) and (47) 
exhibit, in a reference buffered phosphate solution, intense transitions in the range 335-
339 nm, which are assigned as ligand-to-metal charge-transfer transitions 
characteristically associated to the gold(III) center [181].  In related compounds, these 
absorption bands were assigned as NH
-
 to a gold(III) charge-transfer bands [181].  It is 
worth to notice that these spectral features appear only at relatively high pH values (pH > 
6-7) at which ligand deprotonation has fully occurred.  According to crystal field theory 
for d
8
 compounds the LUMO orbital is dx
2
-y
2
, so ligand to metal charge transfer could be 
due to pσ→dx
2
-y
2
 transition [174].  It is worth to notice that mono-1,2-DACH [180] 
compare with their corresponding bis-1,2-DACH gold(III) compounds exhibit different 
λmaxvalues. 
Table 5.18 λmax values for [(1,2-DACH)2Au(III)]Cl3 (45-47) complexes obtained from UV-Vis spectra 
Compound λmax (nm) 
HAuCl4·3H2O 320.0 
[Au{cis-(1,2-DACH)}Cl2]Cl (36) 302.5 
[Au{cis-(1,2-DACH)}2]Cl3(45) 338.0 
[Au{trans-(±)-(1,2-DACH)}Cl2]Cl (37) 301.6 
[Au{trans-(±)-(1,2-DACH)}2]Cl3(46) 339.5 
[Au{(S,S)-(+)-(1,2-DACH)}Cl2]Cl3(38) 301.5 
[Au{(S,S)-(+)-(1,2-DACH)}2]Cl3(47) 339.0 
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The electronic spectra of the compounds (45), (46) and (47) in the buffer solution, were 
monitored at 37 
o
C over 3 days after mixing; electronic spectra for all compounds at 
mixing and after 3 days are depicted in Figure 5.21.  It is apparent that the observed 
transitions remain substantially unmodified over 3 days observation, implying a 
substantial stability of these compounds under the present solution conditions.  
Nevertheless, a slight decrease in intensity, of the characteristic bands, was noticed with 
time without significant shape modifications.  Also, this observation indicates that the 
gold center in these compounds remains in the +3 oxidation state [174,181].  In general, 
however, loss of spectral intensity is lower than 5% of the original intensity within the 
observation period of 3 days which indicates high stability of these compounds in the 
buffer.  This is a possible suggestion that in the physiological milieu, the compounds 
would be able to undergo the necessary reactions required for bioactivity. 
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Figure 5.21 UV-Vis spectra of [(1,2-DACH)2Au(III)]Cl3 (45-47) complexes, followed by dissolution in the buffer 
solution (a) just after mixing and (b) after 3 days at 37 oC. 
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5.2.6 Stability Studies of Gold(III) Compounds (45)-(47) 
NMR spectra of the compounds dissolved in D2O and mixed DMSO-d6/D2O (v/v: 3:1) 
solution were obtained on immediate dissolution to serve as reference spectra and latter at 
24 h and after 3 days at 37 
o
C in D2O and at room temperature in mixed DMSO-d6/D2O 
to determine their stability.  In general, all compounds showed high stability in D2O as 
well as in the mixed DMSO-d6/D2O and their NMR profiles remained unchanged over 3 
days.  For example, Figures 5.22-5.23 illustrated, respectively, 
1
H and 
13
C NMR profiles 
of the compound (46) at mixing and after 3 days in D2O.  Furthermore, these compounds 
in mixed DMSO-d6/D2O were also observed stable and their NMR profiles remained 
unchanged at the experimental conditions.  Figures 5.24-5.25 show, respectively, 
1
H and 
13
C NMR profiles of compound (46) in DMSO-d6/D2O at mixing and after 3 days. 
 
Figure 5.22 1H NMR spectra of compound (46) in D2O (a) just after mixing and (b) after 3 days. 
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Figure 5.23 Solution 13C{1H} NMR spectra of [(trans-1,2-DACH)2Au(III)]Cl3 (46) in D2O (a) after mixing and (b) 
after 3 days. 
 
Figure 5.24 1HNMR spectra of [(trans-1,2-DACH)2Au(III)]Cl3(46) in (DMSO/D2O, 3:1) (a) just after mixing and (b) 
after 3 days. 
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Figure 5.25 Solution 13C{1H} NMR spectra of [(trans-1,2-DACH)2Au(III)]Cl3 (46) in (DMSO/D2O, 3:1) (a) after 
mixing and (b) after 3 days. 
 
5.2.7 Electrochemistry of Gold(III) Compounds (36-38) and (45-47) 
The electrochemical behavior of compounds (45), (46) and (47)along with their 
corresponding mono-DACH gold(III) compounds(36), (37) and (38) was investigated in 
a physiological environment through cyclic voltammetry to study the effect of the 
bidentate amino coordination at gold(III) on the stability of the compounds.   The cyclic 
voltammetric curves of the compounds (45), (46) and (47) and their corresponding mono-
DACH gold(III) compounds(36), (37) and (38) are shown in Figure 5.26and Table 5.19 
summarizes the cyclic voltammetric data of all the studied compounds.  The potential 
values vs. NHE for the reduction processes exhibited by the compounds (45), (46) and 
(47), in a reference buffered phosphate, are in the range (+465)-(+498) mV against the 
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range of (+490)-(+525) mV for their corresponding mono-1,2-DACH gold(III) 
compounds(36), (37) and (38).  In general, bis-1,2-DACH gold(III) compounds showed 
lower peak potential values compare with their corresponding mono-1,2-DACH gold(III) 
compounds as listed in Table 5.19.  This is attributed to the fact that amino bidentate 
ligand stabilized the compounds. In addition to that, cyclicvoltammetric data indicated 
that cis-1,2-DACH configuration is slightly more stable than the trans-(±)-1,2-DACH 
configuration of the compounds which is also indicated by UV-Visible analysis.  All 
studied gold(III) compounds show one irreversible reduction process which, in controlled 
potential coulometry, involves three electrons per mole.  The occurrence of Au(III)/Au(0) 
reduction is confirmed by the appearance of the thin gold layer deposited on the platinum 
electrode surface after exhaustive electrolysis (Ew, -0.7 V).  In general, 
cyclicvoltammetric results suggested that these compounds are quite stableunder the 
physiological conditions. 
 
Table 5.19 Peak potential values (vs ENH) for reduction of compounds [Au(1,2-DACH)Cl2]Cl and [Au(1,2-
DACH)2]Cl3 
Compound Ep(mV) 
[Au{cis-(1,2-DACH)}Cl2]Cl (36) 490 
[Au{cis-(1,2-DACH)}2]Cl3(45) 465 
[Au{trans-(±)-(1,2-DACH)}Cl2]Cl (37) 525 
[Au{trans-(±)-(1,2-DACH)}2]Cl3(46) 495 
[Au{(S,S)-(+)-(1,2-DACH)}Cl2]Cl3(38) 522 
[Au{(S,S)-(+)-(1,2-DACH)}2]Cl3(47) 498 
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Figure 5.26 Cyclic voltammetric curves of the compounds (45-47) and their corresponding mono-DACH gold(III) 
compounds (36-38). Curve labeled with (a) is corresponding to the bis-DACH, while, (b) corresponding 
to mono-DACH 
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5.2.8 Anticancer Activity of [(1,2-DACH)2Au(III)]Cl3(45-47) on PC3 and 
SGC7901 Cancer Cell Lines 
The MTT assay for time dependent inhibitory effect was performed with fixed 
concentration of the synthesized gold(III) compounds (45), (46) and (47) on PC3 and 
SGC7901 cells for 24 h (1day) and 72 h (3 day).  As illustrated in Figures 5.27-5.29, 
compound (46) and purely optical active isomer compound (47) exhibited potentially 
high anticancer activity against gastric cancer cells SGC7901and prostate cancer cells 
PC3 after 24 and 72 h of treatment with 10 μM.  Whereas, compound (45) showed 
substantial inhibition against PC3 and SGC7901 cell lines under the same assay 
experimental condition. 
From Figures 5.30-5.32, it is also quite clear that gold(III) compounds (45-47) under 
study showed concentration dependence in vitro on the growth of cancerous cells PC3 
and SGC7901 after 24 h. In addition to that, Figure 5.33 illustrates the anticancer activity 
of compound 1-3 against the two cell lines for a purpose of compression illustrates that 
compound [{trans-(±)-1,2-(DACH)}2Au]Cl3 shows the highest bioactivity. 
The in vitro cytotoxicity of the compounds (45-47) was evaluated in terms of their IC50 
values against prostate cancer cell lines (PC3) and gastric carcinoma cell lines 
(SGC7901).  The IC50 data is shown in Table 5.20.  The IC50 data for the Au(III) 
complexes (45), (46) and (47) showed reasonable cytotoxicity in the 6–10 μM range for 
SGC7901 cells, as given in Table 5.20.  For SGC7901cells, complex (46) was recognized 
as being as effective cytotoxic agent as cisplatin, while compound (45) and (47) 
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demonstrated about 1.3 to 1.4-fold lower potency.  For PC3 cells line, compounds 1-3 
showed almost 6–13-fold lower cytotoxicity as compared to cisplatin. 
An independent assessment of compounds (45-47) revealed an interesting feature that 
SGC7901 gastric cancer cells exhibit 7 to 8-fold intrinsic resistance relative to the PC3 
cancer cells with respect to cisplatin [182]. However, almost 1-fold resistance to 
compounds (45-47) was observed for PC3, as shown in Table 5.20. This suggests that the 
intrinsic factors regulating cellular sensitivity to cisplatin are different for PC3 and 
SGC7901 cells.  The factors affecting the sensitivity of PC3 and SGC7901 cells are 
analogous in compounds (45-47). There is no doubt that the present study is helpful for 
further exploiting and defining the potential role of gold(III) complexes in the combat 
against prostate and gastric cancers. 
The cytotoxicity result for the compounds (45-47) reveals that gold(III) complex (46) 
with trans-(±)-(1,2-DACH)2 configuration demonstrated higher cytotoxic effect in 
comparison with the  complexes (45) and (47).  It is worth to notice that complex (46) is 
a racemic mixture, consisting of(1S,2S)-bis-(DACH) complex (47) and trans-(1R,2R)-
bis-(DACH) complex.  Comparison of the cytotoxicity values of compounds (46) and 
(47) enable us to conclude that trans-(1R,2R)-bis-(DACH) gold(III) complex poses 
higher cytotoxicity activity than (1S,2S)-bis-(DACH) complex (47). 
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Table 5.20 in vitro cytotoxicity data of compounds [(1,2-DACH)2Au(III)]Cl3 (45-47) for 72 h exposure on PC3 and 
SGC7901cancer cell lines 
IC50 (µM)  
Compound PC3 SGC7901 
Fold resistance 
SGC7901/PC3 
Ref. 
Cisplatin 1.1 ± 0.10 7.3 ± 0.50. 6.64 [182] 
45 13.1 ± 0.13 10.4 ± 0.21 0.79 a 
46 6.5 ± 0.07 5.8 ± 0.11 0.89 a 
47 9.9 ± 0.21 9.5 ± 0.05 0.96 a 
a
this work 
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Figure 5.27 Time dependent inhibitoryeffect of 10 µM [{cis-1,2-(DACH)}2Au]Cl3on growth of (A) PC3 and (B) 
SGC7901 cells for 1 day and 3 days using MTT assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.28 Time dependent inhibitory effect of 10 µM [{trans-(±)-1,2-(DACH)}2Au]Cl3on growth of (A) PC3 and 
(B) SGC7901 cells for 1 day and 3 days using MTT assay. Results were expressed as the mean, SD. 
*P<0.05 
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Figure 5.29 Time dependent inhibitory effect of 10 µM [{(1S,2S)-(+)-(DACH)}2Au]Cl3 on growth of (A) PC3 and (B) 
SGC7901 cells for 1 day and 3 days using MTT assay. Results were expressed as the mean, SD. P<0.05 
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Figure 5.30 Effect of [{cis-1,2-(DACH)}2Au]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured by 
MTT assay. Results were expressed as the mean, SD. P<0.05 
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Figure 5.31 Effect of [{trans-(±)-1,2-(DACH)}2Au]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. 
The cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P<0.05 
0
1
2
3
4
5
6
7
8
1
0
6
 C
e
ll
s
B
0
*
*
10
SGC 7901 Cells
Compound 46
20 µM
Compound  46 
141 
 
 
 
Figure 5.32 Effect of [{(1S,2S)-(+)-(DACH)}2Au]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured by 
MTT assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.33 Comparative time dependent inhibitory effects for 10 µM of compounds (45-47) on growth of (A) PC3 
and (B) SGC7901 cells for day 1, day 2 and day 3 using MTT.  Results were expressed as the mean, SD. 
*P<0.05 
Compound                                       45      46        47                              45      46      47         
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5.2.9 Conclusion 
Three newgold(III) compounds (45), (46) and (47) with general chemical formula 
of[Au(1,2-DACH)2]Cl3have successfully been synthesized. These gold(III)compounds 
were characterized using CHN analysis, UV-Vis, mid-FTIR, Far-FTIR spectroscopy; 
solution and solid-state NMR measurements; and X-ray crystallography. The CHN 
analysis data showed strong support for the formation of the type [(1,2-
DACH)2Au]Cl3compound. Also, the X-ray crystallography demonstrates that gold 
coordination sphere of this compound adopts a distorted square planar geometry. 
According to our biological assays, compound(46)with trans configuration is a more 
promising candidate as an anti-cancer agent than the trans isomers (45) and (47) 
compounds.[(trans-DACH)2Au]Cl3, in particular (1S,2S)-bis-(1,2-DACH) isomer, might 
be a promising chemo preventative and chemotherapeutic agent against human gastric 
carcinogenesis. As cytotoxic activity of [(trans-DACH)2Au]Cl3compound is high 
towards some cancer cell lines; further biological evaluation for this class of compounds 
is worthy of efforts especially in order to evaluate their activities in vivo. 
 
5.3 Mixed-Ligand 1,2-Diaminocyclohexane(ethylenediamine)gold(III) 
Chloride Complexes 
This work reports the synthesis and characterization of 1,2-
diaminocyclohexane(ethylenediamine)gold(III) chloride complexes of the type 
[(DACH)Au(en)]Cl3, (where DACH = cis and trans-1.2-diaminocyclohexane,en = 
ethylenediamine). 
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5.3.1 Electronic spectra 
The λmax values for the complexes studied are shown in Table 5.21. The gold(III) 
complexes (48), (49) and (50)  exhibit, in a reference buffered phosphate solution, intense 
transitions in the range 335-339 nm, which are assigned as ligand-to-metal charge-
transfer transitions characteristically associated to the gold(III) center [181].  In related 
compounds, absorption bands were assignedas -NH
-
 to a gold(III) charge-transfer bands 
[181].  These spectral features appear only at relatively high pH values (pH > 6-7) at 
which ligand deprotonation has fully occurred.  According to crystal field theory for d
8
 
complexes the LUMO orbital is dx
2
-y
2
, so ligand to metal charge transfer could be due to 
pσ→dx
2
-y
2
 transition [175]. 
The electronic spectra of the complexes (48), (49) and (50) in the buffer solution, were 
monitored at 37 
o
C over 7 days after mixing. The spectra for all compounds at mixing 
and after 7 days are depicted in Figure 5.34.  It is apparent that the observed transitions 
remain substantially unmodified over 7 days observation, implying a substantial stability 
of these complexes under the present solution conditions.  Nevertheless, a slight decrease 
in intensity, of the characteristic bands, was noticed with time without significant shape 
modifications.  Also, this observation indicates that the gold center in these complexes 
remains in the +3 oxidation state [175-181]. The minor spectral changes that are 
generally observed within the first hours may be ascribed either to dissociation of the 
amine ligands from the gold(III) complex or to partial reduction of gold(III) to metallic 
gold. In general, however, loss of spectral intensity is lower than 10% of the original 
intensity within the observation period of 7 days which indicates high stability of these 
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compounds in the buffer.  This is a possible suggestion that in the physiological milieu, 
the compounds would be able to undergo the necessary reactions required for bioactivity.  
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Figure 5.34 Time effect on electronic spectra of complexes (48)-(50) following dissolution in the buffer solution at 
mixing (a) and after 7 days (b) at 37 oC 
Table 5.21 UV-Vis spectra λmax forcomplexes (48)-(50) dissolved in the reference physiological buffer solution. 
Complex λmax (nm) 
NaAuCl4 293 
[(en)Au{cis-(1,2-DACH)}]Cl3(48) 335 
[(en)Au{trans-(±)-(1,2-DACH)}]Cl3(49) 338 
[(en)Au{trans-(+)-(1S,2S-DACH)}]Cl3(50) 339 
 
5.3.2 Mid and Far-IR Spectroscopic Studies 
The most significant bands recorded in the FT-IR spectra of the free ligands and [(1,2-
DACH)(en)Au(III)]Cl3 complexes have been reported in Table 5.22 and Table 5.23.  It is 
noted that N-H stretching vibrations of complexes (48-50) exhibit, in the range 3386-
3432 cm
-1
, blue shifting compared with the amino group of the corresponding free 
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ligands. This is most likely due to stronger hydrogen bonding interactions in the free 
ligands. The amino coordination with Au(III) ions and Au-N bond formation can be 
supported by the presence of ν(Au-N) at 417-442 cm-1 as indicated by Far-IR data [173].  
The C-N stretching bands also showed a significant shift to higher wave number 
indicating a shorter C-N bond in the complex than in the free ligand.  Furthermore, there 
was no signal observed at 352 and 367 cm
-1
 corresponding to the symmetric and 
asymmetric stretching of the Au-Cl indicating the absence of the gold mono-DACH 
complex [180]. The [(1,2-DACH)(en)Au(III)]Cl3 complexes (48-50) show N-H 
stretching frequencies generally lower in comparison with mono-DACH complexes(36-
38) (Table 5.21), most probably due to stronger hydrogen bonding interactions with the 
chloride anions in the [(1,2-DACH)(en)Au(III)]Cl3 complexes. Furthermore the Au-N 
stretching frequencies are consistent with weaker Au-N bond strength in complexes (48-
50) compared to the mono-DACH complexes. 
 
Table 5.22 Mid-IR frequencies, ν(cm-1) for 1,2-cyclohexanediamine(ethylenediamine)Au(III) chloridecomplexes. 
Species  ν(N-H) νshift ν(C-N) νshift 
(en) 3393 w  1033 m  
[(en)AuCl2]Cl 3422 br 29 1045 m 12 
Cis-1,2-(DACH) (36´) 3356 m, 3286 m  1092 s  
[Cis-1,2-(DACH)AuCl3]Cl (36) 3414 w 93 1183 s 91 
[(en)Au{Cis-1,2-(DACH}]Cl3(48) 3395 br 74
a
, 2
b 
1182 w 90
a
, 149
b
 
Trans-(±)-1,2-(DACH) (37´) 3348 m, 3271 m, 3183 m  1082 m  
[{Trans-(±)-1,2-(DACH)}AuCl2]Cl (37) 3485 w, 3420 w, 3384 w 137, 149, 201 1175 m 93 
[(en)Au{Trans-(±)-1,2-(DACH)}]Cl3(49) 3432 br 168
a
, 39
b
 1180 m 93
a
, 147
b
 
(1S,2S)-(+)-1,2-(DACH) (38´) 3340 m, 3252 m, 3167 m  1082 m  
[(1S,2S)-(+)-1,2-(DACH)AuCl2]Cl (38) 3604 m, 3340 m, 3306 m, 3168 m 132, 27 1171 m 89 
[(en)Au(1S,2S)-(+)-1,2-(DACH)]Cl3(50) 3386 br 132
a
, -7
b
 1180 m 98
a
, 147
b
 
a
 with respect with (DACH), 
b
 with respect to (en) 
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Table 5.23 Far-IR frequencies, ν(cm-1) for 1,2-cyclohexanediamine(ethylenediamine)Au(III) chloridecomplexes. 
Species Au-Cl Au-N Refs. 
NaAuCl4 365 - 
a 
[(en)AuCl2]Cl - 391,474 [183] 
[Cis-1,2-(DACH)AuCl3]Cl (36) 352, 367 437 [180] 
[(en)Au{Cis-1,2-(DACH}]Cl3(48) - 326, 417 
a 
[{Trans-(±)-1,2-(DACH)}AuCl2]Cl (37) 353, 365 437 [180] 
[(en)Au{Trans-(±)-1,2-(DACH)}]Cl3(49) - 391, 442 
a 
[(1S,2S)-(+)-1,2-(DACH)AuCl2]Cl (38) 353, 366 395, 436 [180] 
[(en)Au(1S,2S)-(+)-1,2-(DACH)]Cl3(50) - 376, 440 
a 
a
 this work 
 
5.3.3 Solution NMR Characterization 
The 
1
H and 
13
C NMR chemical shifts are given in Table 5.24 and Table 5.25, 
respectively.  All 
1
H NMR supported the structures of the synthesized complexes as 
indicated by the integration of the signals of C-H protons connected to the amino groups 
of the (DACH) and (en).  For example, the ratio of the protons attached to amino group in 
both (DACH) and (en) for complex (50) is 1:2 as depicted in Figure 5.35.  Its 
13
C NMR 
spectrum is also confirmed the complex‘s structure as shown in Figure 5.36.  The 1H and 
13
C NMR chemical shifts of compounds (48-50) along with their corresponding free 
ligands are listed in Tables 5.24 and 5.25, respectively. In the 
1
H and 
13
C NMR spectra of 
complexes (48), (49) and (50), one half of the total expected signals were noticed because 
of the C2 symmetry axis.  1,2-diaminocyclohexane ring is considered as a rigid conformer 
that allowed, for instance, to distinguish equatorial H3 and H6 from axial H3 and H6 at 
room temperature. The signals of C-H protons connected to the amino groups for both 
149 
 
(DACH) and (en) occur in the spectra at 3.05 to 3.61 ppm, shifting downfield compared 
with the corresponding signals (2.23-2.65 ppm) in the free diamine ligands. The 
significant downfield shift was observed at 3.62 ppm for (48) complex with respect to the 
free DACH ligand at 2.23 ppm. This can be attributed to the donation of nitrogen lone 
pairs to the gold that causes de-shielding of the proton(s) next to the bonding nitrogen. 
On the other hand, 
13
C NMR downfield shift was observed only for the carbon next to the 
bonding nitrogen and the others carbons in the complex for (DACH) showed upfield 
shift.  For instance, chemical shift of C3 and C4 for complex (48) observed at 26.13 and 
20.64 ppm, respectively, whereas, for free diamine ligand it occurs at 35.26 and 26.36 
ppm.  It is also worth to mention that complexes (48-50), even though they have the same 
skeleton of (DACH) and (en), their NMR chemical shifts specifically for (DACH) aren‘t 
the same due to a different stereochemistry upon complexation. 
Table 5.24 1H NMR chemical shifts of free ligands and 1,2-cyclohexanediamine(ethylenediamine)Au(III) chloride 
complexes in D2O 
Compound 
1H(δ in 
ppm) 
    
 
 
H1,H2, 
 
H3,H6 
(eq) 
H3,H6 
(ax) 
H4,H5 
(eq) 
H4,H5 
(ax) 
H1´,H2´ 
(en) - - - - - 3.2, s 
(36´) 2.23, m 1.85, m 1.69, m 1.28, m 1.12, m - 
(37´) 2.25, m 1.85, m 1.68, m 1.28, m 1.11, m - 
(38´) 2.24, m 1.85, m 1.69, m 1.28, m 1.11, m - 
(48) 3.61, m 1.96, m 1.77, m 1.59, m 1.41 , m 3.16, s 
(49) 3.05, m 2.11, m 1.54, m 1.48, m 1.10 , m 3.14, s 
(50) 3.08, m 2.19, m 1.63, m 1.54, m 1.19 , m 3.17, s 
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Table 5.25 13C NMR chemical shifts of free ligands and 1,2-cyclohexanediamine(ethylenediamine)Au(III) chloride 
complexes in D2O. 
Compound 
13C(δ in ppm)  
 C1,C2 C3,C6 C4,C5 C1´, C2´ 
(en) - - - 37.67 
(36´) 58.20 35.26 26.36 - 
(37´) 58.46 35.55 26.63 - 
(38´) 58.27 35.32 26.43 - 
(48) 61.74 26.13 20.64 50.39 
(49) 64.59 32.95 24.12 50.63 
(50) 64.44 32.84 24.02 50.48 
 
 
Figure 5.35 The 500-MHz 1H solution NMR spectrum of [(1S,2S)-(+)-(DACH)Au(en)]Cl3 complex. 
151 
 
 
Figure 5.36 The 125.65-MHz 13C{1H} solution NMR spectrum of [(1S,2S)-(+)-(DACH)Au(en)]Cl3 complex. 
 
5.3.4 Solid-State NMR 
As listed in Table 5.26, solid state NMR spectrum of complex (50) showed equivalency 
in the chemical shifts of carbon atoms (C1,C2), (C3,C6), (C4,C6) and (C1´,C2´) where 
two sets of peaks were observed, whereas, a similar behavior was not observed for carbon 
atoms of (DACH) in complexes (48)&(49).  This indicates that these complexes 
(48)&(49) in the solid state lack C2 symmetry.  In contrast, all synthesized complexes 
(48), (49)&(49) showed C2 symmetry in the solution state as indicated earlier by solution 
1
H and 
13
C NMR.  
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Compared to solution chemical shifts, significant de-shielding in solid state is observed 
with similarity in the chemical shift among all synthesized complexes (Table 5.28) which 
is a clear indication of stability of the prepared complexes in solid state. 
Table 5.26 Solid 13C NMR chemical shifts of free ligands and 1,2-cyclohexanediamine(ethylenediamine)Au(III) 
chloride complexes. 
Compound 
 13C(δ in ppm)  
 C1,C2 C3,C6, C4,C5 C1´, C2´ Refs. 
Cis-1,2-(DACH)AuCl3 66.20, 65.35 30.98 27.02, 22.12 - [180] 
(48) 64.32 28.85 28.85, 22.94 54.30 
a 
Trans-(±)-1,2-(DACH)AuCl3 69.60 37.37 27.99 - [180] 
(49) 69.60, 65.45 36.63 27.53 54.08 
a 
(S,S)-(+)-1,2-(DACH)AuCl3 70.21 37.86 29.16 - [180] 
(50) 67.1 36.19 27.65 54.18 
a 
a 
this work 
5.3.5 Computational Study 
The optimized structures of the [(DACH)Au(en)]
3+
 complexes as obtained from the 
B3LYP/LANL2DZ level of calculations are shown in Figure 5.37. Selected quantitative 
structural parameters are also listed in Table 5.27. The complexes show a distorted square 
planar geometry structure around the gold atom. The N – Au – N angles in most of the 
conformations are within less than a degree from the perfect square planar geometry. The 
Au – N bond distance was predicted to be in the range of 2.12 to 2.15 Å for both (DACH) 
and (en) bidentating ligands. The C – N bond length shows a significant increase (by 
approximately 0.1 Å) when compared with the same type of bonds in normal amines 
[184]. The four nitrogen atoms are predicted to adoptsp
3
 type of hybridization as can be 
viewed from the calculated bond angles (Table 5.27).  From the computed energetics of 
the four structures of the complex (Table 5.28), the trans conformations are more 
preferable compared to the cis conformations with more than 3.5 kcal/mol difference. 
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The most possible explanation of this energy variation is the ring configuration of the 
DACH ligand, where in the cis form the CH2 units experience more steric repulsion 
compared to the trans form. 
Table 5.27 Calculated bond lengths and bond angles of the [(1,2-DACH)(en)Au(III)]3+complexin its four possible 
conformations 
 48(a) 48(b) 49(a) 49(b) 
Bond lengths (Å)     
Au – N1 2.147 2.140 2.145 2.146 
Au – N2 2.147 2.132 2.145 2.146 
Au – N3 2.131 2.118 2.134 2.135 
Au – N4 2.132 2.127 2.134 2.135 
N1 – C 1.538 1.540 1.539 1.539 
N2 – C 1.538 1.541 1.539 1.539 
N3 – C 1.544 1.559 1.545 1.544 
N4 – C 1.545 1.552 1.545 1.544 
Bond angles (deg.)     
N1 – Au – N3 177.7 179.5 179.4 179.5 
N2 – Au – N4 177.6 179.4 179.4 179.5 
N1 – Au – N2 81.8 82.1 82.0 81.9 
N2 – Au – N3 100.5 98.3 98.6 98.6 
N3 – Au – N4 77.2 81.7 80.9 80.9 
N4 – Au – N1 100.6 97.9 98.5 98.6 
Au – N1 – C 109.3 109.1 109.0 109.0 
Au – N2 – C 109.1 109.1 109.0 109.0 
Au – N3 – C 111.4 109.5 110.7 110.8 
Au – N4 – C 111.8 109.4 110.7 110.8 
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Table 5.28 Relative energies (kcal/mol) of the four possible conformations of [(1,2-DACH)(en)Au(III)]3+ complexes. 
Conformation Relative Energy (kcal/mol) 
48(a) 3.61 
48(b) 3.10 
49(a) 0.00 
49(b) 0.11 
 
 
48(a) 
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48(b) 
 
49(a) 
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49(b) 
Figure 5.37 Optimized geometries of [(1,2-DACH)Au(III)(en)]+3, obtained at the B3LYP/LanL2DZ level of theory 
using GAUSSIAN09 W 
 
5.3.6 NMR Profiles Stability Study. 
NMR spectra of the complexes dissolved in D2O and mixed DMSO-d6/D2O (v/v: 2/1) 
solution were obtained on immediate dissolution to serve as reference spectra and latter at 
24 h and after 7 days at 37 
o
C in D2O and at RT in mixed DMSO-d6/D2O to determine 
their stability.  In general, all complexes showed high stability in D2O and their NMR 
profiles remained unchanged over 7 days.  For example, Figures5.38-5.39 illustrated, 
respectively, the 
1
H and 
13
C NMR profiles of the compound (48) at mixing and after 7 
days.  Whereas, these compounds in mixed DMSO-d6/D2O were slightly less stable at the 
experimental conditions, in which, minor dissociation of (en) out off the gold complexes 
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was observed from day one.  On the other hand, no dissociation was observed for 
(DACH).  Among all synthesized complexes, the maximum dissociation for (en) after 7 
days was experienced for compound (50) with 25%.  Figures 5.40-5.41showed, 
respectively, 
1
H and 
13
C NMR profiles of compound (50) in DMSO-d6/D2O at mixing 
and after 7 days.  
1
H and 
13
C NMR of compound (50)spectra after 7 days in DMSO-
d6/D2O showed extra peak at 3.07 and 37.24 ppm as shown in Figures5.40 (b)-5.41 (b), 
respectively, corresponding to the free (en) atoms.  It is clear that the bond between 
gold(III) and (DACH) is stronger than the bond between gold(III) and (en) in these 
complexes suggesting that (en) could be a better leaving group.  
 
 
Figure 5.38 The 500-MHz 1H solution NMR spectra of [cis-1,2-(DACH)Au(en)]Cl3 complex in D2O at mixing (a) and 
after 7 days (b) 
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Figure 5.39 The 125.65-MHz 13C{1H} solution NMR spectra of [Cis-1,2-(DACH)Au(en)]Cl3 complex in D2O at 
mixing (a) and after 7 days (b). 
 
Figure 5.40 The 500-MHz 1H solution NMR spectra of [(1S,2S)-(+)-(DACH)Au(en)]Cl3 complex in D2O/DMSO at 
mixing (a) and after 7 days (b) 
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Figure 5.41  The 125.65-MHz 13C{1H} solution NMR spectra of [(1S,2S)-(+)-(DACH)Au(en)]Cl3 complex in 
(DMSO/D2O, 1:2) at mixing (a) and after 7 days (b) 
5.3.7 Electrochemical Studies of Compounds 48-50. 
The electrochemical behavior of compounds (48), (49) and (50) was investigated in a 
physiological environment through cyclic voltammetry.   The voltammetric curves of the 
complexes (48), (49) and (50) are shown in Figure 5.42, and Table 5.29summarizes the 
voltammetric data of all the study compounds.  The potential values vs. NHE for the 
reduction processes exhibited by the complexes (48), (49) and (50), in a reference 
buffered phosphate, in the range (+0.46)-(+0.51) V.  Voltammetric data indicated that 
trans-DACH conformer isomer is slightly more stable than the cis-DACH conformer of 
the complexes which is consistant with UV-Visible analysis.  Gold(III) complexes (48), 
(49) and (50)  show one irreversible reduction process which in controlled potential 
coulometry involves three electrons per mole.  The occurrence of Au(III)/Au(0) reduction  
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is confirmed by the appearance of the thin gold layer deposited on the platinum electrode 
surface after exhaustive electrolysis (Ew, -0.7 V).  In general, voltammetric results 
suggested that these compounds are quite stable under the physiological conditions. 
We also checked the stability of the gold(III) compounds in the reference buffer 
following addition of stoichiometric amounts of the biologically important reducing agent 
sodium ascorbate.  It was observed that all complexes were quickly and completely 
reduced and the process was nearly complete after 60 min. 
Table 5.29 Peak potential values (vs ENH) for reduction of the gold(III) complexes (48-50) in the buffered aqueous 
solution processes at the platinum electrode. 
Complex Ep(V) 
[(en)Au{Cis-1,2-(DACH}]Cl3(48) +0.49 
[(en)Au{Trans-(±)-1,2-(DACH)}]Cl3(49) +0.46 
[(en)Au(1S,2S)-(+)-(DACH)]Cl3(50) +0.51 
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Figure 5. 42 Cyclic voltammograms of compound 48, 49 and 50 in the phosphate buffer at platinum electrode. 
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5.3.8 Effect of Compounds (48), (49) and (50) on Cell Proliferation 
The bioassay tests were completed for compounds (48)-(50) under various experimental 
conditions.  The cytotoxicity assay was performed with various concentrations of the 
synthesized gold(III) complexes on PC-3 and SGC-7901 cells. The PC-3 and SGC- 7901 
cell lines were treated with various concentrations of (48), (49) and (50) for 24-72 h and 
the cell viability was determined as described above by MTT assay and the results are 
shown in Tables 5.32 and 5.33 as well as in Figures5.43-5.49. Complexes[cis-1,2-
(DACH)Au(III)(en)]Cl3(48), [trans-(±)-1,2-(DACH)Au(III)(en)]Cl3(49) and purely chiral 
[trans-(+)-1,2-(DACH)Au(III)(en)]Cl3(50) exhibit potentially high activity against gastric 
cancer cell SGC-7901 as well as human prostate cancer cells after 24 and 72 h of 
treatment with 10 μM (see Table 5.30) under the same assay experimental conditions.  In 
addition to that and as illustrated inFigures5.46-5.48, The gold(III) complexes under 
study showed concentration dependent cytotoxic effect on cancerous cells PC-3 as well 
as SGC-7901. Also, it can be concluded from Figures 5.43-5.48that [cis-1,2-
(DACH)Au(III)(en)]Cl3 (48) complex demonstrates higher anti-proliferation activity 
compared with both trans isomers [trans-(±)-1,2-(DACH)Au(III)(en)]Cl3(49) and [trans-
(+)-1,2-(DACH)Au(III)(en)]Cl3(50).  In addition to that and as shown in Figures5.44, 
5.45, 5.47 and 5.48 that illustrated the cells anti-proliferation assay of trans complexes 
(49) and (50),there is a significant difference in the bioactivity between [trans-(±)-1,2-
(DACH)Au(III)(en)]Cl3(49) and [trans-(+)-1,2-(DACH)Au(III)(en)]Cl3(50).  The former 
possesses higher cytotoxicity activity as well as its cellsanti-proliferation activity is 
similar to the cis-DACH compound (48).  To the best of our knowledge this is the first 
bioassay tests has been reported for gold(III) complexes based on cyclohexane-1,2-
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diamine and ethylenediamine.Figure 5.49 illustrates the anticancer activity of compound 
(48)-(50) against the two cell lines for a comparison purpose. 
In a time dependent activity studies, it is revealed that after 72 h of the experiment with 
the cis isomer (48) on SGC-7901cells, the cells anti-proliferation is bit higher than that of 
the PC-3 cells at fixed 10 μM concentration (Figures5.43-5.48). While, with trans 
complexes (49) and (50) it is reversed where the PC-3 cells anti-proliferation is bit higher 
than that of the SGC-7901 cells at the same concentration.   
 
Table 5.30 Effect of compounds 48, 49 and 50 on cell/proliferation and cell cycle of  PC3 cell line and SGC-7901 cell 
line (Mean, SD) after incubation for 24 h and 72 h. 
 PC3 Cell line SGC-7901 Cell line 
Group Day 1 (24 h) Day 3 (72 h) Day 1 (24 h) Day 3 (72 h) 
Control 1.48 ±  0.03 2.86 ± 0.04 1.56 ±  0.02 2.64 ± 0.04 
(48) 0.49 ±  0.34 0.49 ±  0.19 0.83 ±  0.21 0.68 ±  0.19 
(49) 0.35 ±  0.11 0.37 ±  0.14 0.64 ± 0.20 0.44 ± 0.19 
(50) 0.25 ± 0.09 0.22 ± 0.07 0.64± 0.21 0.45 ± 0.16 
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Figure 5.43 Effect of [cis-1,2-(DACH)gold(III)(en)]Cl3complex on cell growth in (A) PC3 and (B) SGC7901 cells. 
The cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured by 
MTT assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.44 Effect of [trans-(±)-1,2-(DACH)gold(III)(en)]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P < 0.05 
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Figure 5.45 Effect of [(S,S)-(+)-1,2-(DACH)gold(III)(en)]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P < 0.05 
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Figure 5.46 Effect of [cis-1,2-(DACH)gold(III)(en)]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 cells. 
The cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P < 0.05 
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Figure 5. 47 Effect of [trans-(±)-1,2-(DACH)gold(III)(en)]Cl3 complex  on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with various concentrations for 24 h. The anti-proliferative effect was 
measured by MTT assay. Results were expressed as the mean, SD. *P < 0.05 
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Figure 5.48 Effect of [(S,S)-(+)-1,2-(DACH)gold(III)(en)]Cl3 complex on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with various concentrations for 24 h. The anti-proliferative effect was 
measured by MTT assay. Results were expressed as the mean, SD. *P < 0.05 
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Figure 5. 49 Effect of compounds (48-50) on cell growth in (A) PC-3 and (B) SGC-7901 cells. The cells were treated 
with 10 µM for day 1 and day 3.  The anti-proliferative effect was measured by MTT assay. Results 
were expressed as the mean, SD. *P < 0.05 
The in vitro cytotoxicity of the compounds (48-50) was evaluated in terms of their IC50 
values against prostate cancer cell lines (PC3) and gastric carcinoma cell lines 
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(SGC7901).  The IC50 data is shown in Table 5.31.  The IC50 data for the Au(III) 
complexes (48-50) showed reasonable cytotoxicity in the 5–9 μM range for SGC7901 
cells, as given in Table 5.31.  For SGC7901cells, complexes (48) and (50) were 
recognized as being as effective cytotoxic agent as cis-platin, while compound (49) 
demonstrated about 1.1-fold lower potency.  For PC3 cells line, compounds (48-50) 
showed almost 4–8-fold lower cytotoxicity as compared to cisplatin. 
An independent assessment of compounds (48-50) revealed an interesting feature that 
SGC7901 gastric cancer cells exhibit 7 to 8-fold intrinsic resistance relative to the PC3 
cancer cells with respect to cis-platin [182]. However, almost 1-fold resistance to 
compounds (48-50) was observed for PC3, as shown in Table 5.31.  This suggests that 
the intrinsic factors regulating cellular sensitivity to cis-platin are different for PC3 and 
SGC7901 cells.  The factors affecting the sensitivity of PC3 and SGC7901 cells are 
analogous in compounds (48-50). There is no doubt that the present study is helpful for 
further exploiting and defining the potential role of gold(III) complexes in the combat 
against prostate and gastric cancers. 
Table 5.31 IC50 Cytotoxicity values of the complexes towards different tumor cell lines. The data were collected 
after 72 h exposure to compound (48-50) 
IC50 (µM)  
Compounds PC3 SGC-7901 
Fold resistance 
SGC7901/PC3 
Ref. 
Cis-platin 1.1 ± 0.1 7.3 ± 0.5 6.64 [182] 
(48) 4.8 ± 0.1 5.5 ± 0.2 1.15 b 
(49) 8.9 ± 0.1 7.9 ± 0.2 0.89 b 
(50) 6.1 ± 0.1 5.8 ± 0.2 0.95 b 
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5.3.9 Conclusion 
These gold(III) complexes were characterized using elemental analyzer, solution and 
solid NMR, UV, IR, Far-IR spectroscopy and cyclic voltammetry. The analytical data 
showed strong support for the formation of the [(1,2-DACH)Au(en)]Cl3 complexes, 
exhibiting fair stability in the reference buffer.  The computational study demonstrates 
that [trans-(1,2-DACH)Au(en)]Cl3 isomer is more stable than the [cis-(1,2-
DACH)Au(en)]Cl3 isomer and gold coordination sphere of these complexes adopt 
distorted square planar geometry. According to the biological assays, complexes (48) and 
(50), with cis and transconfigurations of (DACH), respectively, are more promising 
candidates as anti-cancer agents than the (1S,2S) isomers of (49). The exact mechanisms 
are not clearly known, but the inhibitory effect of [(cis-1,2-DACH)Au(en)]Cl3 on the 
proliferation of rapidly dividing cells would be attributed to the induction of cell cycle 
blockage, interruption of the cell mitotic cycle, programmed cell death (apoptosis) or 
premature cell death (necrosis). Therefore, [(cis-1,2-DACH)Au(en)]Cl3 isomer, might be 
a promising chemo preventative and chemotherapeutic agent against human gastric 
carcinogenesis. As cytotoxic activity of [(cis-1,2-DACH)Au(en)]Cl3 complex is high 
towards some cancer cell lines; further biological evaluation for this class of complexes is 
worthy of efforts especially in order to evaluate activities in vivo. 
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5.4 Mixed-Ligand Diaminocyclohexane(propylenediamine)gold(III) 
Chloride Complexes 
This work reports the synthesis and characterization of 1,2-
diaminocyclohexane(propylenediamine)gold(III) chloridecomplexes of the type [(1,2-
DACH)Au(pn)]Cl3, where DACH and pn are 1,2-diaminocyclohexane and 1,3-
propylenediamine, respectively. 
 
5.4.1 Electronic Spectra 
The λmax values for the complexes studied are shown in Table 5.32. The gold(III) 
complexes (51), (52) and (53) exhibit, in a reference buffered phosphate solution, intense 
transitions in the range 330-340 nm, which are assigned as ligand-to-metal charge-
transfer transitions characteristically associated to the gold(III) center [181].  These 
absorption bands were previously assignedas NH
-
 to a gold(III) charge-transfer bands 
[181].  It is worth to notice that these spectral features appear only at relatively high pH 
values (pH > 6-7) at which ligand deprotonation has fully occurred.  According to crystal 
field theory for d
8
 complexes the LUMO orbital is dx
2
-y
2
, so ligand to metal charge 
transfer could be due to pσ→dx
2
-y
2
 transition [175]. 
The electronic spectra of the complexes (51), (52) and (53) in the buffer solution, were 
monitored at 37 
o
C over 7 days after mixing. The electronic spectra for all compounds at 
mixing and after 7 days are depicted in Figure 5.50.  It is apparent that the observed 
transitions remain substantially unmodified over 7 days observation, implying a 
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substantial stability of these complexes under the present solution conditions.  
Nevertheless, a slight decrease in intensity, of the characteristic bands, was noticed with 
time without significant shape modifications.  Also, this observation indicates that the 
gold center in these complexes remains in the +3 oxidation state [175-181]. The minor 
spectral changes that are generally observed within the first hours may be ascribed either 
to dissociation of the amine ligands from the gold(III) complex or to partial reduction of 
gold(III) to metallic gold. In general, however, loss of spectral intensity is lower than 
15% of the original intensity within the observation period of 7 days which indicates high 
stability of these compounds in the buffer.  This is a possible suggestion that in the 
physiological milieu, the compounds would be able to undergo the necessary reactions 
required for bioactivity.  
 
Table 5.32 UV-Vis spectra λmax for complexes of [(diaminocyclohexane)(ethylenediamine)Au(III)]chloride dissolved 
in the reference physiological buffer solution. 
Complex λmax (nm) 
NaAuCl4 293 
[(pn)Au{cis-(1,2-DACH)}]Cl3(51) 332 
[(pn)Au{trans-(±)-(1,2-DACH)}]Cl3(52) 339 
[(pn)Au{trans-(+)-(1S,2S-DACH)}]Cl3(53) 341 
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Figure 5. 50 Electronic spectra with time of 1,2-diaminocyclohexane(propylenediamine)gold(III) chloridecomplexes 
following dissolution in the buffer solution at mixing (a) and after 7 days (b) at 37 oC. 
 
5.4.2 Mid and Far-IR spectroscopic studies 
The most significant bands recorded in the FT-IR spectra of the ligand, [(1,2-
DACH)Au(III)(pn)]Cl3 complexes have been reported in Table 5.33 and Table 5.34.  It is 
noted that N-H stretching vibrations of complexes (51-53) exhibit, in the range 3444-
3452cm
-1
, blue shifting compared with the amino group of the corresponding free 
ligands. This is most likely due to stronger hydrogen bonding interactions in the free 
ligands. The amino coordination with Au(III) ions and Au-N bond formation can be 
supported by the presence of ν(Au-N) at 420-447 cm-1 as indicated by Far-IR data [173].  
The C-N stretching bands also showed a significant shift to higher wave number 
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indicating a shorter C-N bond in the complex than in the free ligand.  Furthermore, there 
was no signal observed at 325 and 388 cm
-1
 corresponding to the symmetric and 
asymmetric stretching of the Au-Cl indicating the absence of the gold mono-DACH 
complex [180]. The [(1,2-DACH)Au(III)(pn)]Cl3 complexes (51-53) show N-H 
stretching frequencies generally lower in comparison with mono-DACH complexes (36-
38) (Table 5.33), most probably due to stronger hydrogen bonding interactions with the 
chloride anions in the [(1,2-DACH)Au(III)(pn)]Cl3complexes. Furthermore the Au-N 
stretching frequencies are consistent with weaker Au-N bond strength in complexes (51-
53) compared to the mono-DACH complexes. 
Table 5.33 Mid IR frequencies, ν(cm-1) for 1,2-cyclohexanediamine(1,3-Propylenediamine)Au(III) 
chloridecomplexes. 
Complex ν(N-H) νshift ν(C-N) νshift 
(pn) 3357 m, 3282 m  1093 w  
(pn)AuCl3 3447 br 127 1178 s 85 
Cis-1,2-(DACH) 3356 m, 3286 m  1092 s  
Cis-1,2-(DACH)AuCl3 3414 w 93 1183 s 91 
(51) 3427 br 106
a
, 108
b 
1139 w 47
a
, 46
b
 
Trans-(±)-1,2-(DACH) 3348 m, 3271 m, 3183 m  1082 m  
Trans-(±)-1,2-(DACH)AuCl3 3485 w, 3420 w, 3384 w 137, 149, 201 1175 m 93 
(52) 3409 br 141
a
, 90
b
 1179 m 97
a
, 86
b
 
(S,S)-(+)-1,2-(DACH) 3340 m, 3252 m, 3167 m  1082 m  
(S,S)-(+)-1,2-(DACH)AuCl3 3604 m, 3340 m, 3306 m, 3168 m 132, 27 1171 m 89 
(53) 3433 br 179
a
, 113
b
 1184 m 102
a
, 91
b
 
a
 with respect with (DACH), 
b
 with respect to (pn),
 c
 this work. 
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Table 5.34 Far-IR frequencies, ν(cm-1) for 1,2-cyclohexanediamine(1,3-Propylenediamine)Au(III) chloride 
complexes. 
Species ν(Au-Cl) ν(Au-N) 
NaAuCl4 365 - 
[(pn)AuCl2]Cl - 391,474 
[Cis-1,2-(DACH)AuCl3]Cl (36) 352, 367 437 
[(pn)Au{Cis-1,2-(DACH}]Cl3(51) - 331, 425 
[{Trans-(±)-1,2-(DACH)}AuCl2]Cl (37) 353, 365 437 
[(pn)Au{Trans-(±)-1,2-(DACH)}]Cl3(52) - 392, 448 
[(1S,2S)-(+)-(DACH)AuCl2]Cl (38) 353, 366 395, 436 
[(pn)Au(1S,2S)-(+)-(DACH)]Cl3(53) - 383, 451 
 
5.4.3 Solution NMR characterization 
. All 
1
H NMR supported the structures of the synthesized complexes as indicated by the 
integration of the signals of C-H protons connected to the amino groups of the (DACH) 
and (pn).  For example, the ratio of the protons attached to amino group in both (DACH) 
and (pn) for a complex (53) and (51) is 1:2 as depicted in Figures5.51 and 5.52. Their
13
C 
NMR spectrum is also confirmed the complexes‘ structure as shown in Figures 5.53 and 
5.54.  The 
1
H and 
13
C NMR chemical shifts of compounds (51-53) along with their 
corresponding free ligands are listed in Table 5.35 and Table 5.36, respectively. In the 
1
H 
and 
13
C NMR spectra of complexes (51), (52) and (53), one half of the total expected 
signals was noticed because of the presence of the C2 symmetry axis.  1,2-
diaminocyclohexane ring is considered as a rigid conformer that allowed, for instance, to 
distinguish equatorial H2 and H3 from axial H2 and H3 at room temperature. The signals 
of C-H protons connected to the amino groups for (DACH) occurs in the spectra at 3.07 
to 3.65 ppm, shifting downfield compared with the corresponding signals (2.23-2.25ppm) 
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in the free DACH ligands. The significant downfield shift was observed at 3.65 ppm for 
(51) complex with respect to the free DACH ligand at 2.23 ppm. This can be attributed to 
the donation of nitrogen lone pairs to the gold that causes de-shielding of the proton(s) 
next to the bonding nitrogen. With respect to (pn), no significant change was observed for 
its protons chemical shiftupon the complexation. On the other hand, 
13
C NMR downfield 
shift was observed only for the carbon next to the bonding nitrogen and the others 
carbons in the complex for (DACH) showed upfield shift.  For instance, chemical shift of 
C2 and C3 for complex (51) observed at 26.25 and 20.73 ppm, respectively, whereas, for 
free diamine ligand it occurs at 35.26 and 26.36 ppm.  It is also worth to mention that 
complexes (51-53), even though they have the same skeleton of (DACH) and (pn), their 
NMR chemical shifts specifically for (DACH) aren‘t the same due to a different 
stereochemistry upon complexation. 
Table 5.35 1H NMR chemical shifts of free ligands and cyclohexanediamine propylenediamine Au(III) complexes in 
D2O. 
Compound 
1H(δ in ppm)      
 
H1,H1 
 
H2,H2 
(eq) 
H2,H2 
(ax) 
H3,H3 
(eq) 
H3,H3 
(ax) 
H1´,H1´ H2´ Refs. 
(pn) - - - - - 2.98 t 1.94, p a 
Cis-1,2-(DACH) 2.23, m 1.85, m 1.69, m 1.28, m 1.12, m - - [180] 
Trans-(±)-(DACH) 2.25, m 1.85, m 1.68, m 1.28, m 1.11, m - - [180] 
(1S,2S)-(+)-(DACH) 2.24, m 1.85, m 1.69, m 1.28, m 1.11, m - - [180] 
(51) 3.65, m 1.96, m 1.79, m 1.60, m 1.41 , m 2.94, m 1.96, m a 
(52) 3.07, m 2.11, m 1.56, m 1.47, m 1.10 , m 2.91, m 2.12, m a 
(53) 3.08, m 2.11, m 1.56, m 1.47, m 1.11 , m 2.91, m 2.13, m a 
a 
this work 
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Table 5.36 13C NMR chemical shifts of free ligands and cyclohexanediaminepropylenediamine Au(III) complexes in 
D2O. 
Compound 
13C(δ in ppm)   
 C1,C1 C2,C2 C3,C3 C1´, C1´ C2´ 
(pn) - - - 37.47 25.69 
Cis-1,2-(DACH) 58.20 35.26 26.36 -  
Trans-(±)-1,2-(DACH) 58.46 35.55 26.63 -  
(1S,2S)-(+)-(DACH) 58.27 35.32 26.43 -  
(51) 61.98 26.92 20.73 40.95 26.92 
(52) 64.47 32.88 23.91 40.90 26.90 
(53) 64.50 32.90 23.94 40.92 26.92 
 
 
 
Figure 5.51 The 500-MHz 1H solution state NMR spectrum of [(1S,2S)-(+)-(DACH)Au(pn)]Cl3 complex. 
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Figure 5.52 The 500-MHz 1H solution state NMR spectrum of [cis-1,2-(DACH)Au(pn)]Cl3 complex. 
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Figure 5.53 The 125.65-MHz 13C{1H} solution state NMR spectrum of [(1S,2S)-(+)-1,2-(DACH)Au(pn)]Cl3 complex. 
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Figure 5.54 The 125.65-MHz 13C{1H} solution state NMR spectrum of [cis-1,2-(DACH)Au(pn)]Cl3 complex. 
 
5.4.4 Solid-state NMR 
At the spinning rate of 4 kHz, the isotropic signals for all complexes weren‘t observed for 
the carbons, indicating the absence of the anisotropy that could take place due to the sp
3
 
hybridization of these atoms. Solid state NMR spectrum of complex (53) showed no 
equivalency in the chemical shifts of carbon atoms (C1,C1) and (C2,C2) two sets of 
peaks with the same intensity where observed. Whereas, similar observation didn‘t notice 
for carbon atoms of (DACH) in complexes (51) & (52) as listed in Table 5.37.  This 
indicates that complex (53) in the solid state lacks C2 symmetry.  In contrast, all 
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synthesized complexes (51), (52) & (53) showed C2 symmetry in the solution state as 
indicated earlier by solution 
1
H and 
13
C NMR.  
Table 5.37 Solid 13C NMR chemical shifts of free ligands and (1,2-DACH)Au(III)(pn) complexes. 
Compound 
  13C(δ in ppm)  
 C1,C1 C2,C2, C3,C3 C1´, C1´ C2´ Refs. 
[cis-1,2-(DACH)AuCl2]Cl 66.20, 65.35 30.98 27.02, 22.12 -  [7] 
(51) 64.03 29.31 21.74 44.57 28.01 
a 
[trans-(±)-1,2-(DACH)AuCl2]Cl 69.60 37.37 27.99 
-  [7] 
(52) 66.80 37.35 28.09 45.76 28.09 
a 
[(1S,2S)-(+)-(DACH)AuCl2]Cl 70.21 37.86 29.16 -  [7] 
(53) 67.31, 64.41 36.05, 34.10 27.92 45.65 27.92 
a 
a 
this work 
Compared to solution chemical shifts, significant de-shielding in solid state is observed 
with similarity in the chemical shift among all synthesized complexes (Table 5.37) which 
is a clear indication of stability of the prepared complexes in solid state. 
5.4.5 Computational Study 
The optimized structures of the [(DACH)Au(pn)]
3+
 complexes as obtained from the 
B3LYP/LANL2DZ level of calculations are shown in Figure 5.55. Selected quantitative 
structural parameters are also listed in Table 5.40. The two trans configurations are 
mirror images.  The complexes show a distorted square planar geometry structure around 
the gold atom. The N – Au – N angles in most of the conformations are within less than a 
degree from the perfect square planar geometry. The Au – N was predicted to be in the 
range of 2.14 to 2.15 Å for both (DACH) and (pn) bidentating ligands. The C – N bond 
length shows a significant increase (by approximately 0.1 Å) when compared with the 
same type of bonds in normal amines [76]. The four nitrogen atoms are predicted to adopt 
sp
3
 type of hybridization as can be viewed from the calculated bond angles (Table 5.40). 
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From the computed energetics of the four structures of the complex (Table 5.38), the 
trans conformations are more preferable compared to the cis conformations with more 
than 3.6 kcal/mol difference. The most possible explanation of this energy variation is the 
ring configuration of the DACH ligand, where in the cis form the CH2 units experience 
more steric repulsion compared to the trans form. 
  
[(trans-1R,2R-DACH)Au(pn)]Cl3 [(trans-1S,2S-DACH)Au(pn)]Cl3 
  
[(cis-1S,2R-DACH)Au(pn)]Cl3 [(cis-1R,2S-DACH)Au(pn)]Cl3 
Figure 5.55 Optimized geometries of [(1,2-DACH)Au(III)(pn)]Cl3, obtained at the B3LYP/LanL2DZ level of theory 
using GAUSSIAN09 W 
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Table 5.38 Relative energies (kcal/mol) of the four possible conformations of the [(DACH)Au(pn)]3+ complex. 
Conformation Relative Energy (kcal/mol) 
[(trans-1,2-DACH)Au(pn)]Cl3 0.00 
[(cis-1S,2R-DACH)Au(pn)]Cl3 3.31 
[(cis-1R,2S-DACH)Au(pn)]Cl3 3.59 
 
5.4.6 Crystal Structure of [(cis-1S,2R-DACH)Au(pn)]Cl3. 
The molecular structure of complex [(cis-1S,2R-DACH)Au(pn)]Cl3(51) is shown in 
Figure 5.56. It is a mononuclear complex containing one cis-1,2-cyclohexanediamine 
(DACH) and 1,3-propanediamine(pn)ligand molecules. There are three chloride ions in 
the outer sphere of the complex. The coordination geometry around the gold(III) ion is 
pseudo-square planar as confirmed by crystallographic data and supported by density 
functional calculations, and central gold(III) atom is coordinated with four NH2 donor 
groups of the  cis-1,2-cyclohexanediamine and 1,3-propanediaminemixed ligand 
molecules. Table 5.40 presents a good agreement between the experimental and 
calculated structural parameters for almost all bond distances and angles, which provides 
more support to the crystallographic findings.The mononuclear cation contains one five-
membered chelate cycle AuN2C2 and one six-membered chelate cycle AuN2C3. 
Au1–N1 and Au1–N2 bond distances are 2.03 (3)&2.01 (3) Å, respectively, in a good 
agreement with the calculated DFT values (2.145 & 2.144).The N1–Au1–N1i& N2–Au2–
N2
i
 bond angles are 87 (2)
o
. The bond angles around gold(III) atom in mononuclear 
complex are unexpectedly the same (Table 5.40). These observations provide an 
additional evidence for the presence of centro-symmetricgeometry in [(cis-1S,2R-
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DACH)Au(pn)]Cl3 (51).A summary of crystal data and refinement details for [(cis-1S,2R-
DACH)Au(pn)]Cl3 (51) are given in Table 5.39. 
 
 
Figure 5.56 X-ray structure of [(cis-1S,2R-DACH)Au(pn)]Cl3 (51) 
 
Table 5.39 Crystallographic data for [(cis-1S,2R-DACH)Au(pn)]Cl3 (51) 
 
Empirical formula 
Formula weight 
Crystal size/mm 
Wavelength/Å 
Temperature/K 
Crystal symmetry 
Space group 
C9H24AuCl3N4 
491.64 
0.15 × 0.3 × 0.09 
0.71073 
173 (2) 
Monoclinic 
P21/m 
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a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/ Å
3 
Z 
Dc/Mg m
-3 
μ(Mo-Kα)/mm-1
 
F(000) 
θ Limits/° 
Collected reflections 
Unique reflections(Rint) 
Observed eflections[Fo> 2σ(Fo)] 
Goodness of fit on F
2 
R1(F),
a
[I> 2σ (I)] 
wR2 (F
2
),
b
[I> 2σ(I)] 
Largest diff.peak, hole/e Å
-3 
 
10.139 (2)  
7.2586 (11) 
11.458 (4) 
90 
115.55 (2) 
90 
760.8 (3) 
4 
2.146 
6.92 
472 
2.0–25.7 
5312è 
985 (0.269) 
1565 
1.05 
0.158 
0.407 
7.02, −2.72 
 
Table 5.40 Selected bond distances and bond angles for [(cis-1S,2R-DACH)Au(pn)]Cl3(51) 
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The Au-N bond distances vary from 2.041(12)–2.0375(2) Å andcorrespond to those 
found in the 1,3-diaminopropane and1,2-cyclohexanediamine gold(III)complexes 
[182,186]. Similarly, the N–Au–N bond angles vary from 83.9(2)–94.5 (5)o are much 
different from those found in gold(III) complex [182,186]. 
The presence of Cl
–
 counter ions, lattice water molecule and –NH2 groups of the 1,2-
cyclohexanediamine ligand moleculesresults in hydrogen bond formation in the crystal 
structure of compound (51), which leads to the formation of a low-dimensional hydrogen 
bonded network as shown in Figure 5.57. 
Bond Length (Å) Bond Angles (°) 
 
  
Calculated 
Au1—N1 2.03 (3)      2.147 
Au1—N1i 2.03 (3)      2.147 
Au1—N2i 2.01 (3)      2.138 
Au1—N2 2.01 (3)      2.137 
N1—C1 1.54 (6)      1.537 
N2—C3 1.48 (6)      1.545 
 
 
  
Calculated 
N1—Au1—N1i 87 (2)   88.9 
N1—Au1—N2i 177.8 (15)   174.2 
N1
i—Au1—N2i 93.2 (15)    96.9 
N1—Au1—N2 93.2 (15)     96.9 
N1
i—Au1—N2 177.8 (15)    174.2 
N2
i—Au1—N2 77 (2)      76.3 
C1—N1—Au1 113 (2)     115.9 
C3—N2—Au1 109 (3)      111.3 
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Figure 5.57 View of the hydrogen bonded network of[(cis-1S,2R-DACH)Au(pn)]Cl3 (51) along plane c-axis of the 
unit cell. Blue doted lines show hydrogen bonds between different functional groups of molecules 
5.4.7 NMR Profiles Stability Study. 
NMR spectra of the complexes dissolved in D2O and mixed DMSO-d6/D2O (v/v: 2/1) 
solution were obtained on immediate dissolution to serve as reference spectra and latter at 
24 h and after 7 days at 37 
o
C in D2O and at RT in mixed DMSO-d6/D2O to determine 
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their stability.  In general, all complexes showed high stability in D2O and their NMR 
profiles remained unchanged over 7 days.  For example, Figures 5.58-5.59 illustrated, 
respectively, the 
1
H and 
13
C NMR profiles of the compound (53) at mixing and after 7 
days.  Whereas, these compounds in mixed DMSO-d6/D2O were not stable at the 
experimental conditions, in which, major dissociation of (pn) out off the gold complexes 
was observed from day one.  On the other hand, no dissociation was observed for 
(DACH).  Among all synthesized complexes, the maximum dissociation for (en) after 7 
days was experienced for compound (51) with 80%.  Figures 5.60-5.61 showed, 
respectively, 
1
H and 
13
C NMR profiles of compound (53) in DMSO-d6/D2O at mixing 
and after 7 days.  
1
H and 
13
C NMR of compound (53) spectra after 7 days in DMSO-
d6/D2O showed extra peak at 2.86 & 1.85 and 37.3 & 25.8 ppm as shown in Figures 5.60 
(b)-5.61 (b), respectively, corresponding to the free (pn) atoms.  It is clear that the bond 
between gold(III) and (DACH) is stronger than the bond between gold(III) and (pn) in 
these complexes suggesting that (pn) could be a better leaving group.  
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Figure 5.58 The 500-MHz 1H solution state NMR spectrum of [(1S,2S)-(+)-1,2-(DACH)Au(pn)]Cl3 complex in D2O 
at mixing (a) and after 7 days (b) 
 
 
Figure 5.59 The 125.65-MHz 13C{1H} solution state NMR spectrum of [(1S,2S)-(+)-1,2-(DACH)Au(pn)]Cl3 complex 
in D2O at mixing (a) and after 7 days (b). 
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Figure 5.60 The 500-MHz 1H solution state NMR spectrum of [(1S,2S)-(+)-1,2-(DACH)Au(pn)]Cl3 complex in 
D2O/DMSO at mixing (a) and after 7 days (b) 
 
Figure 5.61 The 125.65-MHz 13C{1H} solution state NMR spectrum of [(1S,2S)-(+)-1,2-(DACH)Au(pn)]Cl3 complex 
in (DMSO/D2O, 1:2) at mixing (a) and after 7 days (b) 
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5.4.8 Electrochemical Studies of Compounds 51-53. 
The electrochemical behavior of compounds (51), (52) and (53) was investigated in a 
physiological environment through cyclic voltammetry.   The voltammetric curves of the 
complexes (51), (52) and (53) are shown in Figure 5.62, and Table 5.41summarize the 
voltammetric data of all the study compounds.  The potential values vs. NHE for the 
reduction processes exhibited by the complexes (51), (52) and (53), in a reference 
buffered phosphate, in the range (+0.48)-(+0.58) V.  Voltammetric data indicated that 
trans-DACH conformer is more stable than the cis-DACH conformer of the complexes 
which is also indicated by UV-Visible analysis.  Gold(III) complexes (51), (52) and (53) 
show one irreversible reduction process which in controlled potential coulometry 
involves three electrons per mole.  The occurrence of Au(III)/Au(0) reduction is 
confirmed by the appearance of thin gold layer deposited on the platinum electrode 
surface after exhaustive electrolysis (Ew, -0.7 V).  In general, voltammetric results 
suggested that these compounds are fairly stable under the physiological conditions. 
We also checked the stability of the gold(III) compounds in the reference buffer 
following addition of stoichiometric amounts of the biologically important reducing agent 
sodium ascorbate.  It was observed that all complexes were quickly and completely 
reduced and the process was nearly complete after 60 min. 
Table 5.41 Peak Potential values (vs ENH) for reduction of the present gold(III) complexes in the buffered aqueous 
solution processes at the platinum electrode 
Complex Ep(V) 
[(en)Au{Cis-1,2-(DACH}]Cl3(48) +0.58 
[(en)Au{Trans-(±)-1,2-(DACH)}]Cl3(49) +0.49 
[(en)Au(1S,2S)-(+)-1,2-(DACH)]Cl3(50) +0.48 
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Figure 5.62 Cyclic voltammograms of compound 48, 49 and 50 in the phosphate buffer at platinum electrode. 
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5.4.9 Effect of Compounds (51), (52) and (53) on Cell Proliferation 
The bioassay tests were completed for compounds (51)-(53) under various experimental 
conditions.  The experimental PC-3 and SGC- 7901 cells were treated with various 
concentrations of (51), (52) and (53) for 24-72 h and the cell viability was determined as 
described above by MTT assay and the results are shown in Tables 10 and 11as well as in 
Figures5.63-5.69.As depicted in Figures 5.63-5.65, complexes (51), (52) and (53) 
exhibited potentially high activity against gastric cancer cell SGC-7901 as well as human 
prostate cancer cells after 24 and 72 h of treatment with 10 μM (see Table 11) under the 
same assay experimental condition.  From Figs. 5.66-5.68, it is also quite clear that 
gold(III) complexes under study showed concentration dependent cytotoxic effect on 
cancerous cells PC-3 and SGC-7901. All synthesized complexes show similar bioactivity 
under the same experimental conditions as indicated by their cytotoxicity results (Table 
5.42).To the best of our knowledge this is the first bioassay tests has been reported for 
gold(III) complexes based on cyclohexane-1,2-diamine and 1,3-propylenediamine. 
Table 5.42 IC50 Cytotoxicity values of the complexes towards different tumor cell lines. The data were collected 
after 72 h exposure to compound (51), (52) and (53) 
IC50 (µM) 
Compounds SGC-7901 PC3 
(1) 
10.8 ± 0.22 9.5 ± 0.22 
(2) 
10.9 ± 0.12 11.2 ± 0.12 
(3) 11.0 ± 0.14 9.1 ± 0.14 
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Figure 5.63 Effect of cis-1,2-(DACH)gold(III)(pn)complex (51)  on cell growth in (A) PC-3 and (B) SGC-7901 cells. 
The cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured by 
MTT assay. Results were expressed as the mean, SD. *P<0.05  
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Figure 5.64 Effect of trans-(±)-1,2-(DACH)gold(III)(pn)complex (52) on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P<0.05 
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Figure 5.65 Effect of (S,S)-(+)-1,2-(DACH)gold(III)(pn) complex (53) on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with 10 µM for 1 day and 3 days. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P<0.05  
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Figure 5.66 Effect of cis-1,2-(DACH)gold(pn) complex (51) on cell growth in (A) PC-3 and (B) SGC-7901 cells. The 
cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured by 
MTT assay. Results were expressed as the mean, SD. *P<0.05  
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Figure 5.67 Effect of trans-(±)-1,2-(DACH)gold(pn) complex (52) on cell growth in (A) PC-3 and (B) SGC-7901 cells. 
The cells were treated with various concentrations for 24 h. The anti-proliferative effect was measured 
by MTT assay. Results were expressed as the mean, SD. *P<0.05  
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Figure 5.68 Effect of (S,S)-(+)-1,2-(DACH)gold(III)(pn) complex (53) on cell growth in (A) PC-3 and (B) SGC-7901 
cells. The cells were treated with various concentrations for 24 h. The anti-proliferative effect was 
measured by MTT assay. Results were expressed as the mean, SD. *P<0.05  
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Figure 5.69 Effect of compounds (51-53) and  on cell growth in (A) PC-3 and (B) SGC-7901 cells. The cells were 
treated with 10 µM for day 1, day2 and day 3.  The anti-proliferative effect was measured by MTT 
assay. Results were expressed as the mean, SD. *P<0.05  
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5.4.10 Conclusion 
These [(1,2-DACH)gold(III)(pn)]Cl3 complexes were characterized using elemental 
analyzer, solution and solid NMR, UV, IR, Far-IR spectroscopy and X-ray 
crystallography. The analytical date showed strongly support for the formation of the 
type [(1,2-DACH)gold(III)(pn)]Cl3 complex. Also, computational study demonstrates 
that trans-(1,2-DACH)-gold-(pn) isomer is more stable than the cis-(1,2-DACH)gold(pn) 
isomer and gold coordination sphere of these complexes adopts distorted square planar 
geometry. According to our biological assays, complexes (51) and (53), respectively, 
with cis and (1S,2S)-(DACH)stractures are more promising candidate as an anti-cancer 
agent than the trans-(±)-(1,2-DACH) isomers of (52). The exact mechanisms are not 
clearly known, but the inhibitory effect of [(1S,2S-DACH)Au(pn)]Cl3 on the proliferation 
of rapidly dividing cells would be attributed to the induction of cell cycle blockage, 
interruption of the cell mitotic cycle, programmed cell death (apoptosis) or premature cell 
death (necrosis). Therefore, [(1S,2S-DACH)Au(pn)]Cl3 isomer, might be a promising 
chemo preventative and chemotherapeutic agent against human gastric carcinogenesis. 
As cytotoxic activity of [(1S,2S-DACH)Au(pn)]Cl3 complex is high towards some cancer 
cell lines; further biological evaluation for this class of complexes is worthy of efforts 
especially in order to evaluate activities in vivo. 
 
5.5 Crystal Structure of Compound [Me3PAu(DMDT)] (70) 
Molecular structure of [Me3PAu(S2CNMe2)] (70) is shown in Figure 5.70A view of the 
molecular structure of complex (70), with partial atom labelling scheme and displacement 
ellipsoids are drawn at 50% probability level.. In this structure gold(I) is coordinated with 
204 
 
one P donor atom of trimethylphosphine and S donor atom of dimethyldithiocarbamate 
ligandmolecules. A summary of crystal data and refinement details for compound (70) 
are given in Table 5.43. 
The Au–Sand Au–P bond distances are 2.326 (3) and 2.249 (3) Å, respectively. The Au–
P and Au–S bond distances are comparable with [Et3PAu(S2CNEt2)] complex [187].  The 
geometry around Au(I) metal atom is linear and similar to other Au(I) complexes [188-
191]. In [Me3PAu(S2CNMe2)] (70) structure S–Au–P bond angle is 176.88 (13). The S–
Au–P bond angle value shows considerable deviation from ideal linear angle of 180° 
(Table 5.44 Selected bond lengths and bond angles in compound  and confirms the 
presence of distorted linear geometry in 0this molecule. The short contacts interactions 
between different functional groups of the molecules result three-dimensional network as 
shown in Figure 5.71 View of the crystal packing diagram of compound (70) along plane 
c-axis of the unit cell. Blue and red dotted lines show short contacts between different 
functional groups of molecules. 
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Figure 5.70A view of the molecular structure of complex (70), with partial atom labelling scheme and displacement 
ellipsoids are drawn at 50% probability level. 
 
 
 
 
Figure 5.71 View of the crystal packing diagram of compound (70) along plane c-axis of the unit cell. Blue and red 
dotted lines show short contacts between different functional groups of molecules. 
 
Table 5.43 Summary of crystal data and details of the structure refinement for compound (70) 
Compound 70 
 
Empirical formula 
Formula weight 
Crystal size/mm 
Wavelength/Å 
C6H15Au1N1P1S2 
393.27 
0.15 × 0.3 × 0.09 
0.71073 
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Temperature/K 
Crystal symmetry 
Space group 
a/Å 
b/Å 
c/Å 
V/ Å
3 
Z 
Dc/Mg m
-3 
μ(Mo-Kα)/mm-1
 
F(000) 
θ Limits/° 
Collected reflections 
Unique reflections(Rint) 
Observed eflections[Fo> 2σ(Fo)] 
Goodness of fit on F
2 
R1(F),
a
[I> 2σ (I)] 
wR2 (F
2
),
b
[I> 2σ(I)] 
Largest diff.peak, hole/e Å
-3 
 
173 (2) 
Orthorhombic 
Fdd2 
32.075 (2) 
24.0898 (14) 
6.1700 (3) 
4767.4 (5) 
8 
2.192 
12.78 
2944 
2.1–25.7 
8135 
2123 (0.082) 
2175 
1.08 
0.043 
0.120 
1.40, −3.10 
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Table 5.44 Selected bond lengths and bond angles in compound (70) 
  
Compound 1 
Bond Length (Å) Bond Angles (°) 
 
Au1—P1 2.249 (3) 
Au1—S1 2.326 (3) 
P1—C1 1.775 (16) 
P1—C2 1.792 (14) 
P1—C3 1.797 (15) 
S1—C4 1.758 (12) 
 
 
P1—Au1—S1 176.88 (13) 
C1—P1—C2 103.7 (10) 
C1—P1—C3 104.1 (9) 
C2—P1—C3 105.0 (8) 
C1—P1—Au1 117.5 (6) 
C2—P1—Au1 113.1 (6) 
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6 CHAPTER 6 
SUMMARYAND CONCLUSIONS 
This work reports the synthesis of gold(III) and gold(I) complexes based on 1,2-
diamnecyclohexane, n,n´-dialkyldithiocarmate, ammonium dithiocarbamate (1-16), 2-
mercaptobenzimidazole (17-23) and chloriditrialkylphospanegold(I) (24-35).   
Various new series of gold(III) 1,2-diaminocyclohexane complexes (36-53) with general 
formula, [(1,2-DACH)AuCl2]Cl, [(1,2-DACH)2Au]Cl3, [(1,2-DACH)Au(en)]Cl3, [(1,2-
DACH)Au(pn)]Cl3, [(1,2-DACH)2Au]Cl3, [(1,2-DACH)Au(NH3)Cl]Cl2 and [(1,2-
DACH)Au(NH3)]Cl3 have successfully been synthesized and characterized by using 
various analytical and spectroscopic techniques. 
A noval series of gold(III) complexes (54-69) based on ammoniumdithiocarbamatewith 
general formal [(ADTC)AuCl2]Cl are reported herethat were characterized by using 
various analytical and spectroscopic techniques.In addition to the synthesis of gold(III) 
complexes, a series of gold(I) complexes (70-93) of the type [(R)3PAu(MDTC)] and 
[(R)3PAu(EDTC)] based on mixed ligands of trialkylphosphane and n,n´-
dialkyldithiocarbamatehave successfully been synthesized and characterized by using 
various analytical and spectroscopic techniques.   
Moreover, various series gold(I) complexes (94-129) based on mixed ligands of 2-
mercaptobenzimidazole of the type, [(2-MBI)AuP(R)3], [(2-MBI)Au(carbene)] and [{(2-
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MBI)Au}2(L)] (L= 1,3-bis(diphenylphosphino)methane), were also prepared  and 
characterized by various analytical and spectroscopic techniques 
These gold complexes were characterized using CHN analysis, UV-Vis, mid-FTIR, Far-
FTIR spectroscopy, solution and solid-state NMR and X-ray crystallography. Analytical 
data showed strong support for the formation of the proposed complexes.  The 
coordination geometry around the gold(III) and gold(I) ions is pseudo-square planar and 
liner, respectively, as indicated by X-ray crystallography analysis.  According to the 
biological assays, all (1,2-DACH) gold(III) chloride complexes are promising candidates 
as anti-cancer agents with [(cis-(1,2)-DACH)2Au(III)]Cl3 is the most active agent. 
Stability study of these bis-amine gold(III) complexes in physiological buffer solution 
studied by UV-Vis and cyclic voltammetry (CV) showed fair stability.  According to IC50 
data, all (1,2-DACH) gold(III) chloride complexes show cytotoxicity better or 
comparable to cisplatin, towards SGC7019 prostate cancer cells. 
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6.1 Future Studies 
 In the same line of Au(III) diamine complexes, Au(III) bipyridine and Au(III) 
phenanthroline complexes can also be synthesized and evaluated in vitrofor 
potential anticancer activity. 
 As in vitro anticancer activity of [(en)Au(1,2-DACH)]Cl3 and its derivatives 
was significantly promising towards some cancer cell line, further in vivo 
anticancer evaluation would be worth-while.  
 With same frame of mind, ammonium dithiocarbamate ligands can also be 
used to synthesize a new series of complexes with different metals and 
evaluated in-vitro for potential anticancer activity. 
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